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Zusammenfassung 
Zusammenfassung 
Hintergrund 
GDF-15 ist ein divergentes Mitglied der TGF- Superfamilie, welches zuerst als 
„macrophage inhibitory cytokine-1“ (MIC-1) mit immunmodulatorischen Eigenschaften 
beschrieben wurde. GDF-15 ist ein lösliches Protein, das unter physiologischen Bedingungen 
hauptsächlich in der Plazenta exprimiert wird und welches im Serum von Schwangeren in 
erhöhten Konzentrationen nachgewiesen werden kann. Mit Ausnahme der Plazenta wird 
GDF-15 in verschiedenen gesunden Geweben gefunden, hier jedoch in deutlich niedrigeren 
Konzentrationen, und ist in vielen soliden Tumoren überexprimiert. GDF-15 werden sowohl 
bei gesunden, als auch bei kranken Menschen, unterschiedlichste Funktionen zugeschrieben. 
Zum einen ist GDF-15 für eine erfolgreiche Schwangerschaft notwendig. Niedrige GDF-15 
Spiegel im Serum während der Schwangerschaft korrelieren mit dem Verlust des Fötus. Zum 
anderen korreliert die Überexpression von GDF-15, welche bei unterschiedlichen 
Malignitäten beobachtet werden kann, mit einer schlechten Prognose. Darüber hinaus 
verursacht das von Tumorzellen sezernierte GDF-15 das sogenannte „Anorexie-Kachexie 
Syndrom“ in Mäusen. Das Ziel meiner Arbeit war es, die immunmodulatorische Funktion von 
GDF-15 im Tumorkontext zu untersuchen, insbesondere durch eine Hemmung des 
Zielmoleküls in vitro und in vivo. Aus diesem Grund wurde der Schwerpunkt auf die 
Generierung und Charakterisierung monoklonaler, GDF-15 spezifischer, blockierender 
Antikörper gelegt. Diese wurden sowohl in vitro als auch in vivo getestet, was einen großen 
Teil dieser Arbeit darstellt.      
 
Ergebnisse 
Es konnte gezeigt werden, dass GDF-15 in humanen gynäkologischen Tumoren wie auch in 
Hirntumoren überexprimiert ist. Weiterhin ließ sich zeigen, dass GDF-15 Effektorzellen des 
Immunsystems in vitro moduliert. Dabei verursacht GDF-15 eine moderate 
Herunterregulation des aktivierenden Killing Rezeptors NKG2D auf NK und CD8
+
 T Zellen, 
welcher eine hohe Bedeutung für eine effektive anti-tumorale Immunantwort hat. Darüber 
hinaus konnten wir zeigen, dass GDF-15 die Adhäsion von CD4
+
 und CD8
+
 T Zellen auf 
Endothelzellen in vitro herabsetzt. Eine daraus resultierende Reduktion der trans-
endothelialen Migration von Leukozyten in entzündetes Gewebe erklärt möglicherweise die 
niedrige T Zell Infiltration in GDF-15 exprimierenden Tumoren, welche in vivo beobachtet 
werden konnten. Mäuse, denen (auf shRNA basierende) GDF-15-defiziente Gliomzellen 
appliziert wurden, zeigten im Vergleich zur Kontrollgruppe, welche GDF-15-exprimierenden 
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Gliomzellen erhalten hatte, ein verlängertes Überleben, vermindertes Tumorwachstum und 
eine erhöhte Immunzellinfiltration in das Tumormikromillieu. GDF-15 ist ein lösliches 
Protein, das von mehr als 50 % aller soliden Tumore sezerniert wird und mit dem Grad der 
Malignität korreliert. Daher wurde postuliert, dass ein neutralisierender monoklonaler 
Antikörper gegen GDF-15 eine effektive neue Antikrebstherapie ermöglichen sollte. Solch ein 
Antikörper wurde entsprechend in GDF-15-defizienten Mäusen generiert. Unter 
verschiedenen Klonen wurde der Antikörper Klon B1-23 identifiziert, welcher  sowohl im 
Western Blot als auch im ELISA anwendbar ist. Dieser Klon detektiert ein drei-dimensionales 
Epitop des maturen GDF-15 Dimers mit hoher Affinität und Spezifität. Um den Antikörper 
für eine spätere Anwendung im Menschen humanisieren zu können, wurden die variablen 
Regionen des Klons B1-23 durch eine spezielle PCR Methode unter Verwendung 
degenerierter Primer und nachfolgender Klonierung in einen Sequenzierungsvektor 
identifiziert. Die hierdurch gewonnenen Sequenzen ermöglichten die Generierung von 
chimären und humanisierten Varianten von B1-23. Nach anschließender intensiver 
Charakterisierung konnte sowohl der ursprüngliche Maus-Antikörper B1-23 als auch der 
chimäre B1-23 Antikörper (ChimB1-23) und der humanisierte B1-23 Antikörper (H1L5) in 
einer Melanom Xenograft Studie in vivo getestet werden. Zwar ließ sich mit keinem der 
Antikörper eine signifikante Hemmung des Tumorwachstums beobachten. Als 
herausragendes Ergebnis zeigte sich allerdings, dass der durch GDF-15 induzierte 
Gewichtsverlust signifikant durch die Verabreichung der GDF-15 spezifischen Antikörper  
verhindert werden konnte, was die antagonisierende Funktionalität des entwickelten 
Immunglobulins bestätigte.    
 
Schlussfolgerung 
GDF-15 ist ein vielversprechendes Zielmolekül bei Krebserkrankungen, welches bei der 
Tumorprogression und Tumor-assoziierter Kachexie beteiligt ist. Es konnte ein monoklonaler 
Anti-GDF-15 Antikörper generiert werden, welcher zum einen molekularbiologisch zum 
Einsatz kam (z.B. Western Blot, ELISA, etc.) und zum anderen als antagonisierender 
Antikörper sowohl in vitro als auch in vivo Anwendung fand. Auch wenn B1-23 scheinbar 
keine Tumorwachstumshemmung durch die Depletion von GDF-15 in T Zell defizienten 
athymischen Mäusen zeigte, konnte derselbe Antikörper wie auch die abgeleiteten Varianten 
(chimärisiert und humanisiert) eindrücklich die Tumor assoziierte Kachexie im UACC-257 
Melanom Modell verhindern. Der ausgebliebene antitumorale Effekt in unserem Melanom 
Modell in Nacktmäusen lässt sich nur zum Teil durch eine fehlende sekundäre 
Immunkomponente, insbesondere das Fehlen zytotoxischer T Zellen, erklären, da es in einem 
 10 
 
Zusammenfassung 
ähnlichen Xenograft Melanom Modell, welches in Auftragsforschung (CRO) durchgeführt 
wurde, zu einer Reduktion des Tumorwachstums durch die Applikation von B1-23 kam. 
Diese Ergebnisse lassen vermuten, dass T Zellen unerlässlich für eine effektive antitumorale 
Antwort sind, eine Annahme, die durch die Ergebnisse des syngenen Gliom Maus-Modells 
unterstützt wird, in welchem es durch das Ausschalten von Tumor produziertem GDF-15 zu 
einer erhöhten intratumoralen T Zell Infiltration und einem längeren Überleben kam.  
Zusammengenommen erlauben uns diese Daten den Schluss, dass eine tumorbedingte 
Kachexie durch den GDF-15-Antikörper B1-23 bekämpft werden kann. Allerdings sind 
direkte B1-23 vermittelte antitumorale Effekte eher in immunkompetenten Modellen mit T 
Zellen als in einem athymischen, T Zell defizienten Nacktmaus-Modell zu erwarten. 
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Abstract 
Background 
GDF-15 is a divergent member of the TGF- superfamily, which was first described as 
macrophage inhibitory cytokine-1 (MIC-1), revealing an immune modulatory function. GDF-
15 is a soluble protein which is, under physiological conditions, highly expressed in the 
placenta and found in elevated levels in blood sera of pregnant women. Apart from the 
placenta, GDF-15 is expressed in healthy tissue, albeit to a lower extent and overexpressed in 
many solid tumors. A variety of different functions are attributed to GDF-15 in healthy as 
well as diseased humans. On the one hand, GDF-15 is required for successful pregnancy and 
low GDF-15 serum levels during pregnancy correlate with fetal abortion. On the other hand, 
overexpression of GDF-15, which can be observed in several malignancies is correlated with 
a poor prognosis. Furthermore, tumor derived GDF-15 leads to cancer associated anorexia-
cachexia syndrome in mice. The aim of my PhD thesis was to further investigate the role of 
GDF-15 as an immune modulatory factor in cancer, in particular, by inhibiting the target 
molecule in vitro and in vivo. Therefore, the main focus was placed on the generation and 
characterization of monoclonal GDF-15 specific blocking antibodies, which were tested in 
vitro and in vivo, which represents a substantial part of my work.  
 
Results 
Here, GDF-15 was shown to be highly expressed in human gynecological cancer and brain 
tumors. We could then demonstrate that GDF-15 modulates effector immune cells in vitro. 
GDF-15 mediated a slight downregulation of the activating NKG2D receptor on NK and 
CD8
+
 T cells, which is crucial for proper anti-tumoral immune responses. Furthermore, we 
could demonstrate that GDF-15 reduces the adhesion of CD4
+
 and CD8
+
 T cells on 
endothelial cells in vitro. A negatively affected trans-endothelial migration of leukocytes into 
inflamed tissue could explain the low T cell infiltration in GDF-15 expressing tumors, which 
were observed in vivo, where mice bearing (shRNA mediated) GDF-15 deficient glioma cells 
revealed enhanced immune cell infiltrates in the tumor microenvironment, compared with the 
GDF-15 expressing control group. Those animals further exhibited a decreased tumor growth 
and prolonged survival. GDF-15 is a soluble protein, secreted by more than 50 % of solid 
tumors and associated with grade of malignancy. Therefore a neutralizing monoclonal 
antibody to GDF-15 was assumed to be an auspicious therapeutically anti-cancer tool. Such 
an antibody was thus generated in GDF-15 knock out mice against human GFD-15. Amongst 
many clones, the GDF-15 antibody clone B1-23 was found to be applicable in Western Blot 
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as well as in ELISA techniques, detecting a three-dimensional epitope of the mature GDF-15 
dimer with high affinity and specificity. To enable the humanization for a later administration 
in humans, the variable regions of antibody B1-23 were identified by a special PCR method 
using degenerate primers and cloned into a sequencing vector. The sequence obtained thereby 
enabled the generation of chimeric and humanized B1-23 variants. After further 
comprehensive characterization, the original mouse antibody B1-23 as well as the chimeric 
antibody (ChimB1-23) and the humanized B1-23 antibody (H1L5) were applied in a 
melanoma xenograft study in vivo. None of the antibodies could significantly inhibit tumor 
growth. .However of utmost importance, body weight loss mediated by tumor derived GDF-
15 could be significantly prevented upon administration of all three GDF-15 specific 
antibodies, which confirmed the antagonizing functionality of the immunoglobulin.  
 
Conclusion 
GDF-15 is a promising cancer target, involved in tumor progression and cancer related 
cachexia. A monoclonal GDF-15 antibody was generated, which served on one hand as a tool 
for molecular biological applications (Western Blot, ELISA, etc.) and on the other hand was 
applied as an antagonizing antibody in vitro and in vivo. Even though tumor growth inhibition 
by GDF-15 depletion in T cell deficient athymic mice failed using B1-23, the same antibody 
and derivates thereof (chimeric and humanized) impressively prevented tumor associated 
cachexia in UACC-257 melanoma bearing nude mice. The missing anti-tumor effect in our 
own melanoma model in nude mice can only partially be explained by the missing secondary 
immunity, in particular cytotoxic T cells, in the athymic animals, since in a similar melanoma 
model, performed by an external company, a tumor reduction in immunocompromised 
animals was observed, when B1-23 was administered. These findings support the idea that T 
cells are substantial for an effective tumor immunity and are in line with the results of the 
syngeneic, T cell comprising, mouse glioma model, where silencing of tumor expressed GDF-
15 led to an enhanced intratumoral T cell infiltration and a prolonged survival.  
Taken together our data allow for the conclusion that tumor associated cachexia can be 
combatted with the GDF-15 antibody B1-23. Further, B1-23 might elicit direct anti-tumor 
effects in immune competent models, which contain T cells, rather than in an athymic, T cell 
deficient nude mouse model.   
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1 Introduction 
1.1 Cancer 
Cancer is a multifactorial disease, which is – since 2012 – the leading cause of morbidity and  
mortality worldwide (Benjamin Anderson, 2011). The international agency for research on 
cancer (IARC) reported about 14 million new cancer incidences and more than 8 million 
deaths in 2012. Amongst men, cancer of lung, prostate, colon, stomach, and liver was most 
frequently diagnosed in 2012, whereas the most frequent tumor types of women were breast, 
colon, lung, cervix, and stomach cancer. The IARC expects an increase in cancer incidences 
from 14 million in the year 2012 to 22 million in the next 20 years. Thus, there is an 
enormous medical and social need to develop new therapeutics in order to fight cancer. Due 
to the various types of cancer, drug development requires comprehensive knowledge about 
the individual malignancy to be treated. In this respect, the following questions must be 
addressed: How do individual cancers develop? Which genetic alterations occurred? Which 
tumor targets are expressed and could they serve as target structures for the development of a 
therapeutic drug?  
 
1.1.1 Development of Cancer 
Tumors can basically develop in any human tissues or organs. In principle, tumors are the 
result of a number of accumulating genetic mutations, which lead to the transformation of a 
normal cell into a malignant cell (see next section) (Finlay, 1993, Vogelstein and Kinzler, 
1993, Lodish H, 2000). Such genomic alterations are triggered by (1) environmental factors, 
(2) endogenous factors as well as (3) inherited aberrations (Devereux et al., 1999, De Bont 
and van Larebeke, 2004). 
Exogenous influences are for example ultraviolet light, carcinogenic chemicals or radiation. 
Ultraviolet light can cause DNA damage in melanocytes and keratinocytes of the human skin 
due to ´non-repairable´ changes in the DNA (Luther et al., 2000, Hussein, 2005, Boniol et al., 
2012, Elsamadicy et al., 2015). Chemicals, as for example carcinogens in tobacco smoke, can 
cause mutations or cell damage in the human lung (Hecht, 1999). Furthermore, ionizing 
radiation, as for example from radioactive substances (-radiation) and x-rays, can lead to 
genomic instability, thereby causing somatic changes followed by cellular transformation 
(Rothkamm and Löbrich, 2003, Hall and Brenner, 2008, Vogiannis and Nikolopoulos, 2014). 
In addition, oncoviruses can cause genetic aberrations. A common example is the 
development of cervical cancer induced by human papilloma virus (Burd, 2003).  
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However, genomic DNA mutations can also occur without environmental influence, as for 
instance sporadic mutations or inherited genomic mutations (Kastrinos and Syngal, 2011). 
Mistakes during cellular replication, e.g. errors in proof reading, can cause damage ranging 
from point mutations to chromosomal aberrations, with risk of ending in cancer (Bernstein et 
al., 2013). All of these factors leading to the transformation of normal cells into cancer cells 
have in common, that somatic mutations have occurred in the genome of the respective cell. 
Analysis of cancer cell genomes identified a variety of such somatic mutations ending inter 
alia in constitutively activated signaling pathways (Vogelstein and Kinzler, 2004). Depending 
on the genomic location, a somatic mutation can result in loss-of-function mutations, 
impairing tumor suppressor genes (e.g. PTEN, p53, RB) and in gain-of-function mutations 
affecting oncogenes (e.g. KRAS, BRAF, FES) (Vogelstein and Kinzler, 2004). As indicated 
by the name, tumor suppressors protect cells from uncontrolled mitotic divisions (Cooper, 
2000) (figure 1-1). In contrast, mutated oncogenes typically affect components of signaling 
pathways such as growth factors and growth factor receptors. Thereby they constitutively 
activate pathways, which drive cells continuously into cellular divisions, ending in an 
uncontrolled tumor growth (Vogelstein and Kinzler, 2004). For example, Davies and Samuels 
reported, that 42 % of melanoma cells display activating mutations, structurally affecting the 
B-RAF protein, leading to constitutive MAP Kinase signaling pathway via RAF (Davies and 
Samuels, 2010). Interestingly, two-thirds of adult cancers develop because of random 
mutations, compared to one-third of cancers induced by environmental factors or inherited, an 
event that Tomasetti and Vogelstein simply termed “bad luck” (Tomasetti and Vogelstein, 
2015). 
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Figure 1-1 Development of tumor cells by somatic mutations  
The illustration represents the sequence from normal cells towards tumor cells. Once a cell has acquired 
mutations, which might be introduced by either radiation, chemicals, failure of the cellular DNA repair system or 
even sporadic mutations, the transformed cell may proliferate in an uncontrolled manner, thereby promoting 
tumor growth (adapted from National Cancer Institute).         
 
 
1.1.2 Tumor Progression and Metastasis 
Many years decay, until cancer results in a clinically manifested disease (Fearon and 
Vogelstein, 1990). The reason is that –as mentioned in 1.1.1 - a series of mutations have to 
accumulate over a certain period of time in order to transform a pre-malignant cell into a 
tumor (Vogelstein and Kinzler, 1993). When either a suppressor gene or an oncogene 
mutation is acquired, transformed cells can be ´forced´ to continuously proliferate, thereby 
either forming a benign neoplasia or a malignant tumor (Gatenby and Gillies, 2004). The 
difference between these two forms of tumors is the local restriction of benign tumor cells at 
the site of the origin organ or tissue, whereas malignant tumors do not remain at their site of 
origin (Alberts B., 2002). The latter ones are further characterized by high proliferation rates, 
invasive behavior, promoting angiogenesis as well as their ability to migrate and disseminate 
into the blood stream (Baba AI., 2007, Alberts B., 2002). Adorno and colleagues reported that 
mutations in the tumor suppressor gene p53 promote cellular migration and invasion (Adorno 
et al., 2009). Furthermore, mutations in the proto-oncogene KRAS are correlated with lung 
metastasis in colorectal cancers (Pereira et al., 2015). Once a tumor achieved such a fate, 
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cancer cells can subsequently form tumors remote of its primary site of development, 
frequently leading to failure of secondary organs (Alberts B., 2002). Such progressively 
growing tumors need to establish their own microenvironment, comprising of host stromal 
cells (e.g. fibroblasts), vasculature, lymphatic vessels and tumor cells (Descot and Oskarsson, 
2013, Tarin, 2013). Interestingly, many immune cells are found in the microenvironment of 
solid tumors, which can be either beneficial or destructive for certain cancers and will be 
further discussed in the next sections (Shiao et al., 2011). 
 
1.1.3 Elimination of Cancer Cells by the Immune System 
One of its most important functions of the immune system is to prevent tumor formation at an 
early stage (Diefenbach and Raulet, 2002). Therefore, certain immune cell subsets play a 
crucial role in the eradication of transformed cells. In the human body, especially two types of 
immune cells are equipped in identifying and eliminating transformed cells and thus prevent 
the outgrowth of a tumor: the natural killer cells (NK cells) and cytotoxic T cells (CTLs) 
(Alderton and Bordon, 2012).  
 
1.1.3.1 Natural killer Cells 
Natural killer cells (NK cells) are part of the innate immunity. These immune cells are able to 
eradicate transformed cells such as virus infected cells or tumor cells independently of MHC-
class I presented peptides (Cerwenka and Lanier, 2001, Waldhauer and Steinle, 2008) (further 
explained in 1.1.3.2). In order to discriminate between transformed cells and healthy cells, 
NK cells express two types of receptors: Inhibitory receptors and activating NK cell receptors 
(Ravetch and Lanier, 2000, Waldhauer and Steinle, 2008). Both receptor types can interact 
with ligands which are expressed on the surface of tumor cells, viral infected cells or host 
cells. Inhibitory receptors, comprising killer inhibitory receptors (KIR), immunoglobulin-like 
transcripts (ILT) and CD94/NKG2A, recognize MHC-I class molecules, which are highly 
expressed on most healthy cells and absent on several transformed cells (Alderson and 
Sondel, 2011, Pegram et al., 2011). Hence, NK cell activation can be described as “missing-
self” recognition (Raulet and Vance, 2006). Activating receptors as for example NKG2D, 
DNAM-1, NKp46, NKp30 recognize their according ligand on tumor cells: NKG2D ligands 
are MIC-A, MIC-B, ULBP1-4 (Bahram et al., 1994, Cosman et al., 2001). DNAM-1 ligands 
are known as CD112 and CD155 (Pende et al., 2005). The NKp46 ligand activates its 
respective NKp46 receptor, whereas tumor cell expressed B7-H6 ligates the NKp30 receptor 
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(Lanier, 1998, Bottino C, 2005, Abul K. Abbas, 2007). Upon target cell ligation, NK cells 
integrate the inhibiting and activating signals, which can be elicited simultaneously, and 
decide to kill or not to kill the target cell, depending on whether NK cell activation exceeds 
inhibition. When an NK cell is finally activated through e.g. the NKG2D receptor, the cell 
releases perforin and granzymes, molecules stored in lytic granula (Smyth and Trapani, 2001). 
Perforin molecules assemble and form a pore in the target cell membrane, which allows 
granzymes to diffuse into the cell (Young et al., 1986, Browne et al., 1999). Subsequently, 
granzymes activate pathways in the target cell inducing apoptosis, thus leading to an early 
eradication of transformed cells (Chowdhury and Lieberman, 2008, van Domselaar et al., 
2012). Another mechanism of target cell killing is FAS ligand mediated cytotoxicity 
(Screpanti et al., 2005). Tumors expressing FAS receptor undergo apoptosis upon ligation by 
either FAS-L or TRAIL (tumor necrosis factor related apoptosis inducing ligand) (Pahl and 
Cerwenka, Chua et al., 2004, Smyth et al., 2005). A further potent anti- tumor function of NK 
cells is the antibody dependent cellular cytotoxicity (ADCC), which is mediated via the Fc- 
-receptor (CD16) expressed on NK cells (Bakema and van Egmond, 2014). The Fc region of 
an antibody can trigger the activation of Fc--receptors, when tumor cells are coated with an 
immunoglobulin (Nimmerjahn et al., 2015). 
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Figure 1-2  Tumor immunity of NK cells 
Target cell killing is dependent on the expression and activation of NK cell receptors and target cell surface 
ligands. (a) tolerance towards a healthy cell is mediated by self-peptide presentation on MHC-I class molecules 
expressed on healthy cell, “activating” inhibitory receptors on NK cells ; (b) NK cells become activated when 
MHC-class I molecules are missing on a target cell; (c) NK cell is activated, when stress induced ligands like 
NKG2D ligands or DNAM-1 ligands are present on target cells, which in turn will be eliminated (adapted from 
Vivier et al., 2012, Nature Reviews Immunology,(Vivier et al., 2012) non-exclusive license received from NPG). 
 
 
1.1.3.2 Cytotoxic T Lymphocytes 
CD8
+
 T lymphocytes belong to the adaptive immune system. Unlike NK cells, CD8
+
 T cells 
need to be specifically activated to differentiate into cytotoxic T lymphocytes (CTLs; see 
figure 1-3). Each T cell has a unique T cell receptor (TCR) recognizing exclusively MHC-
presented peptides, at least in healthy humans (Abul K. Abbas, 2007). Usually, T cells are 
able to differentiate between MHC presented self- and non-self-peptides (Abul K. Abbas, 
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2007). During early developmental stages in the thymus the TCR repertoire is established by a 
process called clonal deletion (Goldrath AW, 1999). This process eliminates T cells, which 
recognize self-peptides, and thus protects healthy tissue of the body from T cell attack, 
thereby avoiding later autoimmune diseases (Palmer, 2003). Such a mechanism leads to 
central immune tolerance (Abul K. Abbas, 2007, Coder et al., 2015). Genetic mutations, 
which lead to an altered amino acid sequence within the native protein upon a malignant 
transformation, predominantly occur after an individual’s T cell repertoire has already 
developed. In general, those tumor antigens are recognized by T cells as non-self-antigens, 
thereby initiating an anti-tumor response (Coulie et al., 2014). Prior to cytotoxic T cell killing, 
the T cell requires an activation mediated by antigen presenting cells (APC), a process, which 
occurs predominantly in draining lymph nodes (Robinson et al., 1999). Here, dendritic cells 
(DCs) cross-present tumor associated peptides via direct ligation of the MHC-I presented 
cancer antigen with the TCR (Palucka and Banchereau, 2012) (figure 1-3). In addition to the 
MHC-I-peptide-TCR interaction, proper T cell activation further requires costimulation, 
which is for example mediated by CD86-CD28 interaction (Boise et al., 2010).  
 
 
 
Figure 1-3 Activation of T cell by cross presentation of tumor antigens on APC                      
The graphic displays the activation of a naïve T cell (grey) by tumor antigen presenting dendritic cell (purple). 
The tumor associated antigen (orange)-MHC-class I complex binds the T cell receptor and initiates T cell 
activation and proliferation. In the second step, the activated T cell (green) recognizes tumor cells expressing the 
tumor associated antigen (loaded on MHC-I molecule) and eliminates the target cell. (adapted and modified from 
Angela Vasaturo et al. Front Immunol.2013)(Vasaturo et al., 2013)  
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It has to be mentioned, that the process of T cell activation described here is rather simplified. 
Once the T cell has been activated, the CTL leaves the lymph nodes and enters the circulation 
to migrate towards the tumor site (Bellone and Calcinotto, 2013, Oelkrug and Ramage, 2014). 
Here, the activated T cell recognizes cancer cells presenting the respective antigen and T cell 
receptor activation is triggered, followed by either FasL mediated killing or the release of 
perforin and granzymes (Smyth and Trapani, 2001) (figure 1-4). The latter effector 
mechanism resembles that of NK cells (see 1.1.3.1). After degranulation, target cells are 
driven into apoptosis and die (Stinchcombe et al., 2001). The CTL is then released and 
capable to eradicate the next target cell (Janeway CA Jr, 2001). 
 
 
Figure 1-4 Cytotoxic T cell killing of a tumor cell presenting a specific peptide tumor antigen on MHC-
class-I molecule 
Schematic illustrates typical sequence of cytotoxic T cell killing: activated T cell recognizes tumor antigen 
presented on MHC-class I molecule expressed on the target cell. TCR-MHC-I interaction plus costimulation 
triggers the release of granzyme A and B as well as perforin from the T cell.  Perforin enables the passage of 
granzymes into the tumor cell, which in turn induce apoptosis. After the target cell is lysed, the T cell leaves the 
destructed target cell, capable to kill further cancer cells.  
 
 
1.1.3.3 Leukocyte Recruitment 
Cytotoxic effector functions of NK cells and T lymphocytes against tumor cells require direct 
cell-cell contact between the immune cell (effector cell) and the tumor cell (target cell) 
(Weigelin and Friedl, 2010). Thus, successful cytotoxic tumor cell killing requires the 
infiltration of immune cells into the tumor microenvironment in order to attain cell mediated 
cytotoxicity. Leukocyte recruitment is initiated upon the activation of CTLs in the lymph 
nodes (see 1.1.3.2). Once activated, cytotoxic T cells enter the circulation and navigate to the 
site of the primary tumor, following a chemokine gradient released from the tumor 
microenvironment (Newton et al., 2009). At tumor site, a process is initiated, which leads to 
the migration of CTLs from the blood vessel into the tumor tissue (Ley et al., 2007). This 
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process can be subdivided into three phases: Rolling of leukocytes (Phase I), adhesion (Phase 
II) and subsequent transmigration (Phase III) (figure 1-5). Rolling of leukocytes requires the 
expression of selectins on the surface of endothelial cells (Kunkel EJ, 2002). Selectins slow 
down leukocytes in the blood vessels by interacting with the selectin ligand on immune cells 
(Ley, Laudanna et al., 2007). Furthermore, expression of integrin-ligand is essential to 
subsequently force leukocytes to arrest on the endothelium (Abul K. Abbas, 2007). This cell-
cell interaction is mediated by ligation to integrin on immune cells (Pindjakova and Griffin, 
2011). Both cell surface molecules can be induced by pro-inflammatory cytokines such as 
TNF-alpha, a factor which is often found in the microenvironment of tumors (Burke-Gaffney 
and Hellewell, 1996). In a third step leukocytes transmigrate through the endothelial cells 
reaching the tumor and stromal tissue. 
 
 
 
 
Figure 1-5 Rolling, adhesion and transmigration of leukocytes at the tumor site                       
The schematic illustrates the required steps of proper leukocyte recruitment to the site of inflammation (e.g. in 
certain tumor tissues), the rolling, the adhesion and transmigration through endothelial cells (adapted from 
Jana Pindjakova and Matthew D Griffin, Kidney International, non-exclusive license received from NPG) 
 
 
Today, several publications demonstrate the importance of proper immune cell infiltration 
(Chew et al., 2012, Fridman et al., 2012) and report a positive correlation between cytotoxic T 
cell infiltrates in the tumor and a good prognosis for the patient (Dahlin et al., 2011, Tumeh et 
al., 2014). Therefore, mechanisms which enforce the infiltration of CTL into the tumor are 
promising approaches to improve tumor therapy.  
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1.1.4 Immune Evasion 
Tumors are under permanent control of a body´s immune system. This circumstance had been 
firstly described by Burnet 1957 as immune-surveillance (Burnet, 1957). Cancer cells or 
transformed cells are eliminated once immune cells are capable to carry out their killing 
function as effector cells (see section 1.1.3). However, successful malignant tumors develop 
“strategies” to escape the control of the immune system by different mechanisms (Kim et al., 
2007, Prendergast, 2008).  
One immune escape strategy of the tumor is to mask itself by cleaving tumor antigens from 
the cell surface, a mechanism termed shedding (Law, 1991). Thereby, the tumor cell releases 
tumor antigens into the circulation, which contribute to immune tolerance (Höchst and Diehl, 
2012). Antigen binding without sufficient co-stimulation, as for example B7 – CD28 ligation, 
results in anergic T cells, which consequently tolerate the tumor cell (Guinan et al., 1994, 
Cuenca et al., 2003). Furthermore, tumor cells are capable to mediate the induction of 
regulatory T cells (Treg) e.g. by TGF- (Fu et al., 2004, Vignali et al., 2008). Regulatory T 
cells suppress the induction and proliferation of cytotoxic T cells, which in turn allows for 
enhanced outgrowth of a tumor (Lu and Finn, 2008). Furthermore, several tumors down 
regulate MHC-class-I molecules on their cell surface, thereby hiding tumor associated 
antigens from T cell recognition (Bubeník, 2003). However, NK cells are able to respond to 
low MHC-I class molecule expression on target cells (Waldhauer and Steinle, 2008). Tumors 
can bypass such NK cell recognition either by upregulating non-classical MHC molecules like 
HLA-G or by downregulating ligands of activating killing receptors, as for instance NKG2D 
of DNAM-1, on their cell surface (Rouas-Freiss et al., 2005, Waldhauer and Steinle, 2008). 
As described above proper effector-to-target-cell-contact is essential for an optimal anti-tumor 
response (Weigelin and Friedl, 2010). Several tumors express Fas ligand, which activates the 
Fas receptor expressed on T cells, thereby driving the CTL into cell death (Lu and Finn, 
2008). A further immune escape mechanism of tumors is the expression and secretion of 
immunosuppressive factors, such as soluble HLA-G, Il-10 and TGF- β (Wittke et al., 1999, 
Rouas-Freiss, Moreau et al., 2005, Thomas and Massagué, 2005). As an example, most solid 
tumors overexpress TGF-β (Teicher, 2007, Wrzesinski et al., 2007). These soluble factors are 
secreted into the blood stream and suppress effector immune cell functions at a distant site of 
the tumor. This is a very effective escape mechanism, which turns NK cells and cytotoxic T 
lymphocytes into tolerogenic cells, before they could reach the target cell. TGF- for instance 
leads to the downregulation of killing receptors on NK and CD8
+
 T cells (Crane et al., 2010). 
Interestingly, Thomas and Massagué could demonstrate, that the neutralization of TGF-β, by 
 23 
 
1 Introduction 
use of soluble TGF- type II receptors, restores the expression of perforin, granzyme A, 
granzmye B, and IFNγ in antigen-specific T cells in vivo (Thomas and Massagué, 2005). As a 
result, T cells regained their cytotoxic effector functions. A finding, which led to the 
conclusion, that tumor secreted soluble factors, especially those of the large TGF- family, 
can act as inducers of immunological tolerance, and thus represent an ideal target structure for 
therapeutic drugs (e.g. blocking antibodies). 
 
 
Figure 1-6 Mechanisms of tumor immune evasion              
(A) Tumors can eliminate T cells by Fas-L mediated Tcell killing, (B) Tolerization of effector T cells by 
secretion of immunosuppressive factors, (C) induction of regulatory T cells, subsequently repressing effector T 
cell functions, (D) insufficient immune cell infiltration, ignorance, I Tolerization via dendritic cell cross 
presentation (adapted from Markus Y. Mapara, and Megan Sykes JCO (Mapara and Sykes, 2004), non-exclusive 
license received from American Society of Clinical Oncology) 
 
 
In my thesis I focused on the soluble and tumor produced target molecule GDF-15, which is 
structurally related to TGF- and reported to be involved in immune tolerance, thus possibly 
contributing to tumor immune escape.  
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1.2 The TGF- Superfamily     
The TGF- superfamily comprises about 33 members known so far (figure 1-7). Proteins of 
this family regulate cellular functions including cellular growth, differentiation, adhesion, 
migration and apoptosis and are structurally related to each other (Santibanez et al., 2011). 
Typically, members of that family are dimeric proteins, which are synthesized and secreted as 
homodimeric precursor proteins (Kingsley, 1994). After processing of the precursor 
molecules, the mature proteins display a typical seven cysteine knot, a characteristic structure, 
which is conserved throughout the entire TGF- superfamily (Kingsley, 1994, Weiss and 
Attisano, 2013).  
This family of sequence- and structurally related molecules can be further subdivided into 
four major groups (Santibanez, Quintanilla et al., 2011) (figure 1-7). The TGF- group, 
consisting of TGF- 1,-2,-3, Activing/Inhibins, Mullerian IS (MIS) and the bone morphogenic 
proteins (BMPs). Most of these family members function as ligands, thereby inducing cellular 
responses (Wakefield and Hill, 2013). These ligand receptor interactions are mediated by 
heteromeric receptor complexes, comprising type I and type II serine/threonine receptors 
(Weiss and Attisano, 2013). In humans, type I and type II receptors are subdivided into seven 
receptors and five receptors, respectively (Weiss and Attisano, 2013).  
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Figure 1-7  The TGF- superfamily, major groups and members (adapted from Santibanez et al., Clinical 
Science, 2011) 
GDF-15, among further growth and differentiation factors, belongs to the group of bone morphogenic proteins 
(BMP). The TGF- superfamily further comprises the TGF-group, the activins/inhibins group and the 
Mullerian IS group. 
 
 
1.2.1 TGF-  
The transforming growth factor- (TGF- is a highly immunosuppressive cytokine in 
humans which and is involved in malignant cancer progression (Wahl et al., 1988, Massague, 
2008). There are three known isoforms denoted TGF- 1, TGF- 2, TGF- 3. Even though 
TGF- and its family members elicit different cellular responses, the signaling pathway was 
described as a linear path from activation of TGF- receptor II, followed by recruitment of 
TGF- receptor I and activation of SMAD proteins (Derynck and Zhang, 2003) (figure 1-8). 
The heterogeneous receptor ligand assembly causes a trans-phosphorylation of the 
cytoplasmic domains of the TGF--R-I by TGF--R-II and followed by the phosphorylation 
of R-SMAD protein (Derynck and Zhang, 2003). SMAD2 and SMAD3 proteins are 
phosphorylated once the canonical TGF- pathway is activated. The SMAD phosphorylation 
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leads to the trimeric complex formation with Smad4, which then translocates into the nucleus 
and initiates transcription of target genes (Derynck and Zhang, 2003). 
 
 
 
 
Figure 1-8 TGF- signaling pathway and its components 
This schematic depicts the canonical TGF beta signaling pathway. Upon ligand receptor complex formation R-
Smad are phosphorylated and complex with Smad4. The heterotrimeric complex functions as transcription factor 
after nuclear translocation, resulting in either activation or repression of target genes (Image source: Rik 
Derynck and Ying E. Zhang, Nature, October 2003; non-exclusive license received from NPG) 
 
 
1.2.2 TGF- and Cancer 
TGF- is one of the most cited molecules in a cancer context. The protein has been 
excessively investigated by tumor immunologists, such as Joan Massagué, who was able to 
elucidate the role of TGF- at certain stages of cancer development (Massague, 2008). TGF- 
was described as a tumor suppressive factor in the pre malignant state of cancer development. 
A fact, which is contradictory to later cancer stages, where TGF- promotes the outgrowth of 
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tumors (Massague, 2008). As one reason for the “switch” from anti- towards pro-tumorigenic 
function is the inactivation of components of the TGF- signaling pathway, as for example 
the TGF- receptors (Biswas et al., 2007, Massague, 2008). A further mechanism to bypass 
tumor suppression by TGF- is the selective decapitation of the tumor suppressive arm of the 
TGF- signaling pathway (Massague, 2008). Such a malfunction of the TGF- signaling 
pathway consequently leads to tumorigenesis. Once this stage has reached, TGF- contributes 
to tumor growth and invasion, helps the tumor to escape the immune system and promotes 
metastasis (Massague, 2008).  
With regard to tumor immune escape, TGF- was reported to diminish the expression of 
NKG2D receptors on both NK cell and CD8
+
 T cells, thereby affecting tumor-immune 
response (Friese et al., 2004). Importantly, Friese and colleagues could demonstrate that the 
NKG2D downregulation could be prevented, when the TGF- synthesis has been silenced, 
which further indicates that inhibition of this immunosuppressive factor might “reactivate” the 
immune system, opening a very attractive target mechanism to therapeutically overcome 
immune escape mechanisms (Arteaga, 2006). Here, soluble and secreted immunosuppressive 
proteins like TGF- and family members thereof offer valuable target structures for 
neutralization, for example with antibody.  
 
 
1.2.3 GDF-15    
The growth and differentiation factor 15 (GDF-15, also known as MIC-1, NAG-1, PTGF-, 
PDF and PLAB) was first described 1997 by Bootcov and colleagues as a divergent member 
of the TGF-β superfamily (Bootcov et al., 1997). At that time the function of GDF-15 had 
been reported as macrophage inhibitory cytokine, consequently named MIC-1. The group 
showed that MIC-1 inhibits the production of TNF-α by macrophages upon 
lipopolysaccharide stimulation, indicating that MIC-1/GDF-15 acts as an autocrine regulatory 
molecule in macrophages (Bootcov, Bauskin et al., 1997). The fact that GDF-15 received so 
many synonyms underlines its various biological involvements in physiological and 
pathological processes (Mimeault and Batra, 2010). However, until today, the biological 
function of GDF-15 regarding its mechanism of action is still not fully unravelled. The 
missing puzzle for understanding the broad spectrum of GDF-15 mediated effects – reported 
in the literature- might be the GDF-15 receptor, which is still unknown. 
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1.2.3.1 GDF-15 - Structure and Biochemistry 
Like TGF- 1, the human GDF-15 gene is located on chromosome 19 (region p13.1-123.2), 
consisting of a nucleotide length of 2746 bps. Similar to other members of the TGF-β 
superfamily, GDF-15 protein sequence comprises a signal peptide encoding 29 amino acids 
(AA), a pro-peptide (167 AA) and a mature-peptide (112 AA) (Bootcov, Bauskin et al., 1997) 
(figure 1-9). GDF-15 is translated into a monomeric full length precursor protein of 308 
amino acids, which dimerizes via a disulfide bond, located within the mature region, into a 
full length protein in the endoplasmic reticulum (Bauskin et al., 2000). This precursor protein 
is either rapidly secreted - a process occurring in the trans Golgi network - or further 
processed by proteolytic cleavage via a furin-like protease at position 196, resulting in N-
terminal monomeric pro-peptides and homodimeric C-terminal mature protein (Bauskin et al., 
2010) (figure 1-10). Because of these alternate secretory pathways, described by Bauskin and 
colleagues, supernatants of GDF-15 expressing cells contain various forms of GDF-15, 
including the pro-peptide and mature GDF-15 dimer (figure 1-10 a, b) as well as the 
dimerized full length precursor protein (Bauskin, Jiang et al., 2010). 
 
 
 
 
Figure 1-9: Full length GDF-15 protein 
The GDF-15 protein comprises a signal peptide of 29 amino acid length, followed by a pro-peptide sequence 
with 165 amino acids and the mature GDF-15 peptide sequence of 114 amino acids. The pro-peptide contains an 
N-glycosylation site at amino acid position 70.  
 
 
Bauskin and colleagues could show that the proform of GDF-15 is capable to bind 
extracellular structures and thereby building up stromal stores of GDF-15 including the 
uncleaved mature GDF-15 dimer (Bauskin et al., 2006, Bauskin, Jiang et al., 2010).   
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Figure 1-10 Processed forms of GDF-15 protein 
The full length protein of GDF-15 is cleaved by a furin like convertase into the monomeric proforms of GDF-15 
(a) and the mature dimer (b). The mature GDF-15 monomer dimerizes into a 25kDa GDF-15 dimer.     
 
 
 
The diversity of GDF-15 and its various forms, which can be found in supernatants of tumor 
cells, is depicted in figure 1-11. 
 
 
 
 
 
 
 
Figure 1-11 Schematic of GDF-15 forms expressed by tumor cells 
In tumor cell supernatants the following forms are predominantly detected: the mature GDF-15 dimer, the pro-
peptide containing GDF-15 hemi dimer, the full length homo dimeric GDF-15 form as well as the singular 
propeptide. It has to be mentioned that the mature monomer is seen to a far lesser extent in supernatants than all 
other forms. Possibly the mature monomer appears due to a disintegration of the GDF-15 dimer during a 
Western Blot procedure.   
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1.2.3.2 Expression of GDF-15 
Under physiological conditions GDF-15 is mainly expressed in high levels in the placenta, 
which explains its synonyms “placental bone morphogenic protein” or “placental TGF-” 
(pBMP / PLAB; PTGF-) (Hromas et al., 1997). By implication, high GDF-15 serum levels 
can be detected in pregnant woman (Moore et al., 2000, Tong et al., 2004). Compared to the 
high expression in the human placenta, GDF-15 can be found to lower extent in the liver, the 
kidney, the prostate, the lung and gastrointestinal tract (Mimeault and Batra, 2010). Further, 
Strelau and colleagues reported that GDF-15 is expressed in the central as well as peripheral 
nervous system in humans (Strelau et al., 2000). In mice, GDF-15 is reported to be expressed 
in and secreted by Schwann cells (Strelau et al., 2009).   
Under pathological conditions the GDF-15 expression profile changes dramatically. GDF-15 
protein level immediately increases in patients suffering from a myocardial ischemia (Kempf 
et al., 2011). Furthermore, GDF-15 serum levels are elevated when nonsteroidal anti-
inflammatory drugs (NSAIDs) are consumed, the reason why GDF-15 is found in the 
literature as nonsteroidal anti-inflammatory drug-activated gene-1 (NAG-1) (Baek et al., 
2001). 
Last but not least, GDF-15 is found to be overexpressed in a variety of different cancers (table 
1). The relevance of the GDF-15 expression in oncological indications will be described in 
detail in section 1.2.3.4. 
 
Solid Cancer Hematologic Cancer 
 
Breast Cancer (Kim et al., 2008) 
Prostate (Brown et al., 2009) 
Ovarian Carcinoma (Staff et al., 2010, Staff et al., 2011) 
Colorectal Carcinoma (Baek et al., 2009) (Brown et al., 
2003) 
Gastric Cancer (Lee et al., 2003) 
Oesophageal adenocarcinoma (Fisher et al., 2015) 
Oral squamous cell carcinoma (Zhang et al., 2009) 
Melanoma (Boyle et al., 2009, Huh et al., 2010) 
Pancreatic Cancer (Koopmann et al., 2004) 
Glioblastoma (Roth et al., 2010) 
 
Multiple Myeloma (Corre 
et al., 2012) 
 
               Table 1:  List of cancer types associated with elevated GDF-15 expression 
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1.2.3.3 GDF-15 and its Function 
A variety of different functions have been reported for GDF-15 in the last two decades. 
Initially the protein revealed an inhibitory effect on macrophages (see 1.2.2), thereby 
suppressing the inflammation through the inhibition of macrophage activation (Bootcov, 
Bauskin et al., 1997). 
GDF-15 plays an important role during pregnancy. When GDF-15 serum levels were below a 
certain amount in the early course of pregnancy, spontaneous abortion and preeclampsia was 
observed in retrospective analysis (Tong, Marjono et al., 2004). One might speculate that 
GDF-15 has an inhibiting effect on the immune system, which goes along with the 
suppressive effect of GDF-15 on human macrophages (Bootcov, Bauskin et al., 1997). 
Strelau and colleagues identified GDF-15 as a trophic and neuroprotective factor in the central 
nervous system in midbrain dopaminergic rat neurons (Strelau, Sullivan et al., 2000). Herein, 
GDF-15 was reported to normalize motor behavior and exerts a protective effect on 
dopaminergic neurons. Furthermore, GDF-15 was reported to promote survival of lesioned 
dopaminergic neurons (Strelau et al., 2003).  
Kempf and colleagues attributed GDF-15 a cardio protective function after a heart attack, 
permitting proper infarct healing (Kempf, Zarbock et al., 2011). The group demonstrated that, 
after a myocardiacal infarction, GDF-15 is rapidly released into circulation and lowers the 
adhesion of peripheral polymorphonuclear leukocytes (PMNs) in mice on the endothelium. 
As a result, leukocyte infiltration into the surrounding of the affected myocardium is reduced. 
The scientists concluded that GDF-15 functions as a protective factor, which prevents the 
heart from cardiac rupture due to massively infiltrating lymphocytes into the ischemic tissue 
(Kempf, Zarbock et al., 2011).  
Recently, GDF-15 was additionally reported as a nuclear factor, modulating the 
transcriptional regulation of the Smad pathway (Min et al., 2015). The group around Min 
proposed that cytoplasmic GDF-15 is imported into the nucleus and interrupts the DNA-
binding capacity of Smad proteins, thereby repressing Smad signaling. However, this finding 
is somewhat contradictory to the activation of the TGF--receptor in hypothalamic neurons 
mediated by GDF-15 (Johnen et al., 2007).   
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1.2.3.4 GDF-15 in Cancer  
As described in 1.2.3.2 GDF-15 is overexpressed in many solid cancers. Hence, the question 
arises, why tumors upregulate GDF-15 expression and which advantage do they have? 
Even though many publications allocate GDF-15 to certain malignancies, one has to 
differentiate between a plain correlation and a functional relevance.  
A lot of opposing effects of GDF-15 are reported in the context of cancer, reviewed in detail 
by Mimeault and Batra (Mimeault and Batra, 2010). Several publications link GDF-15 with 
pro-apoptotic effects on cancer cells (Baek, Kim et al., 2001, Kadara et al., 2006). Others 
associate GDF-15 with pro-tumorigenic effects (Mimeault and Batra, 2010).  
Regarding the pro-apoptotic and anti-tumorigenic effects, GDF-15 was shown to mediate cell 
morphological changes, thereby leading to apoptosis in prostate cancer cell lines in vitro (Liu 
et al., 2003). However, the effect of apoptosis was speculated to be a secondary effect, owed 
to the detachment of cells. Overexpression of GDF-15 in colorectal cancer cells led to an 
increase in cell death and revealed a reduction in colony formation on soft agar plates, which 
led to the authors conclusion that GDF-15 is a tumor inhibiting molecule (Baek, Kim et al., 
2001). Kadara and colleagues could demonstrate that GDF-15 expression is induced in lung 
cancer cells as a response of treatment with apoptosis-inducing agents (e.g. retinoid related 
molecule RRM) (Kadara, Schroeder et al., 2006). However, the authors could also show that 
silencing GDF-15 did not affect the RRM induced apoptosis, concluding that GDF-15 is 
expendable (Kadara, Schroeder et al., 2006). 
Despite the reports on anti-tumorigenic effects of GDF-15, there is accumulating evidence 
that GDF-15 exerts pro-tumorigenic effects and rather negatively influences cancer patients 
than to benefit. Apart from GDF-15´s reported contribution to “all-cause mortality”, its 
overexpression in cancer correlates with poor prognosis in colon carcinoma, endometrial 
cancer and oral squamous cell carcinoma (Boyle, Pedley et al., 2009, Zhang, Yang et al., 
2009, Wiklund et al., 2010, Staff, Trovik et al., 2011). For example, Brown and co-worker 
demonstrated in a study, which included a large number of colorectal carcinoma patients, that 
elevated GDF-15 serum level at the time of diagnosis were associated with decreased overall 
survival (Brown, Ward et al., 2003). Staff and colleagues showed that high GDF-15 plasma 
levels correlate with poor prognosis in women suffering from endometrial cancer (Staff, 
Trovik et al., 2011). Similarly, Zhang et al could demonstrate a correlation between GDF-15 
expression on RNA level and the grade of malignancy in oral squamous cell carcinoma 
(Zhang, Yang et al., 2009).  
 33 
 
1 Introduction 
Elevated MIC-1/GDF-15 serum levels were reported to be frequently observed during the 
progression of a variety of aggressive cancers (Mimeault and Batra, 2010). In a glioma mouse 
model published by our group, GDF-15 contributed to tumor growth and immune escape 
(Roth, Junker et al., 2010). Downregulation of murine GDF-15 resulted in prolonged survival 
of glioma bearing mice, which might be explained by enhanced immune cell infiltration into 
the tumor microenvironment (Roth, Junker et al., 2010). Shnaper and colleagues reported that 
GDF-15 protein levels measured in cerebrospinal fluid correlates with poor prognosis in 
glioma patients (Shnaper et al., 2009).  
Interestingly, Husaini and colleagues reported that GDF-15 has a growth inhibitory effect on 
prostate cancer cells in vivo but increases metastasis in mice (Husaini et al., 2012). 
Surprisingly, a recent publication assigned GDF-15 pro-tumorigenic potential during early 
development of prostate carcinoma, while anti-tumorigenic effects are assumed once prostate 
carcinoma has established (Rybicki et al., 2015). 
Further evidence for its tumor promoting function was given by Lee and colleagues who 
demonstrated that GDF-15 takes part in the malignant progression of gastric cancer cells (Lee, 
Yang et al., 2003). Herein, migration assays were applied to show the GDF-15 mediated 
invasiveness of cancer cells upon activation of the MAPK signaling pathway (Lee, Yang et 
al., 2003).    
Boyle et al could show that GDF-15 protein expression was elevated in more than 65% of 53 
human melanoma cell lines, when compared to the expression of melanocytes (Boyle, Pedley 
et al., 2009). The group further observed strong GDF-15 expression in metastatic melanoma 
tissue, whereas GDF-15 expression in biopsies of primary melanoma was low. Furthermore, 
downregulation of GDF-15 in melanoma cells significantly lowered tumorigenicity (Boyle, 
Pedley et al., 2009). Moreover, Huh and co-workers could show that GDF-15 was able to 
promote angiogenesis in melanoma, leading to the conclusion, that GDF-15 stimulates the 
development of blood vessels in tumors, thereby increasing melanoma outgrowth (Huh, 
Chung et al., 2010). 
Regarding its dual function, GDF-15 may act similarly to what Massagué has elucidated for 
TGF-assague2008 in a pre-malignant cancer stage GDF-15 may act anti-tumorigenic, 
whereas tumor-promoting effects occur, once a progressive tumor stage has reached (Eling et 
al., 2006). Mimeault and Batra even state that GDF-15 “…displays anti-tumoral activities in 
the early stages of cancer development”, while it “…rather promotes the invasion and 
metastases of cancer cells at distant tissues in the late stages of cancer.” (Mimeault and 
Batra, 2010). 
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Summarizing the literature available so far, there is an obvious majority of reports assigning 
tumor promoting effects of GDF-15, thus turning this cytokine in a very attractive therapeutic 
cancer target, which could be neutralized and functionally inhibited. 
 
Interestingly, GDF-15 does not only exert direct effects on the tumors. There is increasing 
evidence that GDF-15 systemically influences patient´s health conditions by contributing to 
tumor associated “cancer anorexia-cachexia syndrome” (Johnen, Lin et al., 2007). Johnen and 
colleagues could impressively elucidate a biological function of GDF-15 in this context. They 
demonstrated, that tumor cell derived human GDF-15 causes anorexia by signalling on 
hypothalamic neurons in the central nervous system, thereby leading to tumor associated 
cachexia in a mouse model bearing human prostate cancer cells (Johnen, Lin et al., 2007). The 
protein is secreted by tumor cells into the blood stream, which could be shown by high GDF-
15 serum levels in the mice, which in turn correlated with the loss of appetite and decreased 
body weight (Johnen, Lin et al., 2007). Using GDF-15 specific antibodies, this pro-cachectic 
effect could be completely rescued. A fact, that offers a new chance for cancer therapy, which 
is highly attractive when having in mind that more than 20% of cancer patients die due to 
cachexia (Warren, 1932, Tisdale, 2002). Furthermore, Tisdale reported that up to 50% of 
cancer patients suffer from cachexia and – referring to Dewys and colleagues- cancer-
associated loss of weight is coherent with shortened survival of the cancer patient (Dewys et 
al., 1980, Tisdale, 2009). Referring to Inui, “progressive wasting is one of the most important 
factors leading to early death in cancer patients” (Inui, 1999).  
 
Taken together, GDF-15 is a versatile molecule overexpressed in many cancers and 
predominantly correlated with worse outcome for cancer patients. Thus, the scientific 
community has recognized GDF-15 as a cancer target, worth to develop therapeutics against 
(Boyle, Pedley et al., 2009, Huh, Chung et al., 2010, Mimeault and Batra, 2010).  
 
 
1.3 Treatment of Cancer with Targeted Therapy 
Today, cancer treatment comprises a variety of methods and technologies such as surgical 
resection, radiation therapy, chemotherapy, hormonal therapy, as well as targeted- and 
immunotherapy (Sudhakar, 2009). Targeted cancer therapy comprises drugs, which 
specifically bind and interfere with molecular targets, thereby inhibiting cancer growth and 
 35 
 
1 Introduction 
spread (Blay et al., 2005) . According to Oldham, “pioneers in monoclonal antibody research 
believed that a new era of cancer therapy had begun” in the early eighties, shortly after the 
first proof of principle with a monoclonal antibody could be demonstrated in humans (Nadler 
et al., 1980, Oldham and Dillman, 2008). At that time, targeted therapy came more and more 
in focus.  
 
1.3.1 Antibodies in the Clinic 
The importance of monoclonal antibodies as therapeutic agent for cancer treatment becomes 
more evident, when looking at the list of FDA approved cancer antibodies (Scott et al., 2012) 
(table 1). Far more antibodies are currently tested in clinical trials (Nelson et al., 2010). The 
advantages of monoclonal antibodies (biologicals) become clear, when looking at the variety 
of potential immunoglobulin derivates, which can be engineered and thus “customized” for its 
optimal effector function (e.g. antibody fragments, Fc engineered antibodies, toxin-conjugated 
antibodies, etc.) (Chames et al., 2009).  
 
International 
non proprietary 
name 
Trade 
name 
Target; Format Indication first 
approved or 
reviewed 
First EU 
approval 
year 
First US 
approval 
year 
Dinutuximab Unituxin GD2; Chimeric IgG1 Neuroblastoma EC decision 
pending  
2015 
Nivolumab Opdivo PD1; Human IgG4 Melanoma, non-small 
cell lung cancer 
EC decision 
pending  
2014 
Blinatumomab Blincyto CD19, CD3; Murine 
bispecific tandem scFv 
Acute lymphoblastic 
leukemia 
In review  2014 
Pembrolizumab Keytruda PD1; Humanized IgG4 Melanoma EC decision 
pending  
2014 
Ramucirumab Cyramza VEGFR2; Human IgG1 Gastric cancer 2014  2014 
Obinutuzumab Gazyva CD20; Humanized IgG1; 
Glycoengineered 
Chronic lymphocytic 
leukemia 
2014  2013 
Ado-
trastuzumab 
emtansine 
Kadcyla HER2; humanized IgG1; 
immunoconjugate 
Breast cancer 2013  2013 
Pertuzumab Perjeta HER2; humanized IgG1 Breast Cancer 2013  2012 
Brentuximab 
vedotin 
Adcetris CD30; Chimeric IgG1; 
immunoconjugate 
Hodgkin lymphoma 2012  2011 
Ipilimumab Yervoy CTLA-4; Human IgG1 Metastatic melanoma 2011  2011 
Ofatumumab Arzerra CD20; Human IgG1 Chronic lymphocytic 
leukemia 
2010  2009 
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Catumaxomab Removab EPCAM/CD3;Rat/mouse 
bispecific mAb 
Malignant ascites 2009  NA 
Panitumumab Vectibix EGFR; Human IgG2 Colorectal cancer 2007  2006 
Bevacizumab Avastin VEGF; Humanized IgG1 Colorectal cancer 2005  2004 
Cetuximab Erbitux EGFR; Chimeric IgG1 Colorectal cancer 2004  2004 
Tositumomab-
I131 
Bexxar CD20; Murine IgG2a Non-Hodgkin 
lymphoma 
NA  2003# 
Ibritumomab 
tiuxetan 
Zevalin CD20; Murine IgG1 Non-Hodgkin 
lymphoma 
2004  2002 
Gemtuzumab 
ozogamicin 
Mylotarg CD33; Humanized IgG4 Acute myeloid 
leukemia 
NA  2000# 
Trastuzumab Herceptin HER2; Humanized IgG1 Breast cancer 2000  1998 
Rituximab MabThera, 
Rituxan 
CD20; Chimeric IgG1 Non-Hodgkin 
lymphoma 
1998  1997 
 
Table 2 List of FDA approved monoclonal antibodies used for treatment of oncological indications 
#, Withdrawn or marketing discontinued for first approved indication  
NA, not approved;  Source: Janice M. Reichert, PhD, Reichert Biotechnology Consulting LLC; updated May 26, 
2015; Use of that table was kindly permitted by Janice Reichert.  
 
 
1.3.2 Antibody Structure 
Antibodies are proteins, consisting of four polypeptide chains: Two heavy and two light 
chains (Janeway CA Jr, 2001). The heavy chain polypeptide has a molecular weight of ~50 
kDa, whereas the light chain assesses 25 kDa (Janeway CA Jr, 2001). Antibodies are further 
subdivided in the variable and constant region. Within the variable region of each chain of an 
immunoglobulin (heavy and light) the complementarity determining regions (CDRs) are 
encoded (Al-Lazikani et al., 1997). Upon assembly of both light and heavy variable chains the 
functional antigen binding site (Fab; fragment of antigen binding) is formed (Abul K. Abbas, 
2007). Since these variable regions define the specificity of an immunoglobulin towards its 
target antigen, its individual antigen binding sequences are also named hypervariable regions 
(Abul K. Abbas, 2007). The constant region is found in the heavy as well as in the light chain 
of an antibody. Depending on the immunoglobulin isotype, the heavy chain comprises three 
constant region Ig domains (IgA, IgD, IgG), or four Ig domains (IgM, IgE) (Janeway CA Jr, 
2001). Typically antibodies contain an Fc part, which is part of the constant region of the 
heavy chain (Woof and Burton, 2004). This Fc part can interact with Fc-receptors on certain 
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immune cells (macrophages and NK cells), representing a further functional element of an 
antibody (Heyman, 1996, Bakema and van Egmond, 2014).     
 
 
 
 
 
Figure 1-12 Schematic of an antibody structure 
Immunoglobulin type IgG illustrates the typical structural and functional elements of antibodies. The heavy 
chain comprises three heavy chain constant regions (CH1, CH2, CH3; black/blue) and the heavy chain variable 
region (VH; gray/purple). The antigen binding site (Fab) is depicted in yellow. Fc part represents a region of the 
constant heavy chains The Fc region of the antibody heavy chain is linked to the Fab site by the hinge region of 
the immunoglobulin. 
 
 
1.3.3 Antibody Humanization    
Mouse antibodies revealed an enormous disadvantage when clinically applied in humans 
(Nelson, Dhimolea et al., 2010). Since murine immunoglobulins are very immunogenic, the 
generation of human anti mouse antibodies (HAMAs) occurs even after single dose 
administration of mouse antibodies, which can either elicit immune responses in patients or 
decreases its therapeutic efficacy (Dillman et al., 1986, Dillman et al., 1994, Kuus-Reichel et 
al., 1994, Baert et al., 2003, Oldham and Dillman, 2008). To circumvent this problem, either 
chimeric, humanized or fully human antibodies are developed prior therapeutic administration 
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(Nelson, Dhimolea et al., 2010). In order to create chimeric antibodies from murine 
antibodies, typically the DNA sequence of the murine Fab region, which contains the antigen 
binding site, in particular the CDRs, is joined to the DNA sequence of the constant region 
coding a human immunoglobulin backbone (Morrison et al., 1984). Subsequent transfection 
of such chimeric DNA constructs into a suitable cellular system results in the expression of 
the designed immunoglobulin (Morrison, Johnson et al., 1984). 
 
Humanized antibodies differ from chimeric ones, in that only the murine CDRs remain in the 
human immunoglobulin, which are - analogous to the above described method- genetically 
engineered, a procedure called CDR grafting (Kettleborough et al., 1991). Here, the murine 
framework regions (FR1-FR4) can be changed towards a more human sequence without loss 
of antigen binding, whereas the CDRs remain of murine origin (Harding et al., 2010) (figure 
1-13). This minimizes the immunogenicity and results in a longer applicability of the drug, 
compared to fully murine antibodies, where a HAMA response is rapidly expected (Klee, 
2000, An, 2008). The least immunogenic antibody form is a fully human antibody itself, 
which can be developed by either using transgenic mice containing the human 
immunoglobulin genes instead of the innate mouse Ig gene sequences or via phage display 
technology (An, 2008, Nelson, Dhimolea et al., 2010).    
 
 
 
 
Figure 1-13 Different forms of clinically applied antibodies 
Murine immunoglobulins: representing the most immunogenic type, when administered in patients. Chimeric 
antibody: containing the murine variable region of an antibody on a human Ig backbone. Humanized antibody: 
represents a human immunoglobulin with only murine CDRs. Fully human antibody: exceptionally human 
immunoglobulin sequences, resulting in lowest immunogenicity, when applied in human patients (e.g. 
Panitumumab, see table 2). 
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1.3.4 Mode of Actions of Antibodies 
Antibodies elicit a variety of different effector mechanisms, which are used clinically to fight 
certain cancer (Weiner, 2007). One of these mechanisms include antibody dependent cellular 
cytotoxicity (ADCC) (Alderson and Sondel, 2011). Monoclonal antibodies bound to the 
cancer cell surface, enhance the recruitment of Fc--receptor positive immune cells, thereby 
enabling a proper anti-tumor response (Weiner and Adams, 2000, Hudis, 2007). NK cells as 
well as macrophages recognize the Fc portion of an antibody via the Fc--receptor, which 
leads to the activation of the immune cell, triggering an anti-tumor response (Janeway CA Jr, 
2001). The FDA approved antibodies Rituximab (MabThera®) and Trastuzumab 
(Herceptin®) are examples for ADCC mediators. Rituximab targets the surface molecule 
CD20 on B cells, eradicating B cell lymphoma (Reff et al., 1994). Trastuzumab can be 
administered in patients with HER2 positive breast cancer (Hudis, 2007, Baselga, 2010). 
Beside further mechanisms of action described for Trastuzumab, ADCC serves as potent 
mechanism to eradicate cancer cells (Baselga, 2010, De et al., 2013).  
Furthermore, antibodies are able to induce complement mediated cytotoxicity (Courtois et al., 
2012). As an example Alemtuzumab, a FDA approved monoclonal antibody directed against 
CD52 expressed on B cell efficiently lyses lymphocytic leukemia B cells (B-CLL) by 
complement activation (Golay et al., 2004).   
A further therapeutic approach is the use of antibody drug conjugates (ADC). Such antibodies 
can be linked to certain payloads, for example toxins, and lead to cell death once the 
antibody-toxin conjugate has been internalized by the target cell (Leal et al., 2014). As an 
example Trastuzumab-Emtansine (T-DM1), which represents the anti-HER2/NEU antibody 
Trastuzumab, conjugated with the toxic derivative of maytansine (DM1) (LoRusso et al., 
2011). 
Several antibodies can be clinically used to prevent signal transduction in cancer cells (e.g. 
targeting EGFR signaling by Cetuximab and Panitumumab), leading to tumor growth 
inhibition (Marcucci et al., 2013). Such interfering antibodies may target surface receptors, 
co-receptors but also the ligands thereof (Marcucci, Bellone et al., 2013).   
Antibodies can also be used for neutralization of target molecules (Marcucci, Bellone et al., 
2013). The most prominent example of this antibody class is Bevacicumab (Avastin®), which 
neutralizes VEGF and thus inhibits neovascularization of tumor tissue (Ferrara et al., 2004). 
In particular immunosuppressive molecules like TGF- are optimal targets for an 
immunotherapy by “simply” antagonizing the soluble protein (Buijs et al., 2012). Although 
there is no FDA approved anti TGF- antibody so far, several approaches to block the TGF- 
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signaling are currently tested in clinical trials (Buijs, Stayrook et al., 2012). Until today, the 
results of a phase II clinical trial testing Fresolimumab (GC1008), a fully human monoclonal 
antibody, which targets and blocks all TGF- isoforms 1, -2, -3 for the treatment of Relapsed 
malignant pleural mesothelioma, were not published yet, despite finalization of the study in 
2010 (Buijs, Stayrook et al., 2012). 
 
1.4 The Aim of the Thesis 
 
GDF-15 seems to be a novel target for treating cancer. Development of a monoclonal 
antibody to GDF-15 seemed promising and was a relevant part of my PhD thesis. Based on 
the findings of our glioma model, in which silenced GDF-15 levels in tumor cells led to 
extended survival of animals, a systemic blocking of GDF-15 seemed to be a promising 
strategy to improve the outcome of tumor patients. Therefore, a monoclonal antibody which 
could block GDF-15 systemically, may act as an immunotherapeutic biological, reducing 
tumor growth, enhancing immune cell infiltration and improving cachexia syndrome at once. 
Accordingly, the goal of my thesis was to further characterize GDF-15 biology in the tumor 
context in vitro, to generate a highly specific blocking monoclonal antibody and to test that 
antibody after an extensive characterization in a xenograft mouse model. 
The results of my work resulted in a substantial grant (“GO-Bio”) from the federal ministry of 
education and research (BMBF; grant no: FKZ031A148). This granted project intended the 
establishment of a spin-off biotech company focusing on immunotherapeutic drug research 
and development, a project which is still ongoing and not further mentioned here. However, 
this affects the freedom to describe several details of this thesis due to patent issues. 
 
 
 
 
 
 
 
 
 
 41 
 
2 Material and Methods 
2 Material and Methods 
 
2.1 Material 
 
2.1.1 Devices 
 
Devices Manufacturer 
ABI TaqMan 7500 Applied    Biosystems,    Life    Technologies, 
Corporation,   Carlsbad,   California   92008,  
USA 
   
Agarose gel electrophoresis apparatus                 MupidexU, Eurogentec GmbH, Cologne,   
Germany 
  
Autoclave H P Labortechnik AG, 85764  
Oberschleißheim, Germany  
 
Balance     Sartorius AG, 37075 Goettingen, Germany   
 
Centrifuges 5810 R, 
5424 R 
Eppendorf, 22339 Hamburg, Germany 
   
Jouan C4i,  
Heraus Megafuge 16 
Thermo     Electron     GmbH,     63303  
Dreieich, Germany 
  
CO2 Incubator Thermo   Electron   GmbH,   63303   Dreieich,  
Germany  
 
Digital camera Canon, USA 
 
ELISA-Reader Sunrise TECAN, 74564 Crailsheim, German 
 
Flow cytometer FACS Calibur, Becton    Dickinson,    Franklin    
Lakes,    NJ 07417, USA 
 
Attune®, Focusing Cytometer, Thermo Fisher 
Scientific 
 
Freezers  (-20°C, -86°C) Liebherr, Germany ; Thermo Electron GmbH, 
63303 Dreieich, Germany  
Philipp   Kirsch   GmbH.   77608   Offenburg,  
Germany 
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Heat block Biometra    GmbH,    D-37079    Goettingen, 
Germany 
   
Laminar flow hood Heraeus, Hanau, Germany 
 
Luminometer Orion II Berthold Detection Systems, Germany    
 
Microscope (inverted) Leica, 35606 Solms, Germany 
 
Photometer Thermo   Electron   GmbH,   63303   Dreieich,  
Germany 
  
Power-Supply Thermo   Electron   GmbH,   63303   Dreieich, 
Germany 
 
SDS gel electrophoresis system Whatman, GE Healthcare, D-80807 Munich, 
Germany 
 
UV lamp Biometra   GmbH,      D-37079   Goettingen,   
Germany  
 
Water bath Julabo, 77960 Seelbach, Germany  
 
 
Thermocycler Biometra    GmbH,    D-37079    Goettingen,   
Germany  
 
Table 3  Instruments and devices 
 
 
2.1.2 Chemicals and reagents 
The chemicals and reagents used for my thesis were obtained from Sigma-Aldrich 
(Taufkirchen), Roth (Karlsruhe), Applichem (Darmstadt), Merck (Darmstadt), Roche, 
Calbiochem (Darmstadt) and Peqlab. 
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2.1.3 Material for Immnunohistochemistry 
Item Manufacturer/Provider 
Paraffin embedded human ovarian cancer 
tissues (block)  
Department of Obstetrics and 
GynecologyUniversity Hospital of Wuerzburg,  
Germany 
Paraffin embedded human glioblastoma 
tissue (block) 
Dpt. Of. Pathology,  
Goethe-University Frankfurt,  
Germany 
Xylol Sigma-Aldrich, Taufkirchen, Germany 
 
Ethanol 70%-100% (Sigma) 
 
PBS 1x 
(Phosphate buffered saline) 
PAA Laboratories,  
A-Pasching, Austria 
pH 7.4 
 
Tissue mount DABCO 25 ml PBS, 0.625 ml DABCO   
225 ml Glycerin 
 
Haemalum solution (Mayer’s 
haematoxylin) 
Roth,  
Karlsruhe, Germany 
VitroClud Langenbrinck,  
Emmendingen, gErmany 
DAKO Pen 
 
DAKO, Hamburg, Germany 
Antibody Diluent  
 
DAKO, Hamburg, Germany 
Citric acid  500ml aqua dest.,  
10mM citric acid  
pH6 
Dual Endogenous Enzyme Block DAKO (K4065) 
 
Labelled Polymer DAKO (K4065) 
 
Substrate buffer pH7.5, 
containing hydrogen peroxide, 
DAKO (K4065) 
 
DAB + Chromogen Solution 3,3’-diaminobenzidine chromogen solution 
DAKO (K4065) 
 
Anti-mouse-HRP-antibody 
(Used when detection was performed 
without DAKO K4065-polymer)  
 
Cell signaling (cat. # 7076)  
 
Anti-rabbit-HRP-antibody 
(Used when detection was performed 
without DAKO K4065-polymer) 
 
Cell signaling (cat. # 7074) 
 
Table 4 Material and reagents for immunohistochemical staining 
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2.1.4 Material for protein biochemistry 
Item Composition 
Electrophoresis  Running buffer 10x 25 mM Tris, 
193 mM Glycin,  
0,5% SDS  
pH 8,8 
 
Transfer buffer 1x 25 mM Tris,  
192 mM Glycin,  
20% Methanol 
 
Lysis buffer 50 mM Tris-HCl, pH 8,  
120 mM NaCl,  
5mM EDTA,  
0,5% NP-40,  
2 µg /ml Aprotinin,  
10µg /ml Leupeptin,  
100 µg /ml PMSF,  
50 mM NaF,  
200 µM NaVO5 
 
Lämmli-Loading buffer (modified from 
Lämmli UK., Nature 1970) 
100 mM Tris(hydroxymethyl)aminomethane-
HCl (pH6.8)  
10% 2-β-Mercapto-ethanol  
4% SDS  
20% Glycerin 
0.2% Bromophenol blue 
 
TBS 10 mM Tris-HCl,  
150 mM NaCl,  
pH 7,3 
 
TBS-T TBS,  
0,05% Tween20 
 
PBS (1x) 37 mM NaCl,  
2,7 mM KCl,  
80 mM Na2HPO4,  
1,8 M KH2PO4,  
pH 7,4 
 
Table 5 Buffers for SDS-PAGE 
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Buffer Composition 
Blocking buffer 5% skim milk powder in TBS-T 
 
ECL solution A  50 mg Luminol in 200 ml 0,1 M Tris-HCl  
pH 6,8 
 
ECL solution 1.1 mg/ml para-hydroxycoumaric acid in 
DMSO 
 
TS-TM-BSA 10mM Tris-HCL 
150mM NaCl 
5% skim milk powder 
0.1% Tween 20 
2% BSA 
0.1% NaN3 
 
Stripping buffer 0,2 M Glycin, 0,5 M NaCl, pH 2,8 
 
Neutralization buffer 1,5 M Tris Base 
pH 7.4 
 
Table 6 Buffers used for Western Blotting 
 
 
2.1.5 Material for molecular biology 
Buffers and Reagents Composition  
LB Agar 10 g/l Bacto-Pepton   
5 g/l yeast extract   
10 g/l NaCl   
pH 7.0 
 
LB medium (Luria Bertani) 10 g/l Bacto-Pepton   
5 g/l yeast extract     
10 g/l NaCl   
7,5 g/l select Agar  
pH 7,0 
 
Kanamycin 30 mg/ml  
in ddH2O 
diluted 1:1000 to final concentration 
Ampicillin 50 mg/ml  
in ddH2O 
diluted 1:1000 to final concentration 
 
Table 7 Reagents and chemicals for molecular biology 
 
 46 
 
2 Material and Methods 
2.1.6 Kits and kit contents 
Kit Manufacturer 
ADCC reporter Assay Promega  
 
iScript cDNA Synthesis Kit Biorad (methods section) 
 
ABsolute Blue QPCR SYBR Green low 
Rox mix 
Thermo Fischer 
E.Z.N.A tissue DNA kit Omega Biotek 
 
pJet Clone jet  Fermentas 
 
Proteus A antibody purification AbD Serotec  
 
Table 8 Overview of kits   
 
 
 
 
 
Kit  Manufacturer  
7X Lysis Buffer*1  
 
 
 
 
 
 
 
 
ZYMO RESEARCH 
 
„Zyppy™ Plasmid 
Miniprep Kit“ 
Neutralization  
 
Buffer*2 (Yellow)            
                                                                         
Endo-Wash Buffer      
        
Zyppy™ Wash Buffer (concentrate) 
 
Zyppy™ Elution Buffer  
 
Zymo-Spin™ Columns  
 
Collection Tubes 
 
Table 9:  Components of plasmid isolation and purification kit (ZYPPY) for mini preparations  
 
 
 
 
 
 
 
 47 
 
2 Material and Methods 
2.1.7 Reagents, buffers for methods to generate monoclonal antibodies 
Buffers, reagents and media for hybridoma generation and antibody production CELLline 
bioreactor 
 
Buffers and Reagents Composition / Provider 
Adjuvant-TiterMax® Gold Sigma Aldrich (T2684) 
 
Hanks Balanced Salt Solution Sigma Aldrich 
 
PEG Roche (54457-10G-F) 
 
HT Media Supplement (50x) 
 
Sigma Aldrich (H0137) 
HAT supplement (50x) in BSS 
 
Biochrom AG (# F0483; Lot.# 0743S) 
 
Ig stripped FCS Roche (54457-10G-F) 
 
Hybridoma Cloning Supplement 
 
PAA 
Table 10 Buffers and reagents for monoclonal antibody generation and production 
 
 
Buffer formulation for antibody purification (Proteus A kit): 
 
Buffers and Reagents Composition 
Binding buffer A (1.5 M Glycine / NaOH 
buffer, 3 M NaCl, pH 9.0) 
112.6 g glycine (free base; 75.07 g/mol),  
175.3 g NaCl (58.44 g/mol),  
1.0 g NaN3 * 
Up to 1000 ml with ddH2O, 
pH 9.0 (titrated with 5 M NaOH) 
 
Elution Buffer B2 (0.2 M Glycine/ HCl 
buffer pH 2.5) 
 
15.0 g glycine (free base 75.07 g/mol),  
1.0 g  NaN3 *  
to 1000 ml ddH2O 
pH 2.5 (titrated with 5 M HCl)  
 
Neutralization Buffer C (1 M Tris/HCl 
buffer pH 9.0) 
103.72 g Tris base (121.1 g/mol), 
22.72 g Tris hydrochloride (157.6 g/mol),  
1.0 g NaN3 *  
Up to1000 ml ddH2O 
pH 9.0 
 
Table 11 Buffers prepared for antibody purification with the proteus A kit. * NaN3 was not added, when 
antibody was either used for in vitro experiments on primary cells,  cell lines or for in vivo studies.  
 
 
 48 
 
2 Material and Methods 
2.1.8 Antibodies 
Antibody (Clone) Dilution Application Manufacturer 
B1-23 * WB/ELISA/in vivo Result of thesis 
ChimB1-23 * WB/ELISA/in vivo Result of thesis 
H1L5 * WB/ELISA/in vivo Result of thesis 
B12 * ELISA/in vivo Result of thesis 
Fab-(ChimB1-23) * WB/ELISA/in vivo Result of thesis 
GDF-15 (HPA 011191) 1:100 IHC/WB Sigma Aldrich 
pSMAD2/3 (#8828) 1:1000 WB Cell Signaling 
total SMAD2/3 (#3102) 1:1000 WB Cell Signaling 
Human GAPDH (EPR1977Y) 1:1000 WB Epitomics 
Human β Actin (ab8226) 1:10000 WB Abcam 
Mouse IgG (H+L)-HRP 
(# 7076) 
1:3000 WB Cell Signaling 
Rabbit IgG (H+L)-HRP           
(# 7074) 
1:3000 WB Cell Signaling 
polyclonal anti-human-HRP 
 
1:2000 WB Dako 
Human NKG2D-PE (BAT221) 1:100 FACS MiltenyiBiotec 
Human CD3-FITC (MEM-57) 1:50 FACS Immunotools 
Human CD3-PE (MEM-57) 1:100 FACS ImmunoTools 
Human CD4-FITC 1:100 FACS Immunotools 
Human CD8-PeCy5 1:100 FACS eBiosciences 
Human CD56- ACP (N901) 1:200 FACS Beckman Coulter 
IgG1 isotype PE (MOPC-21) 1:100 FACS BioLegend 
Table 12 Table of antibodies (* dilution depended on the application, see methods for applied 
concentrations)  
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2.1.9 Oligonucleotides 
Gene Application Primer Sequence (5´to 3´) 
GDF-15 
(mouse) 
- / -  primer 
(KO) 
PCR-1 
CCC AGT CTT GTA GAC AGA GCA A 
 
TCG CCT TCT TGA CGA GTT CT 
 
+ / + primer 
(WT) 
PCR-1 
ATG CGC ACC CAA GAG ACT 
 
GGC CAC CAG GTC ATC ATA AG 
 
GDF-15 
(mouse) 
- / -  primer 
(KO) 
PCR-2 
GCA GAG AGG CTG AGG AAC TT 
 
GTT CTT GTT GGT CAA AGT AAA CGA 
 
+ / + primer 
(WT) 
PCR-2 
TTG GGA AAA GGT TGG AGA GA 
 
GAT ACA GGT GGG GAC ACT CG 
 
GAPDH Realtime PCR 
CCA TCT TCC AGG AGC GAG ATC C 
ATG GTG GTG AAG ACG CCA GTG 
β-actin Realtime PCR 
TGT TTG AGA CCT TCA ACA CCC 
AGC ACT GTG TTG GCG TAC AG 
18S Realtime PCR 
CGG CTA CCA CAT CCA AGG AA  
GCT GGA ATT ACC GCG GCT  
pJET1.2 Sequencing 
CGA CTC ACT ATA GGG AGA GCG GC 
AAG AAC ATC GAT TTT CCA TGG CAG 
Table 13 List of primers used for genotyping of mice or for realtime PCR 
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2.1.10 Cell lines 
Cell line / primary cells Application (chapter) Provider 
UACC-257 (melanoma) In vitro experiments (3.4)  
In vivo study: Cachexia (3.5) 
 
NCI 
 
CHO Transient plasmid transfection 
/ production of antibodies (3.4) 
 
Dermatology 
 
HEK-293T Transient transfection/ 
expression of GDF-15 (3.4) 
 
Department of Obstetrics 
and Gynecology Wuerzburg 
 
P3-X63.Ag8 myeloma cell Generation of hybridoma for 
antibody production (3.4) 
Professor Dr. Thomas 
Hünig, Dpt.  
Immunobiology and 
Virology,  
University of Wuerzburg 
 
HUVEC cells In vitro experiments (3.2) 
  
 
Millipore 
 
MCF-7 In vitro experiments (3.2)  
 
Department of Obstetrics 
and Gynecology Wuerzburg 
 
PBMC In vitro experiments (3.2)  
 
Obtained from healthy 
blood donors or from the 
Department of Transfusion 
Medicine and 
Hemotherapy, University 
Hospital of Wuerzburg 
 
Table 14 Cell lines and primary cells used in vitro and in vivo  
 
2.1.11 Plasmids 
Vector Application Provider 
pcDNA3.1 Transient transfection / empty 
vector control  
Invitrogen 
 
pcDNA3.1-humanGDF-
15 (full-length) 
Transient transfection/ 
expression of human GDF-15 
Prof. Unsicker, Heidelberg 
pIRES2-eGFP Transient and stable 
transfection/ empty vector 
control 
Clonetech 
pIRES2-eGFP-GDF-15 
(full-length) 
Transient and stable 
transfection/ expression of 
human GDF-15 
Prof. Samuel N. Breit,  
St Vincent´s Hospital, Sydney 
pJet1.2 (Fermentas)  Cloning vector/ sequencing  Fermentas 
 
pEFh-variable-HC1-H1L5 
(evitria) 
Transient transfection/ 
expression of heavy chain 
Evitria AG 
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variable region of H1L5  
pEFh-variable-LC5-H1L5 
(evitria) 
Transient transfection/ 
expression of light chain 
variable region of H1L5  
Evitria AG 
Table 15 List of plasmids 
 
 
 
2.1.12 Reagents for FACS staining  
Reagent Provider 
FACS Clean Solution Becton Dickinson 
 
FACS Flow  Becton Dickinson 
 
FACS Rinse  Becton Dickinson 
 
FACS Buffer (PBS + 2% FCS) PBS (Sigma Aldrich) 
FCS (Sigma Aldrich) 
Beriglobin blocking solution Novartis 
Table 16 List of FACS staining reagents and buffers 
 
2.1.13 Cytokines 
Cytokine/Growth factor Source/ Expression System Manufacturer 
Human GDF-15 Eukaryotic  R&D-Systems 
 
Human GDF-15 Cell Culture Peprotech 
 
Human GDF-15 SF9 cell derived Professor Dr. Thomas Müller, 
University of Wuerzburg 
 
Human GDF-15 E.Coli derived Professor Dr. Thomas Müller, 
University of Wuerzburg 
 
Human GDF-15 E.Coli derived 
 
Pelobiotech 
Human GDF-15 HEK-293 cell derived Invigate 
 
Human GDF-15 HEK-293 crude supernatant Own preparation in this thesis 
 
Human TGF-β-1 E.Coli derived Peprotech 
 
Human TNF- E.Coli derived Peprotech 
 
Table 17 Human cytokines   
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2.1.14 Standard DNA and protein ladder 
As standard on DNA gels, the following DNA ladders were utilized:  
TrackIt™ 1 Kb Plus DNA Ladder (Invitrogen) 
TriDye™ 2-Log DNA Ladder (New England Biolabs) 
As molecular-weight size marker on RNA gels, the RiboRuler High Range RNA Ladder 
(Thermo Fischer) was applied.  
 
 
 
Figure 2-1 DNA and RNA ladders  
 
To determine the molecular weight of proteins on Western Blots Spectra™ Multicolor Broad 
Range Protein Ladder (Thermo Fischer) was loaded on sodium dodecylsulfate polyacrylamide 
gels for separation.  
                      
Figure 2-2 Protein ladder: Spectra™ Multicolor Broad Range Protein Ladder 
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2.2 Methods 
2.2.1 Immunohistochemical staining 
Immunohistochemichal staining of GDF-15 in solid tumors was performed on paraffin 
embedded tissue from patients with ovarian cancer and glioblastoma multiforme as published 
previously (Kammerer et al., 2011, Kammerer et al., 2015). Paraffin blocked ovarian cancer 
tissue was obtained from the Department of Obstetrics and Gynecology at the University 
Hospital Wuerzburg. Paraffin embedded glioma tissue sections (placed on cover slips) were 
provided by Professor Dr. Mittelbronn, University of Frankfurt. 
Sections of 2-4 µm were cut from cancer tissue blocks using a sliding microtom (Leica 
Histoslide SM200R instrument) and placed on cover slips (Superfrost, Langenbrinck). For 
simultaneous tissue processing, up to 16 cover slips were placed in one rack, enabling equal 
IHC-conditions and comparability. To remove paraffin from the tumor tissue, slides were 
placed in a 100% xylole bath twice for 10 minutes each. To attain access of antibodies to their 
target antigen, the tissue was rehydrated and antigen unmasking technique applied. Hereby, 
the slides were first rehydrated by stepwise washing in a series of decreasing ethanol 
concentration (diluted in destilled water; dH2O): 100 % (2x)  90 %  80 %  70 %. 
Finally, slides were washed with dH2O.  
For antigen retrieval, slide holder was placed in a dish filled with citric buffer (10 mM citric 
acid, 500 ml dH2O, pH 6.0) and microwaved at 600W/sec until boiling (10 min). After 
repeating the boiling step, slides were cooled for 20 minutes at room temperature in the 
retrival solution and subsequently carefully washed with dH20. Tissue peroxidases, mainly 
present in erythrocytes, leading to unspecific background signals were inactivated by 
incubation of the sections in hydroxyl peroxide solution (90 ml methanol, 10 ml PBS + 30% 
v/v H2O2) for 10 min at RT. Tissue slides were then washed five times with dH2O and 
incubated in PBS for five minutes. A lipohilic circle was drawn around  the tissue section on 
the glass slides using a fatty pen (DAKO Pen). Possible unspecific binding sites due to Fc 
receptors on tissue samples were blocked for 15 minutes with an immunoglobulin blocking 
solution (Beriglobin, 1:50 dilution in PBS; Centeon, Marburg), before primary antibody 
incubation was performed adding 75 µl anti GDF-15 polyclonal rabbit antibodies (Sigma, 
HPA 011191, 1:100 in antibody diluent) on the tissue sections and incubating slides in 
humide chambers at 4°C overnight. Slides were washed five times in 1x PBS prior to 
incubation with the secondary HRP linked anti-rabbit antibodies diluted 1:100 in antibody 
diluent for 30 minutes at room temperature. After stringent washing, tissue samples were 
counterstained in hemalaune solution (Carl Roth) for one minute, washed twice with dH2O 
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and subsequently repetitively washed using tab water for five minutes, to obtain the blue 
colour of nuclei. Tissues were then dehydrated following the reverse sequence of the above 
described ethanol concentration series, starting from 70% until 100% ethanol. Tissue samples 
were embedded in Vitroclud. 
 
2.2.2 Thawing of cells 
Frozen vials with cryoconserved cells cells were rapidly transferred (less than a minute) in 
from a liquid nitrogen tank (-196°C) to a water bath at 37°C. 1 ml of pre-warmed complete 
medium (RPMI-1640, 10% fetal calf serum, 5% penicillin/streptomycin, sodium pyruvate) 
was added to the cells, once they appeared to have thawed. Subsequently the resuspended 
cells were transferred into a 15 ml Falcon tube containing 10 ml complete RPMI-medium 
(prewarmed to 37°C). Cells were then centrifuged for 8 minutes at 1200 rpm. Supernatants 
were decanted and the resulting cell pellet was resuspended in 12 ml complete medium. 
Depending on the number of frozen cells in a cryopreservation vial, cells were seeded into a 
25cm
2
 or 75 cm
2 
sterile cell culture flask and cultured at 37°C / 5% CO2 in an incubator. 
  
2.2.3 Cryopreservation of cells 
For the generation of a working cell bank or long term storage of cell lines, cells were 
cryopreserved and deposited in a liquid nitrogen tank at -196°C. Therefore cell culture 
medium of adherent cells was aspirated and cells were washed with warm (37°C) PBS to 
remove medium and FCS. For the detachment of cells in flasks, 1 ml accutase (PAA, ready to 
use) was added per 75 cm
2
 growth area and cells were placed in the incubator at 37°C for 5 
minutes or until the cells peeled away from the bottom. The enzymatic reaction was then 
stopped by resuspending detached cells in 5 ml complete medium, followed by centrifugation 
at 1200 rpm for 5 minutes. 1 ml of cryomax II (PAA) was added to the cell pellet, 
immediately resuspended and transferred to a cryopreservation vial (Nunc). The cryo vial was 
then placed in a “slow freezing” device and put in -80°C overnight until storage in a liquid 
nitrogen tank.  
 
2.2.4 Isolation and preparation of human immune cells 
Peripheral human lymphocytes can be used ex vivo to investigate effects of growth factors, 
cytokines, proteins, chemicals, drugs and many more. These cells circulate in the periphery of 
the human blood circulation and can easily be withdrawn for the isolation thereof.     
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2.2.4.1. Isolation of human peripheral lymphocytes from whole blood  
Human PBMC were isolated from peripheral blood from healthy donors by density gradient 
centrifugation. Therefore, 15ml of Ficoll medium was added to 50 ml Falcon tubes under 
sterile conditions. 5% of the anti-coagulant ACD-A (citrate dextrose solution) (v/v) was added 
to 50 ml whole blood and further diluted (1.4 fold) in warm PBS. The diluted blood was 
gently pipetted on the prepared Ficoll medium. The PBMC were then separated from the rest 
of the blood cells by centrifugation at 600 rpm for 30 minutes (acceleration and breaks were 
kept on lowest level) in a swing out bucket. To remove the platelets, 2.5 ml of supernatant 
was carefully removed from the surface. Tubes were centrifuged for another 30 minutes at 
1400 rpm. The “buffy coat”, comprising the PBMC at the interphase between the Ficoll layer 
and the medium was aspirated (~ 5 ml) and washed twice with PBS. The washing steps were 
performed at 1800 rpm to completely remove residual Ficoll medium, which has toxic effects 
on cells. PBMC were resuspended in complete RPMI-medium and placed in the incubator for 
at least two hours before starting the in vitro experiments. In order to obtain periphal blood 
lymphocytes (PBL), defined as cells derived from the lymphoid lineage, monocytes/myeloid 
cells were depleted. Therefore the PBMC were placed in a cell culture dish at 37°C for one 
hour. During that time, most of the monocytes have settled down and remained on the bottom. 
Cells in suspension were carefully aspirated, representing the human PBL. Unless noted 
otherwise, experiments were performed with final PBMC concentrations of 2.5 Mio/ml. 
 
 
 
 
Figure 2-3 Schematic of human blood cells after centrifugation in density gradient                               
PBMC are located in the interphase between plasma and red blood cells. White blood cells are visible as a so 
called buffy coat on top of the opaque Ficoll medium (not shown in this illustration) (Author: Richard Tsai, 
Thermo Scientific)   
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2.2.5 Flow cytometry  
Flow cytometry allows to phenotype primary cells or cell lines according to their 
characteristic surface antigens. A further advantage of this method is the ability to quantify 
cell surface proteins like receptors after various treatment conditions. Apart from immune cell 
surface staining, which is described in the following section, flow cytometry has also been 
performed for MCF-7 tumor cells after transfection with eGFP containing plasmids.  In that 
case, the method was used to differentiate between GFP-positive and GFP-negative 
populations of tumor cells. Antibody staining could be omitted. Between 10
5
 and 10
6
 cells 
were taken up in 200 µl FACS buffer and measured for fluorescence emission in the blue 
laser (488 nm) channel 1, using the Attune FACS instrument (unless otherwise noted).        
 
NKG2D receptor surface staining using flow cytometry analysis:  
For cell surface staining of human lymphocytes from healthy donors, PBMC or PBL were 
either treated with TGF- (2 ng/ml and 5 ng/ml), or with increasing concentrations of 
recombinant GDF-15 (1 ng/ml, 4 ng/ml, 10 ng/ml, 20 ng/ml, 40 ng/ml, 80 ng/ml and 160 
ng/ml) respectively, or left untreated for 24 hours. SD208, a TGF- receptor tyrosine kinase I 
inhibitor, was added as a control. SD208 mediates the inhibition of TGF- pathway and thus 
revealed the autocrine TGF- signaling when compared to the untreated control. After the 
treatment, PBMC were washed with PBS. Cells were then transferred to FACS tubes and 
blocked with Beriglobin (1% in PBS) for 30 minutes at 4°C. Beriglobin contains 
immunoglobulins, thus used to block Fc- receptors on immune cells (e.g. macrophages or 
NK cells). This could avoid unspecific binding of primary antibodies (Honig et al., 2005). 
After blocking, immune cells were transferred to FACS plates and centrifuged at 1800 rpm at 
4°C. To quantify the NKG2D receptor surface expression on NK cells, PBL were stained for 
CD3
-
 CD56
+
 cells and NKG2D receptor for 30 minutes at 4°C in the dark. Unless otherwise 
noted, the dilution for fluorochrome conjugated primary antibodies was 1:100 in FACS buffer 
(1x PBS, 2% FCS). Anti-CD3-APC (1:50), anti-CD56-PeCy5, PE-conjugated anti-NKG2D 
receptor antibody were used for staining. Subsequently, cells were washed twice and the 
pellets were resuspended in 200µl of FACS buffer. Flow cytometric analysis was performed 
on a FACS Calibur instrument (Becton Dickinson). 
Quantification of NKG2D surface receptor on CD8
+
 T cells was performed with the same 
samples as for the NK cell staining (see above). The only difference was, that staining for 
NKG2D receptor on CD8
+
 T cells was carried out with anti-CD8-PECy5 antibody instead of 
the anti-CD56-PeCy5 antibody.     
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Data were analyzed with the summit 4.3 FACS-software (Beckman Coulter). Specific 
fluorescence intensities (SFI) were calculated by the following formula: 
 
SFI (NKG2D) = 
𝑀𝑒𝑑𝑖𝑎𝑛 (𝑓𝑙𝑢𝑜𝑟𝑒𝑠𝑐𝑒𝑛𝑐𝑒 𝑖𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦 𝑁𝐾𝐺2𝐷−𝑟𝑒𝑐𝑒𝑝𝑡𝑜𝑟−𝑃𝐸)
𝑀𝑒𝑑𝑖𝑎𝑛 (𝑓𝑙𝑢𝑜𝑟𝑒𝑠𝑐𝑒𝑛𝑐𝑒 𝑖𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦 𝐼𝑠𝑜𝑡𝑦𝑝𝑒−𝑃𝐸)
 
 
2.2.6 Adherence Assay 
To test the influence of GDF-15 on the adherence of human PBMC on endothelial cells, a 
leukocyte adhesion assay was performed (Kucik and Wu, 2005). Human umbilical vein 
endothelial cells (HUVEC) were seeded at a density of 1 x 10
5 
cells per well into a 24 well 
cell culture dish and cultured in supplemented medium (EndoGRO™, SCCE001, Millipore) 
at 37° C and 5% CO2. After 24 hours and the formation of a confluent monolayer, HUVEC 
were stimulated with 20 ng/ml of recombinant tumor necrosis factor alpha (TNF-) for four 
hours, in order to induce LFA-1 surface expression. As a control, global adherence of 
leukocytes on endothelial cells was induced by pre-treatment of PBMC with 2.4 µg /ml 
phytohemagglutinin (PHA) for 20 minutes. Subsequently, 2 x 10
6
 PBMC per ml were treated 
with 100 ng/ml recombinant GDF-15 for 4 hours or left untreated and were added to the 
HUVEC monolayer. 
Lymphocytes were kept on HUVEC for 90 minutes at 37° C and 5% CO2. Non-adherent 
lymphocytes were collected by aspiration of medium from the endothelial cells. After 
washing of the HUVEC monolayer with RPMI and PBS at 37° C, adherent lymphocytes were 
collected together with HUVEC by trypsination of the cell culture dishes. Both non-adherent 
and adherent cells were sedimented at 500 g for 5 min at 4° C and blocked for 45 minutes at 
4° C after resuspension in PBS containing 1 % FCS. Cells were stained for macrophages 
(CD14
+
), T helper cells (CD4
+
) and cytotoxic T cells (CD8
+
) with fluorophor labeled 
antibodies. Immune cell subset distribution in samples of non-adherent and adherent fractions 
were quantitatively analyzed by flow cytometry (see 2.2.5).   
 
2.2.7 Woundhealing assay 
To investigate the migration of cancer cells under the influence of GDF-15, woundhealing 
assay was performed according to Liang and colleagues (Liang et al., 2007). Therefore, a 
monolayer of wild type- as well as GDF-15-transgenic breast cancer cell line MCF-7 was 
grown in 6 well plates at 37°C in 5% CO2 (for transfection protocol, see section 2.2.12). A 
scratch has been introduced with a 100 µl pipet tip concentrically splitting the 6 well into two 
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halfes. Thereby, the pipet tip was pulled starting from the top margin of the well bottom down 
to the lower side of the well. Subsequently, scratched and floating cells were removed by 
three times washing the 6 well plates with 37°C pre-warmed PBS, followed by adding 2 ml of 
RPMI 1640 containing 2 % FCS and 5 % penicillin/streptomycin. Cells were placed in the 
incubator at 37°C and 5% CO2 for at least two hours prior starting the treatments. 
Wound healing was monitored daily and four pictures of each well were taken with the use of 
a microscope compatible camera and the TS View Digital imaging software. The four 
according pictures were aligned using Adobe photoshop and subsequently loaded in the image 
J software, where the scratch area was measured.       
 
2.2.8 Determination of cell viability using the WST-1 assay 
The WST-1 assay (Roche) served as a cytotoxicity assay to determine the viability of 
lymphocytes in the presence or absence of GDF-15 antibodies od drug substances. The GDF-
15 monoclonal antibody B1-23/ HL5, B12, Ipilimumab and Avastin were added to human 
lymphocytes at a concentration of 10 µg /ml and incubated at 37°C for 24 hours. Untreated 
lymphocytes served as a negative control. Dacarbazine and Paclitaxel (Taxomedac®, medac) 
served for an in vitro comparison with antibodies and small molecules in regard to the 
toxicity. DMSO (5% v/v) served as a positive control for cellular cytotoxicity. WST-1 
substrate was added as 1:10 dilution following an incubation time of at least one hour up to 
four hours. 
Once a turnover of the substrate was visible by eye (yellow colour), the absorbance was 
measured with the Sunrise Reader (Tecan) at a wavelength of 450 nm. 
 
2.2.9 Protein biochemical methods 
2.2.9.1 Preparation of cell lysates from human PBMCs, tumor cells and tissues 
In order to investigate changes of intracellular proteins of human PBMC upon various stimuli, 
between 2 and 5 Mio human leukocytes were transferred from 24 well plates to 15 ml Falcon 
tubes. Then the lymphocytes were centrifuged at 1500 rpm for 8 minutes. The pellet was 
washed in PBS, spun down and the dry pellet thereof was resuspended in Lysisbuffer P 
(composition listed in Table 3) and put on ice for 20 minutes. The resulting lysate was spun 
down at maximum speed to separate the cytoplasmic proteins from cellular debris, cell 
membranes and proteins thereof. Apart from the cell numbers and the necessity to detach 
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adherent tumor cell lines, cell lysis was performed in the same manner as described for the 
human PBMCs. A part of the lysate was used for quantification of the protein content. 
 
2.2.9.2 Determination of the total amount of protein by the Bradford method 
To quantify the amount of intracellular protein of cell lysates or tissue lysates, the Roti®-
Quant assay (Carl Roth) was performed according to the manufacturer instructions. 
 
2.2.9.3 Immunoblotting 
In order to separate proteins according to their mass, sodium-dodecyl-sulfate polyacrylamide 
gel electrophoresis (SDS-PAGE) was performed (Renart et al., 1979). For those Western 
Blots (WB) performed under denaturing and reducing conditions, laemmli-loading buffer was 
added to the protein lysates and put on a heat block at 90°C for 10 minutes. Laemmli buffer 
contains -mercapto-ethanol, which reduces the disulfid bonds in proteins (Laemmli, 1970). 
The high temperature leads to the denaturation of the proteins. 10 µg of protein lysate in 
laemmli was then loaded on the stacking gel, running at 0.2 mA in a Biorad SDS-PAGE 
device.   
For detecting native proteins, so called semi native Western Blot was performed. This is 
inevitable, when an antibody can only detect the native protein and loses its binding 
capability, once the protein has changed its conformation. This was the case for the GDF-15 
antibody B1-23, which was generated as a part of my thesis. Semi native SDS PAG was 
performed without denaturing and reducing conditions. Therefore loading buffer without -
mercaptoethanol was added to recombinant proteins or cell supernatants and loaded on SDS-
PAG without heat denaturing. Unless noted otherwise, SDS PAGE was performed with the 
following polyacrylamide gels: 
 
Stacking gel (5%): 
dd H2O 0.68 ml,  
Acrylamid/Bisacrylamid (30%) 0.17 ml,  
Tris-HCl 1 M (pH 6.8) 0.13 ml, 
SDS (10%) 10 µl,  
APS (10%) 10 µl,  
TEMED 1 µl   
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Separating gel (10%): 
dd H2O 1.9 ml,  
Acrylamid/Bisacrylamid (30%) 1.7 ml,  
Tris-HCl 1.5 M (pH 8.8) 1.3 ml ,  
SDS (10%) 50 µl,  
APS  
(10%) 50 µl,  
TEMED 1 µl 
 
Table 18  Polyacrylamid gels for SDS PAG electrophoresis 
 
Proteins, denatured or native, were transferred from the SDS gel to a nitrocellulose membrane 
using the Biorad semi dry Western Blot apparatus. After the transfer membranes were placed 
in dishes and blocked with TBST buffer, containing 5% (w/v) skimmed milk, for one hour. 
Then, the blocking solution was removed and primary antibody (diluted in blocking buffer) 
was added to the membranes and incubated on a shaker under constant agitation overnight at 
4°C. To investigate the activation of the canonical TGF- signaling pathway, pSmad2 
antibody was used, whereas total Smad2, GAPDH and β-actin served as loading control 
antibodies. The mouse anti-GDF-15 antibody (B1-23, 1µg /ml, generated during my thesis), 
human-(Fc) anti-GDF-15 antibody (ChimB1-23, 1µg /ml, product of the thesis), the human 
anti-GDF-15 antibody (H1L5, 1µg /ml, product of the thesis) were used for the detection of 
recombinant human GDF-15 and UACC-257 melanoma cell expressed GDF-15 under semi 
native SDS-PAGE-conditions. The rabbit anti-pro-GDF-15 antibody (H011191, Sigma Atlas 
antibodies) was used to detect precursor-GDF-15 under denatured as well as semi native 
conditions. 
After three washes with TBST, the following secondary HRP-coupled antibodies, diluted in 
blocking buffer, were added to the nitrocellulose membranes and placed on a shaker for two 
hours at room temperature: polyclonal anti-mouse-(H+L) antibodies, anti-rabbit-HRP 
antibodies, polyclonal anti-human-HRP antibodies. After secondary antibody incubation, 
membranes were washed three times with TBST and placed face down on a drop of ECL 
detection solution (consisting of 1ml ECL-A, 100µl ECL-B and 2µl H2O2) for 2 minutes. 
After that time, membranes were placed in a light protected cassette and exposed on x-ray 
films in a dark room for 2-10 minutes (depending on the signal intensities) until the x-ray 
films were developed. Therefore the films were kept for 3 minutes in a developer solution 
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(Kodak), shortly washed in ion free water and placed in a fixation bath for one minute. After 
the fixation was completed, the films were washed under tab water to remove fixation 
solution. Once dried, the films were scanned and the signal intensities of the protein bands 
were analyzed using the image J software (Schneider et al., 2012). 
 
2.2.10 Methods for gene expression analysis 
2.2.10.1 Isolation of RNA from immune cells and HUVEC cells 
5x10
6
 immune cells and 2.5 x10
6 
HUVEC cells were seeded in 24 well plates in 1 ml RPMI-
complete medium and either treated with 100 ng /ml recombinant GDF-15 (R&D Systems) or 
left untreated for six hours and 24 hours, respectively, at 37°C in the cell incubator. Then cells 
were detached using accutase and transferred to 1.5 ml caps, washed in 1 ml cold PBS (1x) 
and centrifuged at 2000 rpm in a table top centrifuge (Eppendorf). The pellet was resuspended 
in 1 ml Trifast® reagent (Peqlab) for 15 minutes at room temperature. 0.2 ml of chloroform 
was added to each sample and shaken vigorously for 15 seconds. Samples were kept for 
another 5 minutes at room temperature before centrifugation at 15,000 rpm at 4°C. The 
aqueous phase was carefully aspirated and transferred to a new 1.5 ml cap (~ 0.5 ml). 0.5 ml 
isopropanol was added to the RNA and incubated for 15 min at 4°C for RNA precipitation. 
The samples were then centrifuged for 10 minutes at 15,000 rpm at 4°C. The resulting RNA 
pellet was washed twice with 0.7 ml ethanol (100 % ethanol). To dry the RNA pellet, the caps 
were left open and placed under a lamina flow for 10 minutes. The RNA was then 
resuspended in 15 µl aqua ad injectabilia (Braun). To properly dissolve the RNA in water, the 
caps were placed on a heat block at 37° C for 5 minutes. 
 
2.2.10.2 Determination of RNA concentration 
The RNA concentration was determined by measuring the absorbance (OD = optical density) 
at 260nm, 280nm and 320nm using a photometer. The 260 nm/280 nm ratio indicated the 
RNA quality. RNA with a quality of less than 260nm/280nm = 1.6 was not further processed. 
The concentration of the RNA was calculated as follows: 
CRNA [μg / ml] = OD260 nm x dilution factor x 40. 
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2.2.10.3 Synthesis of cDNA from isolated RNA 
In order to generate cDNA of polyadenylated transcripts from monoclonal antibody producing 
hybridoma cells, a reverse transcription was performed. Therefore the iScript kit (Biorad) was 
utilized according to the manufacturer protocol (Geiduschek et al., 1961). A maximum of 1µg 
RNA was used in one reaction (see table 14). The oligo-dT primers, provided in the reaction 
mix of the kit, assured the reverse transcription of protein coding RNA with poly-A tails. The 
cDNA was used for quantitative real time PCR described in section 2.2.9.4. 
 
Component Volume Final concentration 
5x iScript reaction mix 4µl 1x 
 
iScript reverse transcriptase 1µl n.d. 
 
RNA template up to 1µg ~ 20ng/µl 
 
Nuclease free water x µl  
 
Total volume 20µl  
Table 19  Volumes and amounts of components for one iScript cDNA synthesis reaction 
 
cDNA synthesis reaction: 
Duration Temperature 
5 minutes 
 
25°C 
30 minutes 
 
42°C 
 
5 minutes 
 
85°C 
 
∞ 4°C 
 
Table 20 cDNA synthesis program (according to the manufacturer recommendation) 
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2.2.11 Polymerase Chain Reaction (PCR) 
The polymerase chain reaction method (PCR) enables the amplification of genomic DNA 
sequences of interest (Mullis, 1990). Therefore specific primer pairs are used to define the 
starting points of the DNA amplification in forward as well as reverse direction. In short, the 
method is subdivided into three steps: the separation of double stranded DNA (genomic DNA 
as well as primer DNA) at 94°C, the primer annealing at a certain annealing temperature (has 
to be tested for each primer pair), and the elongation step, where a heat stable DNA 
polymerase amplifies the DNA strand, starting with the annealed primer on the DNA. These 
three steps represent one PCR cycle and are repeated up to 40 times, with an exponential 
amplification of DNA.    
 
2.2.11.1 Isolation of genomic DNA from mouse ear punches 
In order to obtain genomic DNA from Bl6/57 GDF-15 knock out mice, a small piece of the 
ear was taken by an ear puncher. Genomic DNA was isolated from the tissue according to the 
E.Z.N.A tissue DNA isolation kit (Omega bio-tek). 
 
2.2.11.2 Mouse GDF-15 genotyping 
Due to breeding of animals being heterozygous for GDF-15-knock-out allele, the genotype 
had to be confirmed by PCR method. Two PCR-programs were run using different primer 
pairs (see table 11). Annealing as well as elongation temperature for the GDF-15 PCR-
program is shown in table 22. 
 
Component Volume Final concentration 
5x Crimson long amp 
buffer 
5µl 1x 
10mM dNTPs 0,75µl 300µM 
 
10 µM Forward Primer 1 µl 0.04 µM 
 
10 µM Reverse Primer 1 µl 0.04 µM 
 
Template DNA Variable < 1ng 
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Crimson LongAmp 
Taq DNA Polymerase 
1 µl 2.5 units/ 25µl PCR 
Nuclease-free water To 25 µl  
Table 21 Reaction setup for standard PCR 
 
 
STEP  Temperature Time Cycles 
Initial Denaturation 
 
94°C 30 seconds  
     Strand separation 
 
94°C 
 
30 seconds 
 
 
 
     
    
 30x 
     Primer annealing 
 
62°C 
 
60 seconds 
 
     Elongation 65°C 
 
50 seconds/kb 
Final extension 
 
65°C 10 minutes  
Hold 
 
4°C ∞  
Table 22 PCR program for GDF-15 knock-out genotyping 
 
 
2.2.11.3 DNA gel electrophoresis  
DNA gel electrophoresis was performed to separate DNA fragments according to their 
nucleotide length (e.g. from PCR products). Therefore 1 % agarose gels were prepared in 
TAE buffer (1x). To visualize the DNA under UV light, 10 µl of Gelred (FIRMA) was added 
to the warm gel. 10µl of the GDF-15 PCR-products were directly loaded on a DNA gel 
(Crimson long amp buffer contained the loading dye) and run at 75V in a 0.5 x TAE buffer 
for one hour. To determine the length of PCR products, a 100 bp DNA ladder (TrackIt™ 1 Kb 
Plus DNA Ladder (Invitrogen), see figure 2.2) was loaded on the gel as a reference standard. 
 
2.2.11.4 Quantitative Realtime Polymerase Chain Reaction (qPCR) 
To quantify the expression of selected mRNAs in PBMC or HUVEC cells, the quantitative 
realtime PCR (qRT-PCR) method with SYBR-Green incorporation was applied. It is based on 
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a standard PCR (described in 2.2.11). mRNA was reverse transcribed to cDNA (described in 
2.2.10.3), which served as the template DNA in the qRT-PCR reaction mix. Individual primer 
pairs were used in the qRT-PCR run to amplify the respective cDNA. 18S RNA primers 
served as reference RNA expression (internal reference gene). 18S RNA is constitutively 
expressed in most cell types. During elongation of transcripts (with cDNA templates 
synthesized from mRNA) by DNA polymerase, the newly generated DNA double strands 
incorporate a fluorescent dye (SYBR Green), which is a component of the master mix (table 
18). SYBR Green labelled dsDNA can be excited by a blue laser (λmax = 488 nm) and emits 
green light (λmax = 522 nm) which can be quantified using the ABI 7500 fast thermocycler 
(Applied Biosystems, Life Technologies). cDNA can thus be PCR-amplified and analyzed 
simultaneously. Quantification of relative mRNA expression was calculated according to the 
CT method described in the journal of molecular medicine (Schefe et al., 2006).  
 
Component Volume Final concentration 
2x Absolute blue qPCR 
SYBR Green low Rox mix 
7.5 µl 1x 
1.1 µM Forward Primer 1 µl 0.07 µM 
1.1 µM Reverse Primer 1 µl 0.07 µM 
cDNA (diluted 1:10 in 
water)    
5 µl < 1ng 
Nuclease-free water to 15 µl total  
Table 23 qRT-PCR Mastermix 
 
 
STEP  Temperature Time Cycles 
Initial Denaturation 
 
50°C 2 minutes  
      
 
95°C 
 
15 minutes 
 
 
 
Strand Separation 
 
95°C 
 
15 seconds 
 
    40x 
Annealing &  
Elongation 
60°C 
 
60 seconds 
Final extension 65°C 10 minutes  
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Hold 
 
4°C ∞  
Table 24  qRT-PCR program on the ABI 7500 instrument 
 
 
2.2.12 DNA-Microarray (Affymetrix) on human PBMCs and HUVECs 
The GeneChip® Human Transcriptome Array 2.0 (Affymetrix) was performed in 
collaboration with the micro-array core unit at the University of Wuerzburg, to investigate the 
effect of GDF-15 on gene expression. Therefore, PBMC or HUVEC cells were treated with 
GDF-15 for six and 24 hours or left untreated. Then, RNA was isolated at each time point (see 
2.2.8) and its quality was analyzed by measuring the OD-260/280-ratio on a NanoDrop 
spectrophotometer. The RNA integrity numbers (RIN) of all samples were validated with a 
bioanalyzer instrument (Agilent). RNA samples of high quality were further processed and 
hybridized on the GeneChip® Human Transcriptome Array 2.0 (HTA 2.0). A cluster analysis 
with PBMC and HUVEC including two kinetics of treatment was performed.  
 
2.2.13 Cloning 
In the underlying work, cloning was used to integrate the – at this particular time - unknown 
DNA sequences of the immunoglobulin B1-23 (heavy chain and light chain) into a pJET1.2 
vector, which could subsequently be sequenced. This sequence information was indispensable 
for humanization of the antibody (described in detail in 2.2.24).    
 
2.2.13.1 Ligation  
In order to insert DNA fragments into the pJET1.2 vector (CloneJet PCR cloning Kit, Thermo 
Fisher Scientific), a ligation reaction was performed according to the CloneJet protocol. Since 
the PCR products were generated by using a DNA polymerase with proofreading activity, 
blunting reaction could be omitted. Furthermore, digestion of the pJET1.2 vector was not 
needed, as the kit contained an already linearized plasmid. After PCR products had been 
quantified photometrically and on DNA gel by comparison with DNA products of known 
concentration (50 bp, 100 bp, 150 bp, 200 bp), ligation reaction was performed at a 3:1 -
(insert: vector) molar ratio as follows: 
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Component Volume 
2x Reaction Buffer  10 µl 
pJET1.2/blunt Cloning Vector 
(50 ng/µl) 
1 µl  
(0.05 pmol ends) 
PCR product 1 µl  
0.15 pmol ends 
T4 DNA-ligase 1µl 
Nuclease free water up to 19 µl 
Total volume 20µl 
Table 25  Ligation reaction mix 
 
STEP  Temperature Time 
Ligation 22°C 20 minutes 
Hold 4°C ∞ 
Table 26 Ligation reaction - program 
 
 
2.2.13.2 Transformation in C2988 bacteria  
In order to amplify the pJet1.2 including the new DNA sequence, competent E. coli bacteria 
(C2988, New England Biolabs) were transformed according to standard procedures 
(Sambrook J., 2001). Therefore, the E. coli bacteria – kept as glycerol stock at -80°C- were 
thawed at room temperature for 5 minutes. 1 µl ligation reaction mix (from 2.2.13.1) was 
added to 50µl of bacteria in a 1.5 ml cap and mixed gently. Cells were incubated in a heat 
block at 42°C for 45 seconds and rapidly put on ice to stop the transformation reaction. 1 ml 
of LB medium was added to the transformation mix and the 1.5 ml cap was placed in a 
bacterial shaker at 200 rpm at 37°C for one hour. Afterwards, cells were plated on LB-
ampicillin dishes and incubated at 37°C overnight. Since the original pJET1.2/blunt vector 
expresses a lethal restriction enzyme, once recircularized during the ligation reaction, vectors 
without insert kill the E.coli hosts after transfection. Therefore, exclusively bacteria 
transfected with vectors containing an insert survive and were propagated after 
transformation.  
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2.2.13.3 Preparation of plasmids  
Plasmid preparations were performed to obtain purified, concentrated and endotoxin free 
vectors for sequencing. Therefore, colonies grown out on LB agar were picked from 
ampicillin plates and transferred to 50 ml Falcon tubes containing 5 ml LB medium (+ 
ampicillin) for an overnight culture at 37°C in the shaker (Brunswick). A mini preparation 
(mini prep) was performed according to the manufacturer recommendation (Zyppy™ Plasmid 
Miniprep Kit). Purified Plasmid DNA was eluted in dH2O and the concentration was 
determined by measuring the absorption at OD260 nm. Using the ZYMO Research mini prep 
kit, plasmid DNA concentration between 0.5 mg/ml and 1.5 mg/ml were obtained.  
 
2.2.13.4 Restriction digest of pJET1.2/blunt (Fermentas) 
Restriction digestion can be used to selectively cut a plasmid or other types of DNA and to 
analyze the fragments obtained thereby (Cohen et al., 1973). Here, restriction digestion was 
performed to proof that an insert has been ligated into the vector. FastDigest (Fermentas) 
enzymes cutting the vector at insert-flanking sequences were chosen in the following 
restriction fast digestion reaction: 
 
Component Volume 
 XbaI (FastDigest) 1 µl 
EcoRI (FastDigest) 1 µl  
Plasmid DNA  1 µg 
10x FastDigest-buffer 2 µl 
Water up to 20 µl 
Table 27  Restriction double digest reaction mix 
 
The reaction was incubated for 10 min at 37°C on a heat block. The product of the restriction 
digest was loaded and run for 30 min on a DNA gel (0.8 % agarose in 1x TAE) to separate 
DNA inserts from linearized vector backbone.   
 
2.2.13.5 Colony polymerase chain reaction (colony PCR) 
A further method to assess proper insertion of DNA sequences in a vector after ligation is the 
colony PCR method. Thereby, single colonies from LB ampicillin plates were picked using a 
1 µl pipette tip and transferred directly into a conventional PCR mastermix (described in 
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2.2.11). In this method, transformed bacteria were used as DNA template in the following 
reaction (adapted from pJET1.2 PCR-protocol): 
 
Component Volume 
5x Crimson long amp buffer 5µl 
10mM dNTPs 0,75µl 
10 µM pJET1.2 Forward Sequencing Primer 1 µl 
10 µM pJET1.2 Reverse Sequencing Primer 1 µl 
Single colony from ampicillin plate Variable 
Crimson LongAmp 
Taq DNA Polymerase 
1 µl 
Nuclease-free water To 25 µl 
Table 28 Components for colony PCR  
 
 
STEP  Temperature Time Cycles 
Initial Denaturation 95°C 3 minutes  
     Strand separation 94°C 30 seconds         
25x      Primer annealing 60°C 30 seconds 
     Elongation 72°C 60 seconds/kb 
Final extension 72°C 10 minutes  
Hold 4°C ∞  
Table 29 Colony PCR program, modified from the original pJet1.2 protocol (Fermentas) 
 
 
2.2.13.6 Vector Sequencing (Geneart) 
To obtain the sequence of a cloned DNA fragment, as in case of the variable light and heavy 
chains of the generated antibody B1-23, the according plasmids were sent to and sequenced 
by Geneart AG in Regensburg (Germany). The pJET1.2 forward sequencing primer supplied 
with the CloneJet kit (Fermentas) was used for sequencing. Geneart AG also performed 
sequence confirmation of the expression plasmids pcDNA-3.1-hGDF-15 and pIRESeGFP-
GDF15 (see table 15 and supplements). 
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2.2.14 Transfection of cells 
To produce the light and heavy variable chains of humanized H1L5 in a suitable expression 
system, chinese hamster ovary cells (CHO) were transiently transfected with two heavy and 
light chain (antibody-) coding vectors: the L5-construct encoding the light chain variable 
region and the H1 construct encoding the heavy chain variable region. To express the entire 
antibody, co-transfection with both constructs was performed. Transfection was carried out 
using the XtremeGene transfection kit (Promega). 24 hours post transfection, the antibody 
was harvested from CHO supernatants. 
 
2.2.15 Generation of monoclonal antibodies against GDF-15 
Monoclonal antibodies can be used as a tool for molecular biological applications, as clinical 
diagnostics and moreover administered as therapeutic drugs. In section 2.2.14, all methods 
described were necessary to generate monoclonal antibodies to human GDF-15, which are 
produced from a single hybridoma clone (Köhler and Milstein, 2005). The reason for the 
immunization of GDF-15 knock out mice was to increase the chance of obtaining antibodies 
to GDF-15, since mouse and human GDF-15 display 70 % sequence similarity (shown in 
table 26), a fact that might lower immunogenicity even for the human homologue. 
 
2.2.15.1 Immunization of mice 
Three female GDF-15 deficient Bl6/57 mice (provided by Dr. Jens Strelau, Heidelberg) were 
immunized subcutaneously with 165 µg native recombinant GDF-15 each (E.coli derived 
material, obtained from Professor Thomas Müller, Würzburg) using TiterMaxGOLD® 
adjuvant. Blood sera from all animals were isolated 3 weeks post immunization to determine 
an antibody titer against the immunogen. Mice received a boost with GDF15-TiterMax 
emulsion 5 weeks after first immunization and a final intravenous boost 3 weeks afterwards. 3 
days after the final boost the animals were sacrified and the spleens thereof were isolated and 
placed in HBSS at 4°C. 
 
2.2.15.2 Hybridoma fusion, selection and expansion 
Splenocytes were isolated from the fresh mouse spleens by straining the spleen through a 70 
µm cell sieve. Cells were collected in RPMI medium and kept in 75 cm
2
 flasks for two hours 
to allow the fibroblasts to adhere. After the fibroblast depletion, 120 Mio splenocytes from the 
supernatant were mixed with 25 Mio HAT- (hypoxanthine-aminopterin-thymidine) sensitive 
 71 
 
2 Material and Methods 
P3-X63.Ag8.653 myeloma cells in 50 ml tubes (final volume) and centrifuged at 1200 rpm to 
receive a dry cell pellet. Fusion of the cells occurred by adding poly ethylene glycol (PEG) to 
the pellet, thereby gently stirring the cells. Subsequently 30 ml HAT medium were drop-by-
drop added to the fused cells. Cells were then carefully transferred into u-bottom plates in a 
final volume of 100 µl per well and cultured for 14 days. Cells were supplemented with 15 µl 
of medium every five days. Since the X63.Ag8.653 cells are deficient for the enzyme 
hypoxanthine guanine phosphoribosyltransferase (HGPRT
-
), these cells are sensitive to and 
die in HAT medium (Szybalski, 1992). When HGPRT
-
 myeloma cells were successfully 
fused with splenocytic cells, which are HGPRT
+
, the hybridoma cells can now survive in 
HAT medium. The HAT selection process was done for 14 days until replacing it by HT-
medium (omitting aminopterin).     
 
2.2.15.3 Screening for GDF-15 positive clones  
After 14 days of hybridoma cell culture, aliquots (10 µl) of cell supernatants were transferred 
without diluting onto a GDF-15 pre-spotted nitrocellulose membrane using a 12-channel 
pipette and incubated for 10 seconds. At that point, membranes were processed analogous to 
the described immunoblot procedure (see 2.2.9.3). Hybridoma cells, of which supernatants 
were positive for GDF-15 antibodies, were subcloned and further expanded (see next section). 
           
2.2.15.4 Cloning/Subcloning for monoclonal antibodies  
Subcloning is a useful method to obtain monoclonal antibodies from a pool of hybridoma 
cells. During the generation of monoclonal antibodies, this method ensures to receive 
antibodies produced by a single cell clone (monoclonal).  
Therefore, the limiting dilution method was performed (Staszewski, 1984). Herein, cells were 
seeded in 96 well u-bottom plates in 100 µl medium at a concentration of 0.5 cells / 100 µl, 
resulting in the majority of wells seeded with one single cell. Single cells can easily be seen 
using a microscope, since the u-bottom shaped wells force the cells to roll into the middle of 
each well. Once the hybridoma cells were outgrown to a visible population in the respective 
wells and the color of the hybridoma supernatant turned yellowish (indicating a metabolic 
turnover), screening for specific antibody production was repeated. This selection procedure 
was repeated twice with positive clones to ensure monoclonal antibodies. Antibody producing 
cell clones were then stored in nitrogen until further characterization or production of larger 
batches. 
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2.2.15.5 Production of mABs in CELLline Bioreactors / Antibody Expression  
To generate monoclonal antibodies (of the selected clone – here B1-23) in larger amounts, the 
static CELLline bioreactor (Integra) was used (see figure 2-4). The reactor comprises two 
compartments. The medium compartment and the cell compartment with a 10 kDa semi-
permeable, cellulose acetate membrane. This membrane allows small molecules to diffuse 
from one compartment to the other, whereas higher molecular weight molecules secreted by 
the proliferating hybridoma are retained within the cell compartment. This leads to a 
continuous flow of nutrients into the cell compartment and a concurrent removal of any 
inhibitory waste products, however the secreted antibodies remained in the cellular 
compartment. After equilibration of the semi-permeable membrane with 10 ml medium for 
five minutes, 8 x 10
6 
viable hybridoma cells from a pre-culture in log growth phase were 
suspended in 5 ml fresh medium resulting in a minimal concentration of 1.5 x 10
6
 viable cells 
/ml and cell compartment was inoculated with hybridoma cells. 340 ml Hybridoma-medium 
was added to the medium compartment and the CELLline reactor was placed in an incubator 
at 37°C. Hybridoma cells were harvested every five days by slowly aspirating the antibody-
hybridoma mix from the cell compartment of the reactor. 1 ml (~ 20 %) cell suspension was 
diluted in 5 ml fresh Hybridoma medium and pipetted back into the cell compartment of the 
bioreactor. The other 4-5 ml were centrifuged at 1200 rpm for 10 minutes and supernatants 
were further affinity purified, described in the next section. 
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Figure 2-4  Illustration of the CELLline Bioreactor system for antibody production                                        
(image kindly provided by     INTEGRA-biosciences)  
 
 
2.2.16 Purification of mABs using Proteus A columns 
To purify the antibodies from the cell supernatant, Proteus A purification columns (AbD) 
were utilized. These columns contain recombinant protein A, derived from expression in E. 
coli, which has a high affinity to the Fc part of an antibody, enabling an affinity purification 
of antibodies from crude hybridoma supernatant. After pre-equilibration of the Proteus A 
columns with  2 ml binding buffer A pH 9 (see table 11), supernatants from CELLline reactor 
were clarified using a 70 µm nylon mesh and diluted 1:1 in binding buffer A. 20 ml diluted 
antibody was transferred on the Proteus A column and centrifuged at 100x g for 30 minutes. 
Flow through was discarded and columns were washed twice with 10 ml of binding buffer. 
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Antibodies bound to protein A within the column were eluted by low pH using the elution 
buffer B2 pH 2.5. The eluate was then spun down into a tube containing 1.3 ml neutralization 
buffer C pH 9 for 3 min at 500x g. In this step, the pH of the sample reaches approximately 
7.5. Depending on the yield, the affinity purified antibody was either used for in vitro 
applications directly after the neutralization step or further concentrated using MWCO-spin 
columns (Sartorius).       
 
2.2.17 Isotyping of GDF-15 positive monoclonal antibodies  
Depending on its application, knowledge about the isotype of an antibody is unevitable. To 
determine the isotype of mouse anti GDF-15 antibody B1-23, AbD serotec isotyping stripes 
were used. The assay principle is based on anti-mouse kappa and anti-mouse lambda 
antibodies coupled onto coloured micro particles and equally reactive to any mouse 
monoclonal antibody regardless of its isotype. The isotyping strip has immobilized bands of 
goat anti-mouse antibodies corresponding to each of the common mouse antibody isotypes 
(IgG1, IgG2a, IgG2b, IgG3, IgM, and IgA) and to the kappa and lambda light chains. Both 
sides of the strip bear a positive flow control band, which indicates that the antibody-coated 
coloured micro particles have migrated through the strip. 
To start the isotyping reaction, the provided stripes were dipped into the diluted antibody 
sample. The results were visible in less than 10 minutes on the assigned stripe (figure 2-5). 
 
 
 
 
Figure 2-5  Mouse isotyping strip (AbD Serotec) for identification of the heavy chain isotype and light 
chain subtype  
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2.2.18 Epitope mapping  
In order to identify the epitope of GDF-15 bound by the antibody B1-23, two different epitope 
mapping methods were applied. Mapping of linear epitopes and mapping of discontinuous 
three dimensional epitopes (Middeldorp and Meloen, 1988, Stefanescu et al., 2007). 
2.2.18.1 Linear epitope mapping (pepperprint GmbH)  
Mapping of linear epitopes was performed externally by pepperprint. Therefore, monoclonal 
mouse antibody GDF-15 (B1-23) was tested for binding linear peptides derived from GDF-15 
on a single array. 
Antigen: GDF-15 
GSGSGSGMPGQELRTVNGSQMLLVLLVLSWLPHGGALSLAEASRASFPGPSELHSED
SRFRELRKRYEDLLTRLRANQSWEDSNTDLVPAPAVRILTPEVRLGSGGHLHLRISRA
ALPEGLPEASRLHRALFRLSPTASRSWDVTRPLRRQLSLARPQAPALHLRLSPPPSQSD
QLLAESSSARPQLELHLRPQAARGRRRARARNGDHCPLGPGRCCRLHTVRASLEDLG
WADWVLSPREVQVTMCIGACPSQFRAANMHAQIKTSLHRLKPDTVPAPCCVPASYN
PMVLIQKTDTGVSLQTYDDLLAKDCHCIGSGSGSG  
(322 amino acids including linker) 
The GDF15 protein sequence was translated into 13mer peptides with a shift of one amino 
acid. The C- and N-termini were elongated by a neutral GSGS linker to avoid truncated 
peptides (bold letters) and spotted on the peptide array. Flag (DYKDDDDKGG) and HA 
(YPYDVPDYAG) served as control peptides in form of 78 spots surrounding the array. 
Monoclonal mouse antibody GDF-15 (1 μg/μl) was stained on the array in incubation buffer 
for 16 h at 4°C at a dilution of 1:100 and shaked at 500 rpm. As secondary antibody, a goat 
anti-mouse IgG (H+L) IRDye680 diluted 1:5000 in incubation buffer, was stained for 30 min 
at room temperature (RT). Monoclonal anti-HA (12CA5)-LL-Atto 680 (1:1000), monoclonal 
anti-FLAG(M2)-FluoProbes752 (1:1000) served as control antibodies and were stained in 
incubation buffer for one hour at RT. The array was scanned using the Odyssey Imaging 
System, LI-COR Biosciences. 
 
Standard buffer: PBS, pH 7.4 + 0.05 % Tween 20 
Blocking buffer: Rockland blocking buffer MB-070 
Incubation buffer: Standard buffer with 10 % Rockland blocking buffer MB-070 
Table 30  Buffers used for linear epitope mapping on peptide array (performed by pepperprint GmbH) 
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2.2.18.2 Epitope mapping of 3-dimensional epitopes (epitope excision)  
Epitope excision and epitope extraction method was externally performed at the Steinbeis 
Zentrum Konstanz together with the group of professor Przybilski according to their 
established and published protocols (Stefanescu, Iacob et al., 2007). 
In short, the antibody B1-23 was covalently immobilized on a sepharose column. 
Subsequently, recombinant human GDF-15 was added on the columns. Bound GDF-15 was 
enzymatically digested by means of different proteases (trypsin). Cleaved peptides were 
harvested and analyzed by liquid chromatography–mass spectrometry (LCMS/MS-) method. 
The antibody shielded peptide fragments were then eluted by trifluoroacetic acid (TFA), a 
very acidic solution, thereby liberating the epitope defining peptides from the monoclonal 
antibody. These peptides were further analyzed by mass spectrometry and LC-
MS/MS
 method. 
 
2.2.19 kD-values-determination of antibodies 
Affinities of humanized GDF-15 antibodies were analyzed externally at the Steinbeis Zentrum 
Konstanz using the SAW Chips according to the manufacturer recommendation (SAW 
instruments). 
 
2.2.20 CDR Cloning of B1-23 heavy and light chains using degenerate primers (mouse 
IgG2a)  
The unknown complementarity determining regions (CDRs) of GDF-15 antibody B1-23 light 
and heavy chains were cloned according to the following procedure: RNA from hybridoma 
clone B1-23 was isolated (RNA isolation 2.2.10.1). Beside numerous transcripts generated by 
the hybridoma, mRNA of the light chain as well as the heavy chain of the antibody B1-23 
were isolated, followed by reverse transcriptase reaction in order to generate cDNA (as 
described in 2.2.10.3). cDNA was subjected to a polymerase chain reaction using specific 
primer combinations enabling the amplification of unknown (but relatively conserved) 
seuqences (Wang et al., 2000). So called degenerate primers were adapted in such way, that 
binding to certain mouse immunoglobulin sequences within the variable region of the 
antibody binding site was able. 
PCR resulted in PCR products of a length of 300nts containing blunt ends, further cloned into 
sequencing vector (further described in 2.2.13.1)  
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2.2.21 Chimerization of B1-23 
Chimerization of the murine GDF-15 binding antibody B1-23 was performed externally by 
evitria AG (using its proprietary technology). Hereby the antigen binding site of the mouse 
antibody (Fab) was grafted on a human IgG1 antibody backbone.   
 
2.2.22 Humanization of B1-23 
Prior to humanization of the monoclonal antibody B1-23, which was performed externally, 
evitria AG performed a codon optimization and offered 5 different light chain variable regions 
as well as 5 different heavy chain regions, which were the transplanted on a human IgG1 
antibody framework (evitria´s proprietary technology). There are a number of methods 
describing the process of humanizing antibodies (Weissenhorn et al., 1991) (Kettleborough, 
Saldanha et al., 1991, Near, 1992). (LoRusso, Weiss et al., 2011)The exact procedure applied 
her underlies evitria´s proprietary technology was protected by the company. 
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2.2.23 Animal Experiments 
2.2.23.1 Glioma model 
Glioma bearing animals, study was performed in collaboration with and details are described 
in the methods section of the publication in Clin Cancer Res. 2010 (Roth, Junker et al., 2010). 
 
2.2.23.2 Melanoma Xenograft model 
In order to assess an effect of GDF-15 antibodies in regard to tumor growth inhibition as well 
as prevention of cachexia, athymic female BALB/C
Nu/Nu
 (CAnN.Cg-Foxn1<nu>/Crl) mice 
(obtained from Charles River) were inoculated with 10 x 10
6
 UACC-257 melanoma cells. 
Prior inoculation, the melanoma cells were diluted 1:1 in matrigel, which was kept on ice until 
injecting the cell suspension. 200 µl of matrigel cell suspension was injected subcutaneously 
in the flank of the animals. Each treatment group contained 10 animals. Antibodies and 
substances (apart from dacarbazine) were administered intraperitoneally twice a week. 
Dacarbazine treatment was performed on 5 consecutive days starting at day 0. All antibodies 
were administered at a concentration of 25 mg/kg body weight. All treatments started on day 
of tumor inoculation, defined day 0. Body weight measured every 3 and 4 days. Tumor 
growth was measured twice a week. Food consumption, body weight, tumor volume 
(measured using a caliper) was analyzed until the end of the study. 
Group nr. 1 - 7  (10 mice each group)                                 amount of substances (for 45 d) 
1. Dacarbazine* (Referenz, Lot.: C120522C) …………..…………...…… 80 mg 
2. PBS (SIGMA, Lot.: RNBD0341)………………………………..………30 ml 
3. B1-23 (murin, Lot.: 515980) …………………………..………………. 75 mg 
4. ChimB1-23 (chim., Lot.: PR0057) …………………………..……….…75 mg 
5. H1L5 (humanis. B1-23, Lot.: PR3176) …………………………..…..…75 mg 
6. B12 (IsoAK, Lot.: ID3195) …………………………..…………………75 mg 
7. Fab (from ChimB1-23 Lot.: PR0057) …………………………..………75 mg 
*Detimedac 500 mg (exp.: 03.2015)   
Table 31 Setup UACC-257 Xenograft Study (Substances & total amounts required) 
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Brief explanation in regard to the individual treatment groups (shown in Table 31): 
1. Dacarbazine: Reference-/positive control for tumor growth inhibition (anti neoplastic         
    chemotherapeutic drug for the treatment of malignant melanoma in human) 
 
2. PBS: Growth-/Vehicle-control (all substances (1, 3-7) were dissolved in PBS) 
  
3. B1-23 (murin): lead antibody, as reference group for comparison with the chimeric and   
    humanized GDF-15 antibodies (ChimB1-23 and H1L5). 
 
4. ChimB1-23: chimeric B1-23 (murine Fab-sequence grafted on human IgG-1 antibody   
    [Trastuzumab-backbone])  
 
5. H1L5: humanized B1-23 (see 3.4.10) [Trastuzumab-backbone]). 
 
6. B12-Iso-antibody: the antibody served as isotype-control, to exclude unspecific effects due     
     to IgG-1-type immunoglobulins. The iso antibody B12 (Lot.ID3195) was generated by     
     Evitria AG. B12 binds HIV antigens and thus should not react with human GDF-15 and   
     neither crossreact with murine antigens. 
 
7. Fab: the Fab fragments were included to enable enhanced tumor penetration due to small      
    molecular weight compared to full antibody size  
    
 
2.2.24 Statistics 
Experiments were performed at least three times independently with similar results. For in 
vivo studies a two-way ANOVA test was performed. The applied statistical tests for in vitro 
experiments are indicated in the results section. 
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3 Results 
3.1 GDF-15 expression in solid tumors 
3.1.1 GDF-15 is highly expressed in ovarian cancer  
GDF-15 is overexpressed in many solid tumors (Corre, Labat et al., 2012). It has been 
reported by Staff and colleagues that high GDF-15 serum levels in patients with ovarian 
carcinoma correlate with a poor prognosis (Staff, Trovik et al., 2011). To visualize the GDF-
15 protein expression and its distribution in the tumor, several ovarian cancer tissues were 
stained immunohistochemically using a commercial anti-GDF-15 antibody (Prestige 
Antibody, Sigma) suitable for paraffin embedded tissues. At least three specimens from each 
tumor type were stained. As a positive control placental tissue was stained, revealing a strong 
GDF-15 expression in the syncytiotrophoblasts, whereas the endothelial cells and stromal 
cells were GDF-15 negative. In ovarian cancer tissue, GDF-15 shows a high expression in 
transformed cells and endothelial cells while stromal cells seemed to be predominantly GDF-
15 negative. Interestingly, the endothelial cells in placental tissue appeared to be GDF-15 
negative (figure 3-1-1).    
 
 
 81 
 
3 Results 
Figure 3-1-1 GDF-15 expression in human malignant ovarian cancer  
Paraffin-embedded tissue sections of human ovarian carcinoma patients were assessed by immunohistochemistry 
(IHC) and. stained for GDF-15 with the GDF-15-Atlas-antibody from Sigma-Aldrich. The presented tissues 
comprised a serous papillary ovarian carcinoma (Nr.1), a mucinous carcinoma (Nr.2) and a high grade 
endometroid carcinoma (Nr.3). Human placenta served as positive control for GDF-15. Placental 
syncytiotrophoblasts, which are known to highly express GDF-15, are indicated by arrows. Representative 
images are shown (original magnification, ×200 for all photomicrographs). 
 
 
3.1.2 GDF-15 is overexpressed in brain tumors  
GDF-15 is highly expressed in different brain tumors (Roth, Junker et al., 2010). It is known 
from literature, that high GDF-15 serum levels found in the cerebrospinal fluid (CSF) in 
glioma patients are associated with a poor prognosis (Shnaper, Desbaillets et al., 2009). For 
that reason we investigated the expression pattern and the intensity of GDF-15 in different 
types of brain tumors, WHO grade I to IV. We observed intensive GDF-15 staining in all 
glioma sections and very rare GDF-15 expression in normal brain tissue. Like seen in ovarian 
cancer, endothelial cells of the blood vessels appeared to be GDF-15 positive as well. 
Interestingly, high levels of GDF-15 did not correlate with the WHO grade (stages I- IV) of 
the malignant tumor. However, the protein expression in tumor tissue was increased 
compared to healthy brain tissue (figure 3-1-2).  
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Figure 3-1-2 Human malignant gliomas express GDF-15 in vivo 
Paraffin-embedded tissue sections of normal human white matter (top left), diffuse astrocytomas (WHO grade I, 
top right), anaplastic astrocytomas (WHO grade III, bottom left), and glioblastomas (WHO grade IV, bottom 
right) were assessed by immunohistochemistry. Five specimens from each entity were stained. Representative 
images are shown (original magnification, ×200 for all photomicrographs). Pathological evaluation was 
performed and pictures were taken by Michel Mittelbronn.  
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3.2 The effects of GDF-15 in vitro 
3.2.1 GDF-15 does not activate the canonical TGF- signaling pathway in human PBMC 
In 2007, it has been reported by Johnen and colleagues, that the TGF- receptor type II is 
likely to be involved GDF-15 mediated effects on hypothalamic neurons in mice, leading to 
anorexia (Johnen, Lin et al., 2007). Furthermore, Tan and colleagues suggested that GDF-15 
inhibits the proliferation of different tumor cell lines through the TGF- signaling pathway 
(Tan et al., 2000). Assuming that GDF-15 signal transduction is a result of the TGF-beta 
receptor activation, we expected an enhanced Smad2/3 phosphorylation in TGF- sensitive 
cells. Human peripheral blood mononuclear cells (PBMC) express the TGF- receptor and 
respond (highly sensitive) to TGF- by activating the canonical TGF- signaling pathway. 
Thus, we investigated the phosphorylation of Smad2/3 protein of human PBMC in response 
to recombinant GDF-15 by Western Blot analysis. First, peripheral blood lymphocytes from 
four different donors were treated with 100 ng /ml recombinant GDF-15 and 5 ng /ml TGF-
beta for 10 minutes. Recombinant TGF- was used as a positive control. SD208, a TGF- 
receptor tyrosine kinase-I inhibitor, was used as an indicator for autocrine TGF- signaling, 
when compared to the untreated control (Sun et al., 2014). TGF- induced the 
phosphorylation of Smad2/3, whereas GDF-15 did not activate the canonical TGF- pathway 
in lymphocytes from four different healthy donors (figure 3-2-1a). Furthermore, different 
GDF-15 batches were used to exclude batch to batch variations or impurities with other 
growth factors and cytokines as for instance TGF- itself. None of the commercially acquired 
recombinant GDF-15 batches led to an increased phosphorylation of Smad2/3, compared to 
recombinant TGF- (figure 3-2-1), confirming the results obtained in figure 3.2-1a. These 
data suggest that recombinant human mature GDF-15 does not activate the canonical TGF-
beta signaling pathway in human peripheral blood mononuclear cells.  
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Figure 3-2-1: Effects of TGF beta and GDF-15 on the phosphorylation of Smad2/3 in PBMC 
Western Blot analysis using lysates of human PBMCs. Lymphocytes were treated with 100 ng /ml recombinant 
GDF-15 or 5 ng /ml TGF-beta-1 for 10 minutes. Furthermore, PBMCs were treated with 1 µM SD208 for 30 
minutes. SD208 was utilized as an inhibitor of the TGF-beta receptor tyrosine kinase 1, disclosing basal TGF-
signaling in the untreated control. (a) PBMC of four different healthy blood donors responded to TGF- with a 
Smad2/3 phosphorylation (C: control, T: TGF-, G: GDF-15 (Peprotech), SD: SD208).-Actin served as 
positive control.(b) Four commercially acquired batches of GDF-15 (1:R&D, 
2:Peprotech;3:Invigate;4:Pelobiotech) were tested for their ability to activate the TGF-beta signaling pathway. 
Total SMAD2 as well as GAPDH served as a loading control. This figure represents 3 individual Western Blots 
with a similar result. (c) Densitometrically quantified pSMAD2/3 using the image J software. The ratio of 
pSMAD2/3 to total SMAD protein was calculated and normalized to the untreated control.  
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3.2.2 The effect of GDF-15 on the NKG2D receptor on NK cells and CD8
+
 T cells 
One of its various effects of TGF beta is the downregulation of the activating killing receptor 
NKG2D on NK cells and CD8
+
 T cells (Lee et al., 2004, Crane, Han et al., 2010). As a 
divergent member of the TGF- superfamily, we raised the question, whether GDF-15 shows 
similar effects on the NKG2D surface expression on immune cells. Therefore, PBMCs were 
treated with recombinant GDF-15 and the downregulation of the surface NKG2D receptor on 
immune cells was assessed by fluorescence activated flow cytometry. We could observe a 
dose dependent reduction of NKG2D receptor expression on NK cells and CD8
+
 T cells with 
increasing GDF-15 concentrations (figure 3-2-2): The strongest effect of GDF-15 on NK cells 
could be observed at a concentration of 80 ng /ml and higher. Compared with the untreated 
control (100 %), GDF-15 treatment revealed a reduction in the surface NKG2D receptor 
expression of about 18 % ± 5.1 with 80ng /ml and 17 % ± 6.0 with 160ng /ml (figure 3-2-2a). 
2ng /ml and 5ng /ml recombinant TGF- lead to a reduction of the surface NKG2D receptor 
of 54.7 % ± 1.2 and 52.2 % ± 4.9, respectively. On CD8
+
 T cells, GDF-15 treatment resulted 
in a reduction of the NKG2D receptor of about 21.6 % ± 10.5 with 40 ng /ml and 21.3 % ± 
12.9 with 80 ng /ml (figure 3-2-2b). 2 ng /ml and 5 ng /ml recombinant TGF- lead to a 
reduction of the surface NKG2D receptor of 45.9 % ± 8.6 and 43.2 % ± 8.1, respectively. On 
NK cells a concentration of 80 ng /ml recombinant GDF-15 reached its maximum effect. On 
CD8
+ 
T cells GDF-15 reached a saturated plateau at 40 ng /ml GDF-15, indicating that T cells 
are more responsive to GDF-15 than NK cells. Recombinant TGF- was used as a positive 
control, showing a far stronger reduction of NKG2D surface expression compared to GDF-15. 
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Figure 3-2-2: NKG2D receptor surface expression on natural killer cells and CD8
+
 T cells 
Human PBMCs were isolated from a blood donor and treated with recombinant GDF-15 (SF9 derived, provided 
by Professor Müller) (6 concentrations) and TGF--1 (3 different concentrations) for 24 hrs. SD208 was used in 
a concentration of 1 µM to inhibit autocrine TGF- signaling within the immune cells. The figure displays the 
specific fluorescence intensities (SFI) of the NKG2D surface expression on CD3
-
 CD56
+
 NK cells, measured by 
flow cytometry. The NKG2D specific intensities were quantified relative to an unspecific isotype-control 
antibody, labelled with the same fluorochrome as the specific antibody. In this experiment TGF-beta-1 served as 
a positive control for the downregulation of NKG2D receptor on NK cells. Only one measurement has been 
performed for the TGF-beta concentration at 0.2 ng /ml (light gray bar). Each bar represents 3 individual 
experiments from different blood donors. The control represents 100 % NKG2D expression.  
 
 
3.2.3 GDF-15 reduces T-cell-adherence on endothelial cells  
Kempf and colleagues reported in 2011 that GDF-15 influences the adherence of mouse 
polymorphonuclear lymphocytes (PMNs) in vitro (Kempf, Zarbock et al., 2011). The authors 
demonstrated that the treatment of mouse immune cells with GDF-15 leads to the inactivation 
of -integrins on the surface of immune cells, suggesting a decreased ability to adhere to the 
blood vessel endothelium. To investigate the effect of GDF-15 on human immune cell 
adherence, human PBMC were treated with recombinant GDF-15 and adherence on HUVEC 
cells was investigated. Prior treatment of GDF-15, the endothelial cells were pre-treated with 
TNF alpha in order to induce the surface exposure of specific adhesion molecules on 
HUVEC. Pre-treatment of PBMC with phytohemagglutinin (PHA) served as control, which 
mediated global adherence of leukocytes on endothelial cells. TNF induced adherence could 
be slightly lowered by the treatment of CD4
+
 T cells and CD8
+
 T cells with 100 ng /ml of 
recombinant GDF-15 (figure 3-2-3). Macrophages (CD14
+
 cells) did not lose their potential to 
adhere to endothelial cells when treated with GDF-15. These data indicate that GDF-15 
influences the leukocyte-endothelial interaction either by suppression of the TNF induced 
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induction of surface molecules on the HUVEC (e.g. LFA-1/ICAMs, CD44, etc.) or 
reduction/inactivation of adhesion molecules on the immune cell surface.    
    
 
 
 
Fig 3-2-3 In vitro adherence of PBMC on HUVEC under the influence of GDF-15 
Human PBMC were co-cultured on a monolayer of the HUVEC cell line for 1 hour. The adherent fraction as 
well as cells in suspension were stained for CD14 (monocytes), CD4 (TH-cells) and CD8 (CTLs) -positive cells 
and quantified using fluorescent activated flow cytometry. In order to induce adhesion molecule expression, 
HUVEC cells were stimulated with TNF- or phytohemagglutinin (PHA). The TNFa induced adhesion could be 
partially suppressed by the simultaneous treatment with recombinant GDF-15 (R&D Systems). CD14 positive 
monocytes were not affected in regard to their adherence on endothelial cells, when treated with GDF-15. (n=3) 
(This experiment was kindly provided by Dr. Dirk Pühringer) 
 88 
 
3 Results 
3.2.4 Microarray Analysis – the influence of GDF-15 on PBMC and HUVEC cells 
Numerous cytokines and growth factors lead to transcriptional deregulations in cells. For 
example, TGF--1 activates the transcription of mammalian genes important for cell cycle 
regulation, for extracellular matrix formation and which are known to promote 
immunosuppressive functions (Docagne et al., 2001). TGF--1 induces the expression of 
PAI-1 in different human tissues (Kutz et al., 2001). We speculated that GDF-15, similar to 
TGF-, leads to an alteration in gene expression in different cell types. To test this hypothesis, 
a DNA Microarray (GeneChip® Human Transcriptome Array 2.0 from Affymetrix) was 
performed in collaboration with the micro-array core facility at the University Wuerzburg, 
analyzing transcriptional regulations in human umbilical vein endothelial cells (HUVEC) as 
well as human PBMC upon GDF-15 treatment. Peripheral human immune cells were chosen 
because of their asserted responsiveness to GDF-15, which has been reported by Kempf and 
colleagues (Kempf, Zarbock et al., 2011). Furthermore, the slight effects shown in section 
3.2.2 and 3.2.3 allowed to hypothesize a transcriptional response of human lymphocytes upon 
GDF-15 treatment. HUVEC seemed to be an appropriate cell type, since Whitson and 
colleagues could demonstrate a suppressive effect of GDF-15 on endothelial growth and thus 
transcriptional alterations might play a role in mediating this effect (Whitson et al., 2013). 
Different treatment conditions were applied on PBMC before analyzing the gene expression 
pattern: Both cell types were treated with recombinant human GDF-15 (R&D Systems) or left 
untreated for six hours and 24 hours. PBMCs were additionally treated with supernatants of 
HEK293-T cells overexpressing human GDF-15 and with supernatants of empty vector 
transfected HEK293-T-cells for six hours and 24 hours. A cluster analysis with all the 
samples being integrated was performed and illustrated in form of a heat map (figure 3-2-4). 
As a result, the transcriptional profile of the HUVEC cells appeared as a separate cluster when 
compared to their gene expression pattern of the PBMC. However, the clustering within the 
different PBMC treatment groups appeared unexpectedly scattered. In regard to the whole 
gene expression array, the effect of GDF-15 seemed to be too weak to lead to an appropriate 
clustering of the different treatment groups. 
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Figure 3-2-4 Heat map for hierarchical clustering of gene expression pattern in HUVEC and PBMC 
The signal intensities (indicating the gene expression level) obtained from the affymetrix microarray of the 
HUVEC cells and PBMC, which were treated for different points of time, were represented in a cluster analysis 
(using the software R). The intensities received from arrays with the GDF-15 treated cells were normalized to 
the intensities of genes resulting from the untreated controls. High gene expression level is indicated in the heat 
map by red. Low gene expression is presented by blue (see colour key, top left). The hierarchical cluster trees on 
top of the heat map indicate the coherence of different samples. The cluster trees on the left side represent the 
coherent genes on the array. The cluster analysis was performed with the help of Dr. Claus Scholz, from the 
microarray core unit of the University of Wuerzburg.    
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Since the array covered 245.000 transcripts, including ~ 40.000 non-coding ones, a stringent 
pre-selection has been performed (tables 32-37). Either protein coding genes or nucleic acids 
with potential regulatory functions were selected for further analysis. 
Exclusion criteria for the selection of either “up regulated or down regulated” transcripts were 
determined as follows: Transcripts with a log2-fold change (log FC) above 0.5 or below -0.5 
compared to the untreated control cells were selected. The statistical significance (FDR) was 
set to a p-value of less than 0.05. As a result, very few and slight deregulations could be 
observed in PBMCs as well as HUVEC cells (tables 32-43). Human PBMCs as well as 
HUVEC responded to recombinant GDF-15 with a slight up regulation of different olfactory 
receptors. While in HUVEC five different olfactory receptor transcripts are up regulated upon 
GDF-15 treatment after six hours and 24 hours, in PBMC two olfactory receptors genes 
(OR104A, OR2M7) are up regulated at the early point of time (six hours) and down regulated 
after 24 hours (OR104A, OR7G2). In HUVEC, BLID, SPINT-3 and CD44 transcripts were 
slightly down regulated after 6 hours of GDF-15 treatment compared to the control HUVEC 
(figure 3-2-4). CD44 has been described to be involved in adherence of immune cells on 
endothelial cells, and is thus an interesting target in the context of the proposed 
immunomodulatory function of GDF-15. This decrease of CD44 in endothelial cells could be 
confirmed by a further quantitative approach using realtime PCR techniques (qRT-PCR, data 
not shown). Interferon gamma, a potent proinflammatory cytokine, was downregulated in 
PMBCs after 6 hours of recombinant GDF-15 treatment (log2-fold change = - 0.69 ; ***p < 
0.00054). Since the values of induction were quite low, an altered protein expression level is 
rather unexpected for the respective genes.   
 
 
Table 32: Upregulated transcripts of PBMCs treated for six hours with recombinant GDF-15 (R&D 
Systems) 
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Table 33: Downregulated transcripts of PBMCs treated for six hours with recombinant GDF-15(R&D-
Systems)  
 
 
Table 34: Upregulated transcripts of PBMCs treated for 24 hours with recombinant GDF-15 (R&D-
Systems) 
 
 
Table 35: Downregulated transcripts of PBMCs treated for 24hours with recombinant GDF-15 (R&D-
Systems) 
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Table 36: Upregulated transcripts of HUVECs treated for six hours with recombinant GDF-15 (R&D-
Systems) 
 
Table 37: Downregulated transcripts of HUVECs treated for six hours with recombinant GDF-15 (R&D-
Systems) 
 
 
Table 38: Upregulated transcripts of HUVECs treated for 24 hours with rhGDF-15 (R&D-Systems) 
 
Table 39: Downregulated transcripts of HUVECs treated for 24hours with rhGDF-15 (R&D-Systems) 
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Table 40: Upregulated transcripts of HUVECs treated for six hours with HEK-GDF-15 
 
 
Table 41: Downregulated transcripts of HUVECs treated for six hours with HEK-GDF-15 
 
 
Table 42: Upregulated transcripts of HUVECs treated for six hours with HEK-GDF-15 
 
 
Table 43: Downregulated transcripts of HUVECs treated for six hours with HEK-GDF-15 
 
 
 
To summarize these preselected microarray data, a comparative analysis has been performed 
in order to see overlapping gene expression patterns within the different samples. This should 
reveal a conserved pathway initiated by GDF-15. Surprisingly, very little overlap could be 
observed, except of transcripts of the olfactory receptor gene family.   
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3.2.5 In vitro scratch assay 
Today, in several publications GDF-15 is described as a cancer promoting factor. Staff et al. 
reported that GDF-15 correlates with metastasis in endometrial cancer (Staff, Trovik et al., 
2011). Furthermore, Bruzzese and colleagues could demonstrate that an overexpression of 
GDF-15 in fibroblasts drives forth proliferation and migration of prostate cancer cells 
(Bruzzese et al., 2014). In order to study effects of GDF-15 on the migration of tumor cells in 
vitro, an in vitro scratch assay, also known as “wound healing assay” was performed 
according to a published nature protocol (Liang, Park et al., 2007). A MCF-7 breast cancer 
cell line was utilized due to their low endogenous GDF-15 expression. These cells were stably 
transfected with a vector encoding human GDF-15 (pIRES-full-length-GDF-15-eGFP-
reporter construct) as well as a control reporter construct (pIRES-empty-eGFP-reporter 
construct). Stable transfection of the vector was monitored by eGFP-expression using flow 
cytometry (figure 3-2-5a). Since the partially disabled IRES sequence leads to a reduced 
eGFP expression compared to the transcripts of the cloned gene of interest (according to the 
manufacturer protocol), the expression of the target protein GDF-15 was assessed indirectly 
by the GFP positive MCF-7 cells. The scratch size was measured daily for a period of 4 days 
after pictures had been taken using of a microscope compatible camera. We observed a 
similar wound closure pattern when comparing MCF-7 cells transfected with the empty 
pIRES-eGFP-vector with the MCF-7 cells overexpressing GDF-15. This observation indicates 
that GDF-15 has no tumor proliferating effect on this particular cell line in vitro. The 
antagonization of GDF-15 with a neutralizing GDF-15 antibody (B1-23, further described in 
section 3.4) had no effect on the migration of tumor cells, when compared to untreated MCF-
7 cells (figure 3-2-5). The difference in wound healing was less than 2 % when using 2 µg /ml 
of the GDF-15 binding antibody B1-23 compared to untreated MCF-7 cells (ctrl: 12.11 % +/- 
1.04, B1-23: 12.76 % +/- 1.63 after 24 hours. ctrl: 28.68 % +/- 1.63, B1-23: 29.28 % +/- 2.67 
after 96 hours). 
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Figure 3-2-5: In vitro scratch assay with a GDF-15 overexpressing MCF-7 breast cancer cell line 
a) GDF-15 expression was measured indirectly by eGFP positive MCF-7 breast cancer cells using flow 
cytometry. Green fluorescence positive cells (pool) were used for the wound healing assay. Empty vector 
transfected MCF-7 cells served as an internal control for transfection efficacy. b) Wound healing of GDF-15 
expressing MCF-7 cells, treated with 2 µg /ml B1-23 or left untreated, was observed for 96 hours. Snapshots 
were taken on day 0, 1 and 4 and analyzed using the image J software. c) % Wound closure represents the % 
change of the scratch area to the starting point at 0 hrs. The scratches were quantified for each snapshot (four 
snapshots were taken for each well and point of time, according edges were realigned using Adobe photoshop).      
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3.3 GDF-15 knock down leads to prolonged survival in mice bearing glioma 
[The following section shows one data set published by Roth, Junker,…Wischhusen 
(Clin.Canc.Res 2010). The in vivo experiment shown here has been performed by Dr. Patrick 
Roth. It is necessary to show this key experiment at this point of my thesis, since it illustrates 
the relevance of the target protein GDF-15 and explains why the main focus of the underlying 
thesis was the generation of a monoclonal anti-GDF-15 antibody, followed by its in vitro-, in 
vivo validation, characterization and preclinical development]. 
The question, whether GDF-15 is just a biomarker or mediates tumor progression should be 
answered in an in vivo approach using the following syngenic glioma mouse model. The 
SMA-560 astroglioma cell line was stably transfected with a short hairpin RNA construct, 
directed against mouse GDF-15. The control SMA-560 cells as well as the GDF-15 
knockdown cells were injected intracerebrally into mice of the same genetic background 
(VM/Dk-mice) and survival of the animals was observed. Mice bearing the pSUPER-GDF-15 
mediated knock-down cells survived about 40 % longer than the mice injected with the 
pSUPER-control cells (figure 3-3-1a). To confirm the knock down of GDF-15 prior to tumor 
inoculation, a Western Blot was performed, revealing the efficient knock down of mouse 
GDF-15 in the respective shGDF-15 glioma cell line. The prolonged survival of animals 
carrying the GDF-15 deficient tumor cells led to the conclusion that GDF-15 has a malignant 
effect on tumor progression in brain cancers. 
 
 
Figure 3-3-1: Kaplan Meier plot of tumor cell bearing mice with pSUPER-control and pSUPER-GDF-15 
knock down construct  
a) SMA-560 control or shGDF-15 transfected cells were inoculated intracerebrally in syngenic VM/Dk mice. 
Survival data for six animals per group were presented as Kaplan-Meier plot. b) Mouse GDF-15 protein amount 
in SMA-560 control cells and shGDF-15 cells were analyzed by Western Blotting. The graphically depicted in 
vivo results were adapted from figure 4 published in Clin Cancer Res. (Roth, Junker et al., 2010). The 
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experiment was performed and kindly provided by Dr. Patrick Roth, USZ Zürich. The Knock-down cells (SMA-
560shGDF-15) were a kind gift of Dr. Jörg Wischhusen. 
 
 
 
When comparing the presence of T cells and macrophages in the glioma tissues of the 
sacrificed animals, GDF-15 knock down tumors could be shown to be infiltrated by T cells, 
whereas the GDF-15 expressing control tumors were lacking these immune effector cells 
(figure 3-3-2). Macrophages were also observed within the GDF-15 deficient tumors, even if 
to a far lesser degree than the T cells. 
  
 
 
 
 
Figure 3-3-2: Immune cell infiltration in mouse glioma tissue sections FFPE sections 
Mice bearing GDF-15 knock-down tumors were analyzed immunohistochemically for immune cell infiltration. T 
cells were highly infiltrated in the microenvironment of GDF-15 deficient tumors. Macrophage infiltration was 
also enhanced compared the GDF-15 expressing glioma tissue. (Figure adapted from Roth, Junker, et al. Clinical 
Cancer Research, 2010). (Roth, Junker et al., 2010) The experiment was performed and kindly provided by Dr. 
Patrick Roth, USZ Zürich. 
  
     
 
 
 
 98 
 
3 Results 
3.4 Generation and characterization of monoclonal anti-GDF-15 antibodies  
There are several reasons why GDF-15 represents a valuable cancer target rationalizing the 
development of a neutralizing antibody for a possible clinical application:  
 
1)  The amount of GDF-15 in tumor patients correlates with tumorigenicity (Boyle, Pedley et 
al., 2009) [gastric-cancer] and a poor prognosis (Brown, Ward et al., 2003, Staff, Trovik et al., 
2011) [endometrial cancer, colorectal cancer] 
 
2)  GDF-15 has been described as a marker for metastasis in uveal melanoma (Suesskind et 
al., 2012), prostate as well as colon carcinoma (Aw Yong et al., 2014) [skin cancer, prostate 
cancer, colorectal cancer]   
 
3)  Own published in vivo data (Roth, Junker, Wischhusen, 2010), demonstrating prolonged 
survival of mice bearing GDF-15 knock down tumor cells [glioma] (see figure 3-3)  
 
4)  GDF-15 is a soluble factor, which is found in elevated levels in the serum of cancer         
patients. A GDF-15 binding antibody could possibly block the tumorigenic effects of GDF-
15. As a consequence, an anti GDF-15 monoclonal antibody was generated for in vitro and in 
vivo application during my PhD thesis. 
 
 
3.4.1 Confirmation of GDF-15 knock-out animals by PCR  
Prior to immunization of GDF-15 knock out mice with recombinant human GDF-15, the 
genotype of the animals was comfirmed by two individual polymerase chain reactions, using 
specific primer pairs. A typical mouse GDF-15 PCR, which is further described in the 
material and method section, is represented in figure 3-4-1. Genotyping was performed 
according to Strelau and colleagues, who generated the GDF-15 deficient animals by  
insertion of a LacZ casette, resulting in the deletion of the murine GDF-15 locus (Strelau et 
al., 2009). Even though the term GDF-15 knock-out mouse is used here, the correct term for a 
GDF-15 deficient animal would be lacZ / knockin mouse.  
Lane 9 and 10 show the verified genotype of a GDF-15 knock-out mouse from the 
homozygous knock-out breeding. The 690bp PCR product represents the partially amplified 
lacZ gene, whereas the 320 bp product embodies the wildtype mouse GDF-15 amplicon 
(figure 3-4-1). 
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Figure 3-4-1: Genotyping of GDF-15 knock-out animals  
The presence or deficiency of wild type genomic mouse GDF-15 was confirmed by PCR with all 
animals/progenies from the GDF-15-knock-out breeding. PCR products were run on a 1 % TAE DNA gel and 
visualized by Gelred™ using a gel-illumination device. As positive control for the wild type GDF-15 PCR, 
genomic DNA from kidney and heart tissue from GDF-15
+/+
 mice were used  (lanes 1, 2 and 5, 6). The positive 
control for the GDF-15 knock-out PCR has been performed with genomic DNA from kidney and heart tissue 
from GDF-15
-/- 
animals and underwent a different PCR program (shown in the methods section). PCR products 
on lanes 1, 3, 5, 7 are from genomic DNA derived from kidney, 2, 4, 6, 8 from heart tissue, respectively). Lane 9 
and 10 represent the PCR products of genomic DNA obtained from ear clips from an offspring of the GDF-15 
knock-out breeding.    
 
3.4.2 Immunization of GDF-15 knock out mice with human GDF-15 resulted in several 
GDF-15 Abs for further characterization and development 
For the generation of monoclonal antibodies to human GDF-15, the standard hybridoma 
fusion technology described by Milstein and Köhler in 1975 was applied (Köhler and 
Milstein, 2005). 2000 hybridoma supernatants were screened for GDF-15 positive clones. 
Screening was performed on a nitrocellulose membrane, which was spotted with recombinant 
mature GDF-15 (described in detail in methods section). Out of these 2000 clones most of the 
supernatants gave no or very low signal. A few supernatants appeared with low to moderate 
signal intensity and less than 10 supernatants emerged as strong GDF-15 binders (figure 3-4-
2). Four hybridoma clones (X5H, X7D, X8C and X8G) displaying the highest signal 
intensities were picked for further subcloning and characterization. The antibodies were 
named according to their plate letter and well position (e.g. X7D). Initially, X5H showed the 
strongest GDF-15 signal and consequently served as a positive control on each screening 
membrane. After the first round of subcloning, the production or the specificity of the 
antibodies for GDF-15 were lost for the X8 clones (X8C and X8G). The subcloned X7D4 
appeared to be a high producing hybridoma clone, binding recombinant mature GDF-15 with 
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high affinity. X5H2-Hybridoma could be expanded, but after further rounds in culture the 
antibodies lost its binding capacity to GDF-15 (figure 3-4-2b). The low percentage of 
monoclonal anti-GDF-15 antibodies from two immunized GDF-15 knock out animals could 
be explained by the applied conditions of the antibody-“screening procedure”: the incubation 
of the supernatants was kept very short due to technical limitations (less than 10 seconds). 
Very stringent washing conditions very applied for the first round of screening. This could 
have resulted in the appearance of mostly high affinity antibodies. Low affinity binding anti-
GDF-15 antibodies could have existed, but have been lost during the screening process.  
 
 
Figure 3-4-2: Screening of GDF-15 antibody producing hybridoma clones 
Recombinant human GDF-15 (SF9, provided by Professor Müller) was spotted on a nitrocellulose membrane in 
its native (nat) and denatured form (den) (each spot contained 20 ng of protein) a) Supernatants of 2000 
hybridomas were harvested after 10 days of culture and transferred from a 96 well plate onto the nitrocellulose 
membrane using a multichannel (12x) pipette. (b) One representative out of 40 second round screening 
membranes, showing mostly GDF-15 negative or low affinity binding hybridoma supernatants (b). The first and 
second row shows the binding of subcloned X7D antibodies. The candidate for further preclinical development 
B1-23 is demarcated with a red circle.   
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A cloning of X7D4 by the limited dilution method and a further subcloning of 
X7D4figure3-4-2b) finally resulted in the hybridoma clone X7D4 -B1-23, which received 
the short name B1-23. This nomenclature is of great importance, since the preclinical 
development of the anti GDF-15 antibody, which is ongoing in the department of gynecology 
and obstetrics of the university hospital of wuerzburg is exclusively based on the clone B1-23 
and a substantial part of that thesis. The hybridoma cell line Bl-23 was deposited at the 
DSMZ, the ´German Collection of Microorganisms and Cell cultures´ under the accession no. 
DSM ACC3142 in agreement of the Budapest treaty, followed by a subsequent patent 
application [PCT/EP2013/070127]: WO2014049087A1.  
 
 
3.4.3 Antibody production of hybridoma clones 
In order to assess the productivity of the antibody expression, supernatants of the selected 
hybridomas X8G9, X5H2 and B1-23 were analyzed by SDS-PAGE using Coomassie stain 
(not shown here) and Western Blot analysis (figure 3-4-3). To visualize murine 
immunoglobulins, an anti-mouse-IgG-(H+L)-HRP-coupled antibody, was used as a secondary 
antibody. To rule out immunoglobulin background from fetal calf serum, two different culture 
conditions were applied on the monoclonal hybridoma cultures: 10 % FCS containing RPMI 
complete (+) and Ig-stripped serum, which is supposed to lack calf immunoglobulins 
according to the manufacturer protocol (-). The clones X8G9, X5H2 and B1-23 from 
hybridoma supernatants were compared to supernatants of the myeloma cell line 
X63AG8.653, which served as an immunoglobulin background control (figure 3-4-3). B1-23 
appeared under reducing conditions as two bands, 25 kDa and 50 kDa, representing the light 
and the heavy chain of the antibody, respectively. We observed one single 25 kDa band using 
supernatants of the clone X5H2, leading to the conclusion that only the light chain of this type 
of antibody cross reacted with the secondary anti-mouse IgG antibody, but not the heavy 
chain. For the clone X8G9 no immunoglobulin signal could be detected, indicating that the 
respective hybridoma clone stopped producing antibodies in general.    
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Figure 3-4-3: Heavy and light chains of hybridoma cell derived antibodies  
To assess the antibody production of hybridoma cells, a Western Blot analysis has been performed with 10 µl of 
hybridoma cell supernatants, cultured for 5 days. The clones X8G9, X5H2, B1-23 were compared to the 
X63AG8.653 myeloma cell supernatants (X63.Ag). Culture conditions of hybridoma cells: (+) normal fetal calf 
serum, (-) Ig-stripped fetal calf serum. A mouse IgG antibody was used as positive control (right lane). An anti-
mouse IgG (H+L)-HRP conjugated antibody was used for detection of the immunoglobulins. 
 
 
3.4.4 B1-23 detects GDF-15 under semi-native conditions on Western Blots 
Preclinical drug development requires an extensive characterization of a lead candidate as 
well as the target molecule. Since a variety of different GDF-15 protein forms can be found in 
supernatants of tumor cells (3-4-3b), we wanted to elucidate, which of these GDF-15 forms 
were engaged by the antibody B1-23. Consequently, B1-23 was used as a “detection” 
antibody for human GDF-15 in a Western Blot under semi-native conditions. B1-23 detected 
recombinant mature GDF-15 dimer at a size of 25 kDa. The calculated molecular weight of 
the mature GDF-15 monomer is about 12.5 kDa. Moreover, the antibody B1-23 was able to 
detect several GDF-15 forms in supernatants of HEK293-T cells overexpressing full length 
GDF-15 (figure 3-4-3a), appearing at the following molecular weights: 25 kDa, 40 kDa and 
70 kDa. These protein bands are likely to represent the mature dimeric GDF-15 (25 kDa), the 
hemi-dimer (40 kDa) and the full length homodimer of GDF-15 (70 kDa) (described in detail 
in section 1.2). The antibody did not detect recombinant GDF-15 under reducing conditions 
together with heat-denaturation at 90°C for 10 minutes (not shown). Instead, B1-23 detected 
all known forms of GDF-15 under non reducing conditions. Since B1-23 was able to 
recognize recombinant GDF-15 in a semi native SDS-PAGE, the antibody was likely to bind 
a discontinuous epitope of GDF-15 rather than a linear epitope. 
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Figure 3-4-4: B1-23 is suitable for WB-detection of recombinant and overexpressed full length GDF-15 
a) Western Blot for the detection of human GDF-15 was performed under non reducing conditions. Accordingly, 
B1-23 detected the increasing amounts of recombinant human GDF-15 (R&D Systems) in lane 1-5 (31ng – 
500ng). Moreover, B1-23 recognizes full length human GDF-15 transiently overexpressed in HEK293 T cells 
using the expression vectors pIRES-hGDF-15-eGFP (lane 6+7) and pcDNA3.1-hGDF-15 (lane 8+9). (b) 
Schematic: GDF-15 forms and B1-23 detection pattern thereof: B1-23 detects mature dimeric GDF-15 at 25 kDa 
(blue dimer), the GDF-15 ´hemi-dimer´ at 40 kDa (blue dimer containing one red precursor protein) and the full 
length homodimer at about70 kDa. (c) B1-23 does not detect the monomeric mature GDF-15 or the monomeric 
full length protein.  
 
 
3.4.5 Isotyping of B1-23 
Human and mouse immunoglobulins exist in different forms of isotypes (IgA, D, G (1,2a, 2b, 
3, 4), E, M). Every isotype behaves differently from each other. Large scale production of an 
antibody requires the information of its isoform, since every isoform requires special 
purification conditions. For example: an IgM cannot be purified using protein A columns 
compared to an IgG1 or an IgG2a. It is also crucial to know the isotype of an antibody used 
for Western Blot staining, since some secondary antibodies specifically bind a sequence of the 
primary antibody in an isotype specific manner. Isotyping stripes from AbDSerotec and 
Roche (IsoStrip, mouse monoclonals) were used to identify the B1-23 as a murine IgG2a 
antibody consisting of the kappa light chain type.     
The isotype of two further supernatants of hybridoma cells producing GDF-15 reactive 
antibodies were tested as well. The candidate X5H2 could be detected as an IgM isotype, 
which matched the immunoglobulin Western Blot in figure 3-4-2. Whereas the light chains of 
the pentameric IgM antibody could be detected on a Western Blot, the secondary anti mouse 
HRP (raised against heavy and light chain) did not cross react with a heavy IgM chain. The 
isotype of the hybridoma clone X8G9 was also tested. No isotype could be determined, since 
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the production of antibodies from that specific clone had come to an end and could be 
confirmed by SDS-PAGE, shown in 3-4-2.    
 
 
3.4.6 Epitope mapping of B1-23 
 
• mapping of linear epitopes [Pepperprint GmbH] 
 
To investigate whether B1-23 binds a continuous epitope within the GDF-15 protein, an 
epitope mapping for linear epitopes was performed externally by the company Pepperprint 
GmbH (Heidelberg, Germany). Therefore, a customized chip with spotted peptides of the full 
length human GDF-15 protein sequence was generated. The 324 linear GDF-15 peptides 
comprised a length of 13 amino acids, with an overlap of one amino acid. The secondary 
goat-anti-mouse IgG (H+L) IRDye680 was applied separately as a background control. B1-23 
was applied on the peptide array over night at 4°C, followed by the secondary antibody 
incubation. The arrays were subsequently analyzed using the Odyssey Imaging System. A 
weak interaction of the arginine-rich peptides (ELHLRPQAARGRR, LHLRPQAARGRRR, 
HLRPQAARGRRRA, LRPQAARGRRRAR, RPQAARGRRRARA, PQAARGRRRARAR 
and QAARGRRRARARN) could be observed using the secondary anti-mouse antibody 
alone. According to the report provided by the company, these sequences and the basic 
peptide MHAQIKTSLHRLK are known to be frequent binders due to ionic interactions with 
the charged antibody dye (figure 3-4-5, a). None of the linear 13mer peptides derived from 
human full length GDF-15 interacted with the monoclonal GDF-15 antibody B1-23, even at 
overregulated intensities (figure 3-4-5, b). A positive control staining of Flag and HA control 
peptides that frame the array, resulted in clear and homogeneous spot intensities, 
demonstrating that no technical problems occurred while the experimental setup and 
performance. 
 
 
 
 
 
 
 
 105 
 
3 Results 
 
 
Figure 3-4-5: Linear epitope mapping of full length GDF-15 with anti GDF-15 antibody B1-23 
324 linear peptides (13mers) of human GDF-15 were spotted on a microarray. As a blank subtraction, 
background intensities were analyzed using the secondary goat anti-mouse IgG(H+L) IRDye680 antibody 
separately (a); B1-23 was subjected to the microarray, followed by staining with the anti-mouse (H+L)-
IRDye680 antibody, resulting in no specific signal to the spotted GDF-15 peptides. The green and red spots 
framing the array comprised HA and Flag control peptides. (The linear epitope mapping data were performed 
and kindly provided by Pepperprint GmbH, Heidelberg).  
   
 
 
The mapping of monoclonal mouse GDF-15 antibody against the human full length GDF-15 
did not reveal a single linear epitope with the 13mer peptides derived from the antigen. 
According to this finding it is likely that B1-23 recognizes a three-dimensional or 
discontinuous epitope with low or no affinity to linear stretches of the protein.  
 
 
• mapping of discontinuous epitopes by epitope excision [Steinbeis-Zentrum]  
 
 
B1-23 did not bind a continuous linear epitope within the GDF-15 amino acid sequence, as 
shown in figure 3-4-5. We hypothesized that the interaction between GDF-15 and B1-23 
occurred exclusively when GDF-15 maintained its three-dimensional protein conformation. In 
order to reveal a discontinuous epitope of B1-23 on its target molecule, an epitope excision 
method was performed externally in collaboration with the Steinbeis-Zentrum Konstanz. 
Therefore, the immobilized antibody-antigen-complex B1-23-rhGDF-15 was digested with 
trypsin followed by the elution of the resulting antibody shielded peptides under acidic 
conditions. Eluates were analyzed using a high resolution spectrometer LC/MS-MS. 
(Professor Przybilski, Steinbeis-Zentrum Konstanz, for detailed information see methods 
section, chapter 2). By this method, two peptide stretches of mature human GDF-15 were 
identified being protected by B1-23, representing the epitope engaged by the antibody: 
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Peptide sequence 1: evqvtmcigacpsqfr 
Peptide sequence 2: tdtgvslqtyddllakdchci 
   
Table 44  B1-23 interacting peptides 1 and 2 located in the mature GDF-15 sequence   
 
 
Peptide 1 and peptide 2 (in red) are linked by a peptide sequence, which could not be shielded 
by B1-23 during tryptic digestion (blue letters). This result demonstrated that the monoclonal 
antibody B1-23 detects a discontinuous epitope comprising the peptides 1 and 2 listed above 
and confirmed the missing reactivity of B1-23 to shorter linear epitopes, covering a length of 
only 13 amino acids (figure 3-4-5).    
 
For further characterization of B1-23, the antibody was produced in a larger scale, culturing 
the hybridoma cell clone in a CELL-LINE bioreactor (Integra). The resulting antibody titer 
revealed concentrations between 0.5 mg/ml and 2 mg/ml. These hybridoma cell supernatants, 
received from the static bioreactor, were harvested in an interval of 5-7 days of culture and 
affinity purified on protein A columns.  
Using the purified and specifically formulated antibody B1-23, functional assays and 
cytotoxicity tests were performed as shown in the following sections. 
 
 
3.4.7 Sequence identification of the hypervariable regions of B1-23 
To receive the nucleotide sequence of the murine anti GDF-15 antibody B1-23, a proprietary 
PCR based method described by Wang and colleagues was applied (Wang, Raifu et al., 2000). 
Thereby, the hypervariable regions and thus the antigen binding site of the antibody B1-23 
could be amplified using degenerate primers. These primers had been validated to bind the 
variable regions of many different mouse IgG2a isotype antibodies. The light chain and heavy 
chain sequences of the antibody were amplified in individual polymerase chain reactions 
using cDNA templates from the B1-23-hybridoma RNA (the procedure was described in 
detail in chapter 2). The resulting PCR products (figure 3-4-6), comprising the 
complementarity determining regions (CDRs) of the light and heavy chain of the B1-23 
 107 
 
3 Results 
antibody were cloned into the clone JET vector (pJET1.2/blunt, Life Technologies), which 
was then successfully sequenced by GENEART AG (table 45). 
 
 
 
 
Figure 3-4-6: Amplification of heavy and light chain DNA of hybridoma antibodies 
In order to receive the unknown Fab sequences, cDNA of the monoclonal hybridoma cell clones B1-23, X8G9 
and X5H2 were PCR-amplified for further cloning into the pJET1.2 vector for sequencing. Therefore, degenerate 
primers were used for either the light chain (5´Mk + 3´Ck primers) or the heavy chain (5´MH1 + 5´MH2 + 
3ÍgG2a primers) of murine antigen binding sequences. After the first PCR, the amplified sequences were hardly 
visible on the DNA gel. Following the protocol for degenerated primers, the PCR product was used for a second 
PCR, revealing the visible bands, representing the amplified CDRs of the according chains. The heavy chain 
PCR failed for the hybridoma cell clones X8G9 and X5H2.    
 
 
Sequence of the light chain variable region of B1-23:  
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Sequence of the heavy chain variable region: of B1-23: 
 
Table 45: Sequence of the Fab region of B1-23 after amplification with degenerate primers 
(Green) forward primer sequence, (Red) Fab-sequence including 3 complementarity determining regions, 
comprising CDR1, CDR2, CDR3, which are interconnected with 3 framework sequences (FR1, FR2, FR3). 
(Black) Framework 1-reverse primer. For the heavy chain variable region the priming sequence is demarcated as 
a short sequence, since 2 different primer pairs are used (MH1 + MH2).    
  
 
3.4.8 Chimerization of B1-23 
The development of the chimeric anti GDF-15 antibody was an intermediate step prior the 
humanization of B1-23. The “grafting” of the B1-23-Fab-site on a human IgG1 backbone, 
done externally by evitria´s proprietary technology, was performed to confirm the cloned 
hypervariable regions in the antigen binding site of B1-23 as the correct sequence. The 
functionality of the designated ChimB1-23 was still given, the Fabs of B1-23 (CDRs) were 
properly integrated into a human IgG1 antibody framework. The resulting chimeric antibody 
was transiently expressed by evitria and supernatants thereof were tested in regard to their 
quality and specificity to GDF-15. Three different recombinant GDF-15 batches (B41 [E. 
coli], SF9B [eukaryotic], R+D-Systems [eukaryotic]) could be detected by the chimeric 
antibody ChimB1-23, indicating the correct sequence of the antigen binding site of B1-23 
(figure 3-4-7). Using the chimeric immunoglobulin resulted in the same staining pattern 
compared to the origin B1-23, which was used as a positive control. Interestingly, the E. Coli 
derived GDF-15 (B41) appeared on the SDS-Gel as two distinct bands, one of them 
representing the expected 25 kDa dimeric GDF-15 and the other band at about 40 kDa. We 
assume that the higher band, which is also slightly visible in the eukaryotic derived GDF-15 
(SF9, R&D), embodies multimers of GDF-15 molecules.   
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Figure 3-4-7 Detection of mature human GDF-15 by the chimeric antibody ChimB1-23    
Chimeric B1-23 was compared to the murine B1-23 in regard to its GDF-15 binding ability. 100 ng of 
recombinant human GDF-15 was added on each lane on the SDS-PAG (B41, SF9, R&D are different GDF-15 
batches). A Western Blot was performed under non reducing (semi native) conditions to retain the 3 dimensional 
structure of GDF-15. Whereas B41 is an E. coli derived protein, the SF9 and R&D-GDF-15 proteins were 
produced in eukaryotic cells. 
 
 
3.4.9 Humanization of B1-23 and characterization of the humanized variants 
Based on the CDR sequence shown in section 3.4.7, the expression constructs encoding the 
heavy and light chains of the humanized B1-23 were generated externally by evitria AG. Five 
different heavy chain variants and five light chain variants of the original antigen binding site 
of B1-23 were generated (table 46). Amino acids were altered exclusively within the 
framework sequence of the immunoglobulin, but not in the CDRs of the respective antibody 
chains. The in silico generated derivatives of the hypervariable regions of B1-23 were 
synthesized and cloned into a proprietary expression vector of evitria. All 25 combinations of 
the heavy and light chains of the antibody (H1L1-//-H5L5, table 46) were transiently co-
expressed in CHO cells and tested for their binding specificity to GDF-15. The humanized 
antibody H1L5, comprising the humanized heavy chain H1 and light chain L5, was selected 
as the candidate for further preclinical development due to its highest affinity to GDF-15. 
The KD -value of H1L5 was 5.6 nM (list of humanized KD values in table 47). 
H1L5 consisted of the following amino acid sequences: 
 
Heavy chain 1: 
QITLKQITLKESGPTLVKPTQTLTLTCTFSGFSLSTSGMGVSWIRQPPGKGLEWLAHIY
WDDDKRYNPTLKSRLTITKDPSKNQVVLTMTNMDPVDTATYYCARSSYGAMDYWG
QGTLVTVSS 
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Light chain 5:  
DIVLTQSPSFLSASVGDRVTITCKASQNVGTNVAWFQQKPGKSPKALIYSASYRYSGV
PDRFTGSGSGTEFTLTISSLQPEDFAAYFCQQYNNFPYTFGGGTKLEIKR   
 
Table 46: Sequences of the humanized light and heavy chains (performed by evitria AG)  
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Table 47: KD value determination of 13 pre-selected humanized antibodies derived from B1-23 
(performed by Steinbeis Zentrum Konstanz) 
 
    
 
The expression vectors for H1 and L5 were obtained from evitra AG and tested for their “in-
house” expression in CHO cells.  
Transient co-expression of both vectors (pHC1 +pLC5) in CHO cells resulted in specific anti-
GDF-15 antibody expression (figure 3-4-8). We observed no binding to GDF-15, when CHO 
cells were transfected exclusively with either the light chain expression vector pLC5, or the 
heavy chain expression vector pHC1. This result led to the conclusion, that the variable 
regions of both the light and heavy chain of the humanized antibody H1L5 are necessary for 
proper antigen binding. This information is useful for prospective construction of modified 
GDF-15 binding proteins derived from the B1-23 sequence, such as single chain variable 
fragments (scFv), diabodies and many other Fc-lacking proteins with preserved neutralizing 
potential. 
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Figure 3-4-8 GDF-15 is detected by co-expression of light and heavy chain constructs of H1L5  
Semi native Western Blot was performed with 100ng recombinant GDF-15 (Invigate) on all 4 lanes. After the 
transfer the PVDF membranes were cut in four stripes and incubated (according to the Western Blotting 
procedure described in the methods section) with supernatants from CHO cells, transiently transfected with the 
light chain pLC5, heavy chain pHC1 and co-expression of light and heavy chain pHC1 + pLC5 constructs (lane 
1,2,3, respectively). The expression vectors containing the humanized light and heavy chain sequence (table13) 
were designed by and obtained from evitria AG). Binding of the recombinant human GDF-15 was observed only 
when both chains of H1L5, light and heavy, were overexpressed and thus assembled. As a positive control, the 
purified and Western Blot validated H1L5 was used on lane 4 (number of lanes from left to right). 
 
 
As shown in figure 3-4-8, only in the presence of both light and heavy chain of B1-23/H1L5 
the antigen GDF-15 could be targeted by the antibody. Using the IMGT database, an 
alignment of B1-23 variable regions with existing IgG2a mouse immunoglobulins resulted in 
antibodies with 97 % and 9 6% sequence homology for the heavy chain and light chain, 
respectively (table 48). The CDR1 and CDR2 of both the light and the heavy chain of our 
drug candidate revealed a sequence similarity of 100 % with one antibody from that database. 
The CDR3 appeared as the most altered sequence when compared to the even most similar 
immunoglobulin from the IMGT library. Because of the unique CDR3 sequence of B1-23, we 
assumed that this particular hypervariable region is necessary for the antigen binding. To test 
the hypothesis that the CDR3 is required for proper binding of the antigen, the CDR3 
sequence of B1-23 was exchanged by a CDR3 sequence of an antibody engaging an HIV 
epitope (performed by evitria AG). The replacement of the CDR3 within the anti-GDF-15 
antibody B1-23 resulted in a complete loss of binding to recombinant GDF-15 (figure 3-4-9). 
As an additional proof that the antigen binding to B1-23 is mediated by its CDRs and not by 
the interaction of the framework sequences of the antibody, all 3 CDR sequences have been 
replaced by 3 hypervariable regions of an HIV specific antibody, without changing the 
framework amino acids. As an expected consequence, the antibody completely lost its ability 
to bind GDF-15 (figure 3-4-9). 
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Figure 3-4-9 Replacement of the CDR3 of B1-23 leads to the loss of antigen binding 
Antibody binding was tested in a colorimetric assay. Recombinant GDF-15 was coated on Maxisorp™ 96 well 
plates. Antibodies were incubated at six different concentrations ranging from low to high concentrations. H1L5 
served as a positive control for GDF-15 binding. The modified antibodies designated “B1-23 Anti-GDF-15 
CDR-1,-2& Anti-HIV CDR-3” and “B1-23 framework Anti-HIV CDR-1,-2,-3” were grafted on a human IgG1 
antibody, the reason why the humanized H1L5 had to be used in this experiment. As a secondary antibody, an 
anti-human-HRP conjugated antibody was used. Antibody binding was assayed by conventional ELISA 
measurement determining the optical densities at 450 nm.     
 
 
 
Table 48: IMGT database: Sequence alignment of B1-23 hypervariable regions including framework 
sequence 
Variable heavy chain: 
 
Variable light chain: 
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3.4.10 In vitro effects of the developed anti GDF-15 antibodies 
Preclinical development of a drug substance requires a very intensive characterization of the 
therapeutic biological. This is one reason, why my thesis has a substantial focus on the 
antibody development and characterization. Whereas externally performed proliferation 
assays with LnCap cells seemed to reveal a moderate antitumor effect in vitro when using 100 
µg /ml B1-23 for 72 hrs (not shown here), own experiments could not significantly confirm 
such a result. Neither the addition of recombinant GDF-15 on tumor cell lines nor the 
antagonization of mature GDF-15 led to an altered proliferation in vitro (data not shown).  
As GDF-15 is a soluble protein being elevated in the serum of a variety of cancer patients, we 
hypothesized that B1-23 should complex this growth factor in vitro. As a first step we 
monitored the secretion of GDF-15 into supernatants of the melanoma cell line UACC-257 
over a period of six days by Western Blot analysis (figure 3-4-10, a). 20 µl of UACC-257 
supernatants were taken from the same well every 24 hours. The mature GDF-15 hemidimer 
(40 kDa) as well as the GDF-15 homodimer (~70 kDa) accumulated over time reaching a 
saturated protein level between day 4 and day 5.      
To answer the question of how much antibody is necessary to antagonize the tumor cell 
produced GDF-15, B1-23 was given in different concentrations to UACC-257 melanoma cells 
cultured for 48 hours. 10 µg /ml B1-23 and higher concentrations thereof resulted in a 
complete loss of signals representing the mature GDF-15 dimer as well as all isoforms 
containing the mature dimer (figure 3-4-10, b). A concentration of 1 µg /ml anti-GDF-15 
antibody resulted in a decrease of GDF-15 related signals in the cell culture supernatant, but is 
not enough to remove the molecule from supernatant completely (figure 3-4-10, b). 
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Figure 3-4-10: GDF-15 accumulation in supernatants of UACC-257 cells and its depletion by B1-23    
(a, b)Western Blot analysis was performed with 20 µl of supernatants from each sample of UACC-257 
melanoma cells. The anti-pro-GDF-15 antibody (Sigma) was used for the detection of the GDF-15 protein. (a) 
50 µl of supernatants of UACC-257 cells was harvested daily, starting at day 0 (2 hours after seeding the 
melanoma cells), ending on day six. On the last lane a control supernatant was utilized as a technical control. (b) 
UACC-257 melanoma cells were cultured and treated for 48 hours with different concentrations of the anti-
GDF-15 antibody B1-23 (from left to right lane: 100, 10, 1, 0.5, 0.1 µg /ml; last lane: untreated supernatant).  
 
 
Knowing that 10 µg /ml of B1-23 sufficiently depletes tumor cell derived GDF-15 in vitro, we 
investigated the derivatives of B1-23 in the same “antagonization-assay” described in 3.4.10. 
All applied substances, comprising GDF-15 blocking antibodies and control antibodies, were 
administered at a concentration of 10 µg /ml. Beside B1-23, the antibodies ChimB1-23, 
H1L5, B12 (isotype-antibody), Rituximab as well as Fab fragments of ChimB1-23 were 
tested on UACC-257 melanoma cells for 48 hours. All GDF-15 antibodies were capable to 
efficiently clear the cell derived GDF-15 from the supernatant (figure 3-4-11). This effect 
could also be observed with the Fab fragments of B1-23, indicating that the antigen binding 
site of the antibody is sufficient for the clearance of GDF-15 in vitro. As expected, Rituximab 
and the isotype antibody B12 did not lead to a decrease of GDF-15 in the respective cell 
culture supernatants.  
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Figure 3-4-11: Antagonization of tumor cell derived GDF-15 with B1-23 
Western Blot analysis with supernatants from UACC-257 cells. The melanoma cells were seeded in 24 well 
plates and incubated for 24 hours. Subsequently, these cells were treated with the anti-GDF-15 antibodies B1-23 
and ChimB1-23 (Chim), an Iso-antibody (B12), Rituximab (Ritux), antibody fragments of the chimeric B1-23 
(Fabs) and PBS for 48 hours. Rituximab and the Iso-antibody B12 served as negative controls, PBS represents 
the vehicle control. 
 
 
3.4.11 Assessment of cytotoxic effects of B1-23 
Preclinical development of a drug substance requires a very intensive characterization of the 
therapeutic biological in regard to its toxicity profile. Many side effects of antibodies have to 
be examined precautious, before entering clinical trials in humans. 
As a first approach, we tested the drug candidate B1-23 in vitro on human blood cells. B1-23 
had no toxic effect on human peripheral lymphocytes, when compared to small molecule 
inhibitors, which are frequently dissolved in DMSO due to solubility issues (figure 3-4-12).  
Compared to the untreated control, we observed an equal turnover of WST-1 substrate, when 
treating peripheral blood lymphocytes with 10 µg /ml B1-23/H1L5 for a period of 24 hours. 
In addition, B12, an unspecific isotype, and the FDA approved antibodies Ipilimumab and 
Bevacizumab were tested. These antibodies were applied at a concentration of 10 µg /ml and 
did not reveal a negative effect on the viability compared to the untreated control. Treatment 
of 5 % DMSO, which served as a control condition, resulted in a viability of 40 %, compared 
to the untreated control PBMC. Similarly, Paclitaxel, which was applied on PBMC at its IC50 
of 5nM (Liebmann et al., 1993), which negatively affected the leukocyte viability, resulting in 
60 % decreased WST-1 turnover. Dacarbazine, which is a FDA approved substance for the 
treatment of metastatic melanoma, was further applied to assess its toxicity on leukocytes 
(Hill et al., 1984). Dacarbazine was dissolved in PBS and added to the lymphocytes at a 
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concentration of 50 µM (Samulitis et al., 2011). Dacarbazine had no effect on human immune 
cells when compared to the control group (figure 3-4-12).        
 
 
 
 
Figure 3-4-12 Toxicity test of B1-23 on blood lymphocytes  
2 x 10
6
 PBMC from different blood donors were seeded in 24 well plates (in triplicates) and treated with B1-
23/H1L5, B12, Ipilimumab, Bevacizumab (Avastin), 5 % DMSO, Paclitaxel, Dacarbazine or left untreated for 
24 hours. Then WST-1 substrate was added to the cells for a period of two hours. The measurement of the 
absorbance was performed using the Tecan Sunrise Reader (OD450nm). This figure represents 3 individual 
experiments with similar results.   
 
 
Furthermore, we did not observe any adverse events in mice - related to direct or indirect 
toxic effects - after B1-23 had been administered intraperitoneally. The antibody was found in 
high concentrations (> 2 mg/ml) in the blood of the animals at the time of necropsy, 
suggesting a systemic distribution of the immunoglobulin, “reaching” all organs of the 
animal. The nude mice treated with the anti GDF-15 monoclonal antibodies resembled the 
PBS treated control mice, which did not show any symptoms. Parameters to investigate the 
physiological condition of the treated animals were body weight, activity, social interactions, 
alertness, perception, moving and reaction to stimuli. 
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3.5 B1-23 prevents tumor associated cachexia in BalbCnu/nu mice   
Johnen and colleagues reported in 2007 that tumor derived GDF-15 leads to anorexia 
resulting in body weight loss in mice (Johnen, Lin et al., 2007). In this publication it could be 
demonstrated that anti-GDF-15 antibodies are able to reverse the cachectic effect of GDF-15 
in nude mice xenografted with GDF-15-transgenic prostate cancer cells. To investigate 
whether B1-23 and the chimeric and humanized forms thereof are able to revert the effect of 
body weight loss, we used an own melanoma tumor model, in which we observed a tumor 
mediated cachectic effect in Balb/c
nu/nu
 mice. In this model, 1.0 x 10
7
 UACC-257 melanoma 
cells, which produce high endogenous GDF-15 levels (shown in figure 3-4-10a), were 
subcutaneously inoculated into the immunocompromised animals (details in section 2). The 
antibodies were administered twice a week starting at day 0 (day of tumor inoculation). Body 
weight as well as food uptake was measured twice a week until day 38. At day 38, we 
observed a decline of body weight to 85 % of the initial body weight (set to 100 %) for the 
PBS treated group (figure 3-5). The administration of the iso-antibody B12 resulted in a 
decline of body weight to 82 %. Conversely, the application of B1-23, ChimB1-23 and H1L5-
B1-23 led to a total increase in body weight on day 38. Compared to the initial body weight of 
each treatment group on day 0, mice treated with the GDF-15 antibodies reached the 
following body weights at the end of the experiment (day 38): 102 % for the administration of 
the murine antibody B1-23, 105 % with ChimB1-23 treatmet and 107 % when animals where 
treated with the humanized H1L5 (figure-3-5). The effect was significant for all of the groups 
treated with anti-GDF-15 antibodies (two-way ANOVA; p<0.05). Interestingly, the Fab 
fragments of ChimB1-23 could not prevent the loss of body weight in the animals, but even 
led to a decline of the initial body weight to 78 %.   
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Figure 3-5 B1-23 prevents GDF-15 mediated cachexia in vivo 
Treatment of mice with anti GDF-15 antibodies B1-23, ChimB1-23, H1L5-B1-23 prevented tumor induced body 
weight loss in mice. The antibodies were given on the day of tumor cell inoculation. As a control antibody B12 
was used. Beside the exchanged CDRs (anti-HIV epitope CDRs) the iso-antibody B12 is almost identical to the 
humanized antibody H1L5-B1-23. Dacarbazine was used as a positive control for tumor growth reduction (data 
not shown in this thesis). This experiment was performed together with Dr. Tina Schäfer and Dr. Dirk 
Pühringer.* 
 
 
At this point of the thesis it has to be mentioned that the melanoma xenograft experiments 
were initially performed to investigate antitumor effects of the generated GDF-15 antibodies 
and variants thereof. Even though external data from independent contract research 
organizations demonstrated tumor growth reduction using B1-23, we did not observe 
significant tumor inhibiting effects using the GDF-15 antibodies B1-23, ChimB1-23 as well 
as H1L5. However, cachexia could be completely prevented in this model. 
 
 
 
 
 
* Dr. Tina Schäfer subcutaneously inoculated the tumor cells in the animals. Dr. Dirk Pühringer and I labelled 
the tails of the animals, measured the body weight and food intake. Intraperitoneal injection of antibodies and 
drug substances were performed by myself, Dr. Dirk Pühringer and Dr. Tina Schäfer. Mice were sacrified using 
CO2.        
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4 Discussion 
 
Tumors are facing an enormous challenge: they need to protect themselves from immune cell 
destruction by host cytotoxic effector cells. Therefore, malignant tumors develop certain 
strategies to escape anti-tumor immunity (see section 1.2) (Hanahan and Weinberg, 2011, 
Vinay et al., 2015). The expression of immunosuppressive cytokines, which are essential in 
healthy humans to prevent autoimmunity, can be “abused” by tumors, leading to a 
microenvironment which favors the recruitment of and polarization towards tolerized immune 
effector cells, sparing the transformed cells from immune attack, and allowing an unrestricted 
tumor growth (Bommireddy and Doetschman, 2004, Massague, 2008, Caja and Vannucci, 
2015). TGF- is one of the best studied molecules with such immune inhibitory effects (Wahl 
et al., 1988, Thomas and Massagué, 2005, Massague, 2008, Caja and Vannucci, 2015). GDF-
15, as a member of the TGF-superfamily, is far less understood, even though many 
publications arose in the last years with regard to its pro-tumorigenic and anti-inflammatory 
functions and the conclusion that GDF-15 is a promising target in the field of cancer therapy. 
GDF-15 is, like TGF-, a self-tolerated antigen, which is “temporally” required during 
pregnancy – conceivably to avoid immune mediated fetal abortion (Tong, Marjono et al., 
2004). Except during human pregnancy, GDF-15 has not been reported to exceed 
physiological levels in healthy humans. Of note, non-steroidal-anti-inflammatory drugs 
(NSAID) lead to an increase in GDF-15/NAG-1 expression, thus reflecting a non-
physiological condition (Baek et al., 2002). Under pathological conditions, GDF-15 can be 
found in high amounts in different tissue and blood sera, where several “pleiotropic roles”, in 
particular in “cancer, obesity and inflammation” were attributed to GDF-15 (Breit et al., 
2011). Interestingly, GDF-15 was reported to promote angiogenesis in tumors via hypoxia 
induced factor-1 alpha (HIF-1. This transcription factor induces vascular endothelial 
growth factor (VEGF) expression, the primary growth factor related to angiogenesis (Lin et 
al., 2004, Song et al., 2012) Of note, Krieg and colleagues could demonstrate that HIF-1 
itself mediated the expression of GDF-15 in the HCT116 colorectal cancer cell line under 
hypoxic conditions (Krieg et al., 2010). Since the GDF-15 promoter contains a HIF-1 
recognition sequence, this underlines the strong interrelation of these two molecules (Krieg, 
Rankin et al., 2010). When combining the models of Song et al. and Krieg et al., hypoxia 
would lead to HIF-1 mediated GDF-15 expression, which in turn promotes angiogenesis and 
further enhances HIF-1 expression ending in a positive feedback loop (Krieg, Rankin et al., 
2010, Song, Yin et al., 2012). In fast growing solid tumors, which develop a hypoxic 
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environment, the expression of GDF-15 seems to be essential in order to activate 
angiogenesis-promoting pathways. This represents an elegant strategy for tumors to achieve a 
growth advantage – to express a multimodal factor, which on the one hand promotes the new 
formation of blood vessels in the tumor (oxygen and nutrients supply) and on the other hand 
exerts an immunosuppressive function (protection of the tumor). Evidence that GDF-15 is 
involved in immunological processes became clear when it was first described as macrophage 
inhibitory cytokine 1 (MIC-1) (Bootcov, Bauskin et al., 1997). Under pathological conditions, 
a variety of influences of GDF-15 on immune cells have been described, including decreased 
macrophage adherence under diagnosed atherosclerosis and prevention of PMN infiltration in 
heart tissue upon myocardial infarction in mice (de Jager et al., 2011, Kempf, Zarbock et al., 
2011, Bonaterra et al., 2012). Most importantly, GDF-15 was shown to contribute to tumor 
progression and immune escape in glioma bearing mice, by keeping T cell and macrophages 
out of the tumor microenvironment (further discussed in 4.3) (Roth, Junker et al., 2010). 
These data were giving rise to investigate the role of GDF-15 in cancer and to develop 
antibodies against the human growth factor. 
 
4.1 GDF-15 expression and physiological relevance  
To identify a biological factor for a prospective therapeutic intervention in cancer, the target 
needs to be substantially analyzed in regard to its tissue expression and distribution, as well as 
its association between expression and grade of malignancy. Further, its physiological and 
pathophysiological function must be elucidated ex vivo as well as in vivo. From the present 
knowledge, the target’s function can be turned off e.g. by direct blockade of the target protein 
(as for instance by use of a monoclonal antibody), by complete knock down of the protein, 
and eventually by inhibiting its receptor. Peer reviewed reports in the literature, online 
databases (Sigma Atlas database) as well as own tissue staining confirmed the elevated 
expression of GDF-15 in many cancer types, compared to the respective healthy tissue. 
Comparability between own findings and the published data was given, since GDF-15 
expression was analyzed with the Atlas-GDF-15-antibody HPA1109 suitable for formalin 
fixed paraffin embedded tissue, and being the basis for the Atlas Database 
(http://www.proteinatlas.org/) (Uhlen et al., 2010). In accordance to a publication by Staff, 
our data confirmed that ovarian carcinoma tissues were highly positive for GDF-15, whereas 
in contrast to the malignant tissue, GDF-15 protein is not detected in female reproductive 
system, including ovaries, cervix, fallopian tube and endometrium (human tissue information 
is provided in the human protein atlas) (Staff, Bock et al., 2010). Most intense GDF-15 
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staining could be observed in own studies in a serous papillary type of ovarian carcinomas 
(section 3.1). Our data demonstrate that GDF-15 expression is not restricted to the tumor cells 
itself, but also expressed in endothelial cells. Similarly to the ovarian carcinoma, we could 
show that GDF-15 expression is increased in human brain tumors, which is in accordance 
with the literature, where several correlations between GDF-15 expression and grade of 
malignancy have been reported (Staff, Trovik et al., 2011, Mehta et al., 2015). However, in 
these sections, endothelial cells were also GDF-15 positive within normal white matter. It was 
further reported, that high cerebrospinal fluid GDF-15 level correlate with shorter survival in 
glioma patients (Shnaper, Desbaillets et al., 2009). Interestingly, Shnaper and colleagues did 
not observe a correlation between the high GDF-15 values measured in human CSF and the 
according plasma levels (Shnaper, Desbaillets et al., 2009). These observations are not in line 
with our findings, where GDF-15 tissue expression correlates with the GDF-15 serum level 
(Roth, Junker et al., 2010).  
Despite all these findings, the question of whether GDF-15 is concomitantly apparent in 
progressed malignancies, or whether it plays a functional tumor promoting role, still remains 
unclear (Mehta, Chong et al., 2015).  
The strongest GDF-15 protein expression described so far can be seen in placental syncytio-
trophoblasts (section 3.1 and atlas database). Under physiological conditions, GDF-15 was 
shown to exert a life-saving function during embryonic and fetal development (Tong, 
Marjono et al., 2004). Here, low GDF-15 serum levels during pregnancy were reported to 
correlate with fetal abortion. This allowed Tong and colleagues the suggestion, that GDF-15 - 
as an immunmodulatory molecule, which “favors fetal viability”- possesses not only 
predictive but also causative role during pregnancy (Tong, Marjono et al., 2004). 
But still, the function of GDF-15 under pathological conditions remains unclear. Since the 
synthesis of GDF-15 in cells requires a lot of energy, its overexpression by several solid 
tumors needs to yield an advantage for the neoplastic tissue, otherwise it would be an 
implausible waste of energy. The function of GDF-15 as an immunomodulatory molecule, 
contributing to immune evasion, might be a plausible reason for tumor cells to produce it in 
high amounts.  Still, the mode of action in this respect is unknown so far. 
Johnen and co-workers could elucidate one mechanism of action of human GDF-15 on 
murine neurons: Here, GDF-15 mediates cancer associated cachexia (Johnen, Lin et al., 
2007). GDF-15 was shown to induce anorexia in animals, which is followed by loss of body 
weight, revealing symptoms of cancer related anorexia-cachexia. Accordingly, our own 
xenograft studies confirmed this function of GDF-15 on body weight loss of tumor 
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transplanted animals (further discussed in 4.5). However, the influence of GDF-15 on weight 
loss due to neuronal induced anorexia rather seems to be an adverse reaction and cannot 
explain the findings of us and others, namely direct tumor-promoting effects and an 
immunomodulatory influence of GDF-15 (Kim, Lee et al., 2008, Roth, Junker et al., 2010, de 
Jager, Bermudez et al., 2011, Kempf, Zarbock et al., 2011, Bonaterra, Zugel et al., 2012). 
Therefore, further approaches were undertaken, to elucidate the mode of action, confirming a 
pathological function in regard to tumor immunity.  
 
4.2 GDF-15: Growth Factor and Ligand - without a yet known receptor? 
Growth factors and cytokines play an important role in physiological processes, e.g. tissue 
development, homeostasis as well as the coordination of organ- and cellular function 
(Dinarello, 2007). The impact of cytokines on human health can be observed best, when the 
respective protein is deregulated (Orzechowski et al., 2014). This can occur, when a cytokine 
is lacking, mutated and thus dysfunctional or even overexpressed (for instance by cancer 
cells). At that time, the cytokines can contribute to life threatening pathological conditions. 
 
In the tumor-immunological context, TGF- reveals a variety of different functions. On one 
hand, TGF- suppresses immune cells by modulating lymphocytes upon ligation of the TGF-
 receptor complex (Thomas and Massagué, 2005). On the other hand, TGF- was described 
to promote tumor growth directly by autocrine signals on cancer cells (Massague, 2008). 
However, at earlier stages of cancer development, TGF- exerts tumor inhibiting functions 
(Massague, 2008). The functional complexity of that molecule impedes to dissect singular 
effects in vitro.  
As a member of the TGF- super-family, GDF-15 is far less characterized compared to the 
other family members and little is known about its mode of action on cellular level. Therefore, 
characterization of GDF-15 and its role in cancer is the object of my thesis. To elucidate its 
biological function, several experimental in vitro and in vivo approaches were performed, 
allowing for the first time not only to identify the tissue distribution and influence on 
signaling pathways, but also to demonstrate effects on tumor growth and immune reaction in 
vivo (Roth, Junker et al., 2010). 
GDF-15 was demonstrated by Johnen and colleagues to activate hypothalamic neurons via the 
TGF- receptor I in mice (Johnen, Lin et al., 2007). These in vivo results would be very 
attractive to be translated into an in vitro model. Tsai and colleagues dissected certain brain 
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regions in regard to their anorexic area (Tsai et al., 2014). They were able to demonstrate that 
laser depletion of neurons located within the area postrema, results in animals being 
unresponsive to GDF-15 induced anorexia. The isolation of certain neuronal cell types 
represent an enormous obstacle for in vitro investigations not only because of technical issues 
but also because of the enormous amount of animals required for a sufficient number of 
primary cells (Strelau J., personal communication). 
Since my work predominantly focused on the function of human GDF-15 on human cells,  
signaling pathway analysis had to be performed in cell types differing from the above 
mentioned murine cells in terms of species and anatomic location. It is known, that TGF- is 
able to activate the canonical TGF- pathway in various different benign and malign cell 
types. This ends in the same pattern of kinase activity, ending in a phosphorylated Smad2/3 
protein level (Santibanez, Quintanilla et al., 2011). In case, a GDF-15 induced signaling 
pathway was conserved throughout different cellular populations, even other than neuronal 
cell types should respond to the “ligand”. Since the literature described GDF-15 to be 
involved in anti-inflammatory processes, human immune cells seemed to be an optimal 
“cellular target” to confirm the observations of Johnen and colleagues in vitro (de Jager, 
Bermudez et al., 2011, Kempf, Zarbock et al., 2011, Li et al., 2013). Unexpectedly, 
recombinant GDF-15 was not able to activate the canonical TGF- signaling pathway in 
human peripheral blood lymphocytes in our experiments. Whereas TGF- potently activated 
Smad signaling pathway, four commercially acquired GDF-15 batches left the Smad2/3 
proteins de-phosphorylated, indicating that immune cells do not respond to recombinant 
human GDF-15 in regard to canonical TGF- signaling pathway in human PBMC. One could 
speculate that immune cells lack a GDF-15 receptor, which could unfortunately not be 
verified due to the yet unknown nature of this presumable receptor. Human GDF-15 evoked 
TGF- signaling in mouse neurons in vivo (Johnen, Lin et al., 2007). However, the human 
GDF-15 may not activate a respective receptor expressed on immune cells, which could be 
due to tissue specific receptor polymorphisms. Furthermore, one cannot exclude that human 
GDF-15 only specifically - more or less non-physiologically- evokes a response on murine 
cells in regard to TGF- receptor activation. The latter suggestion would complicate to further 
elucidate the role of GDF-15 in human pathogenesis, particularly in cancer.  
Even though the signaling pathway of TGF- and GDF-15 did not resemble in human 
lymphocytes, we wanted to see whether a temporally later effect of TGF-, the 
downregulation of NKG2D receptor on NK cells and CTLs, converges between the two 
family members (Crane, Han et al., 2010). Therefore, we compared direct effects of both 
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recombinant GDF-15 and TGF- on NK cells and CTLs, respectively, by analysis of the 
NKG2D receptor surface expression using flow cytometry. Whereas TGF- revealed more 
than 50 % NKG2D receptor downregulation, GDF-15 could only slightly downregulate 
NKG2D (section 3.2). The fact, that GDF-15 was capable to diminish NKG2D at least at high 
cytokine concentrations, could be explained by a signaling event on lymphocytes, which 
follows a new pathway. Importantly, NKG2D reduction on NK cells, which were treated with 
GDF-15, seemed to occur in a dose dependent manner, further consolidating a direct effect of 
the ligand GDF-15 on immune cells. 
 
Since GDF-15 was further reported to reduce adherence of polymorphonuclear leukocytes 
(PMNs) to the endothelium after myocardial infarction, a next step was to investigate the 
influence of GDF-15 on the adherence of immune cells on endothelial cells (Kempf, Zarbock 
et al., 2011). Mechanistically, GDF-15 is essential to prevent the arrest of PMNs on the 
endothelium by inactivation of -integrins on immune cells (Kempf, Zarbock et al., 2011). 
This effect described by Kempf, represents a potent approach to investigate GDF-15 mediated 
effects in vitro and would support the finding that GDF-15 lowers the number of infiltrating T 
cells and macrophages in glioma bearing mice (see section 3.3) (Roth, Junker et al., 2010). In 
accordance to Johnen and co-workers, immune cell adherence on endothelial cells was 
slightly reduced by GDF-15 in vitro. However, our experiments revealed effects of GDF-15 
rather on lymphoid immune cells than myeloid cells, as shown by Kempf and colleagues. In 
our own study, macrophages hardly showed a loss of adherence after GDF-15 treatment, 
whereas for CD4
+
 T cells a reduction of adherence of ~24 % and of ~20 % for CD8
+
 T cells 
was observed upon GDF-15 pre-incubation. We could not recognize a change from the active 
state of 2 integrin towards the inactive one on immune cells, as observed by Johnen and 
colleagues (data not shown in my thesis, part of a running project). However, the group 
examined the effect on mouse PMN whereas human PBMC were used here. 
 
Taken these GDF-15 mediated effects on both NKG2D receptor expression as well as 
immune cell adherence on endothelial monolayers, we suggested that GDF-15 might ligate a 
yet unknown receptor on either immune or endothelial cells, possibly leading to 
transcriptional activation in the respective cell. Therefore, a micro array was performed, after 
human PBMC and HUVEC cells were treated with GDF-15 or left untreated. Unexpectedly, 
the changes in gene expression upon recombinant GDF-15 treatment were only marginal. 
Therefore, further investigation of those genes “seemingly” being deregulated, was not of 
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highest priority. Surprisingly, the most notable group of genes deregulated upon GDF-15 
stimulation of both HUVEC and PBMC were the olfactory receptors. Interestingly, olfactory 
receptor activation was reported to promote cancer cell invasiveness and metastasis (Sanz et 
al., 2014), a possible hint for tumor-promoting effects of GDF-15. Expecting genes involved 
in cancer, the clarification of the causal relationship between GDF-15 and olfactory receptors 
should be further investigated, however, this was not part of this thesis). 
  
A last step of my thesis was to investigate the influence of GDF-15 on migration and thus 
indirectly on metastasis: GDF-15 was reported to significantly increase invasiveness when 
overexpressed in gastric cancer cell line SNU-216 (Lee, Yang et al., 2003). Furthermore, 
Senapati demonstrated that GDF-15 overexpression leads to metastasis of human prostate 
cancer cells by promoting cellular motility (Senapati et al., 2010).  In contrast to those data, 
we could not observe enhanced migration of GDF-15 overexpressing breast cancer cell line 
MCF-7, compared to low GDF-15 expressing cells (see 3.2.5). Neither could we observe an 
effect when blocking GDF-15 with an antibody, drawing the conclusion that MCF-7 breast 
cancer cell line cannot be influenced by GDF-15 in regard to motility. The MCF-7 cells were 
chosen because of their low GDF-15 expression, expected to be even more responsive to 
GDF-15. Probably cells, which are not dependent on GDF-15, lack its potential receptor, 
which could otherwise be activated in an autocrine signaling manner.  
 
 
4.3 GDF-15 and its function in vivo 
To unmask the function of GDF-15 in vivo, mouse GDF-15 was silenced in the SMA-560 
glioma cell line and compared to the GDF-15 expressing wild-type SMA-560 cells by our 
group. Here, GDF-15 deficient animals showed prolonged survival (section 3.3) (Roth, Junker 
et al., 2010). From these studies one could conclude that GDF-15 negatively influences 
survival of brain tumor bearing animals and promotes tumor growth in vivo. However, studies 
with MIC-1/GDF-15 overexpressing animals revealed no tumor growth promoting effects of 
GDF-15, but high metastatic potential in the TRAMP transgenic prostate cancer model 
(Husaini, Qiu et al., 2012). As discussed in our publication (Roth et al.), overexpression of 
GDF-15, which reaches concentrations far beyond the physiological amount of GDF-15 in 
tumors, might exert unexpected effects (Roth, Junker et al., 2010). This implicates that GDF-
15 overexpression could change its function compared to the pathophysiological tumor-
produced GDF-15 and thus cannot mimic the “behaviour” of tumors in patients. As an 
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example, the group around Hegi published two opposing functions of GDF-15 in human 
glioma: An ectopic expression of GDF-15 in the glioblastoma cell line LN-Z308 led to the 
complete loss of tumorigenicity in nude mice and thus GDF-15 was described to act as an 
anti-tumorigenic protein (Albertoni et al., 2002). However, the same group demonstrated that 
glioblastoma patients with elevated GDF-15 levels in the cerebrospinal fluid have a shorter 
survival, which allowed Shnaper and colleagues the conclusion, that GDF-15 may serve as a 
prognostic factor in humans suffering from intracranial tumors (Shnaper, Desbaillets et al., 
2009). These findings demonstrate, that investigations based on ectopic overexpression of 
certain molecules, have to be interpreted very carefully and eventually lead scientists on the 
wrong track, regarding the function of a protein. 
Since GDF-15 has been associated with inflammation and was reported as macrophage 
inhibitory cytokine 1 (MIC-1), the focus was further placed on immune cell infiltrates within 
the SMA-560 glioma tissue, which was known to have an enormous impact on a patients 
prognosis (Pages et al., 2009, Kmiecik et al., 2013). Therefore, T cells and macrophages were 
stained immunohistochemically on SMA-560 glioma sections. Surprisingly, GDF-15 deficient 
animals revealed a strong infiltration of intratumoral T cells, whereas in GDF-15 producing 
glioma tissue T cell infiltrates could hardly be observed (section 3.3). Unexpectedly, 
macrophage infiltration in GDF-15 deficient tumors was lower than T cell infiltrates, even 
though the presence of macrophages within the GDF-15 knock-down glioma sections were 
enhanced, when compared to the wild-type tumors. However, we speculated that GDF-15, in 
its role as the macrophage inhibitory molecule, would rather influence the macrophages and 
not the T cells. Still, these findings from mouse models are in line with our results on the 
adherence assay (see 4.2) and implicate that GDF-15 not only acts on myeloid derived 
immune cells, but also on T cells, which belong to the lymphoid lineage.             
Summing up the information about GDF-15 in the cancer context this molecule can be 
attributed to… 
 
I) tumor promoting effect in glioma bearing mice with shorter survival, 
II) correlations of serum levels and poor prognosis in cancer patients 
III) its pathological function of tumor associated cachexia.  
 
Therefore, the blockade of GDF-15 was postulated to be a potent therapeutic approach to cope 
with the above mentioned unwanted effects of GDF-15 in cancer. As a consequence, the next 
step was to develop an antibody against GDF-15, which was a major part of the experimental 
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setting of this thesis and finally resulted inter alia in two patent applications of the monoclonal 
GDF-15 antibody suitable for cancer- as well as cancer associated cachexia treatment.  
 
 
4.4 Generation of GDF-15 antibodies and preclinical testing thereof 
Preceding in vivo data demonstrated the therapeutic potential of targeting GDF-15 and 
reinforced the intention to generate neutralizing immunoglobulins against that protein. 
Therefore, a monoclonal antibody was strategically generated in GDF-15 knock-out animals. 
The GDF-15 deficient mouse was utilized, since human and mouse GDF-15 exhibit 70 % 
DNA-sequence homology (see supplements, table 42), probably decreasing the 
immunogenicity of human recombinant GDF-15. The monoclonal antibody B1-23, which was 
developed during my thesis, was deposited under the Budapest treaty at the DSMZ 
(Accession number: DSM_ACC_3142). The immunoglobulin revealed a high affinity to 
GDF-15, with a dissociation constant (KD-value) of less than 1 nM (WO2014049087A1), 
which could be explained by the specific immunization protocol in GDF-15 knock out mice 
and resulted in a mouse monoclonal IgG2a isotype. For comparison, the KD-value of the 
Rituximab (Rituxan®), a FDA approved monoclonal anti-CD20 specific antibody, is at ~ 
8nM (http://www.rxlist.com/rituxan-drug.htm). We thus concluded that B1-23, which had a 
more than eight times higher affinity to its target antigen compared to the clinically applied 
antibody Rituximab, might represent an optimal preclinical drug candidate with neutralizing 
potential. With the focus on clinical applicability of the antibody in humans, further 
considerations regarding regulatory demands, such as knowledge about target expression and 
antibody cross reactivity, were inevitable. According to the literature and open access 
databases (see section 4.1), GDF-15 could be shown to be overexpressed in several types of 
cancer (see section 1, table 1), but hardly in healthy tissue (Uhlen, Oksvold et al., 2010). 
Consequently, as GDF-15 is highly upregulated in the human placenta and required during 
pregnancy, pregnant women would represent a contra-indication for a clinical application of 
GDF-15 antibodies in humans (Tong, Marjono et al., 2004). Once a monoclonal antibody 
represents a suitable drug candidate, a tissue cross reactivity panel (as for example 
FDA/EMEA panels of normal tissue) is an inevitable part of the preclinical development. This 
will, apart from the underlying thesis, be further performed for the anti-GDF-15 antibody B1-
23/H1L5. In order to prevent human anti mouse antibody (HAMA) generation, which in some 
cases can be followed by an uncontrollable immune response in humans, the immunoglobulin 
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B1-23 has been humanized as part of my thesis (Brennan et al., 2010, Nelson, Dhimolea et al., 
2010).  
Taken together the utility of the antibody B1-23 in vitro, the antibody is applicable for the 
detection of native GDF-15 in a semi native Western Blot system (3.4.4). This enabled to 
intensively characterize GDF-15 and its various forms. Importantly, B1-23 revealed to bind a 
conformational epitope of GDF-15 (3.4.6), which is preferred for a clinical application as a 
neutralizing antibody (Forsstrom et al., 2015). B1-23 can further be used as detection 
antibody in a colorimetric assay, e.g. when maxisorb plates are coated with recombinant 
GDF-15. Moreover, B1-23 or the humanized variant thereof is able to serve as a capture 
antibody in a sandwich ezyme linked immunosorbent assay (ELISA), which allows for the 
measurement of patients GDF-15 serum level, which could then be stratified according to 
defined GDF-15 thresholds of the individual cancer type. Most importantly, B1-23 reveals 
antagonizing effects in vitro (3.10). Here, B1-23 was capable to deplete tumor cell derived 
soluble GDF-15 in cell culture, an effect which is desired to occur in tumor patients.  
 
 
4.5 Therapeutic potential of B1-23 / H1L5 
GDF-15 was shown to induce cancer associated cachexia when expressed in prostate cancer 
cells inoculated in mice (Johnen, Lin et al., 2007). Here, anti GDF-15 antibodies were able to 
reverse the effect of body weight loss. However, the model used by Johnen and colleagues 
was based on a transgenic prostate carcinoma cell line. Here, GDF-15 was ectopically 
overexpressed in DU145 cells, which were transfected with a pIRES2-EGFP overexpression 
vector containing the human GDF-15 sequence. As discussed in the previous section, 
artificially overexpressed GDF-15 might act contrarious to from tumors physiologically 
secreted GDF-15. Therefore, we used the human melanoma cell line UACC-257, which 
highly expresses endogenous levels of GDF-15, representing a more clinically relevant model. 
Furthermore, we administered purified and toxicity tested monoclonal antibodies, which 
reduced the risk of undesired side effects due to cross reactivity with other molecules. The 
murine (B1-23), chimeric (ChimB1-23) as well as the humanized (H1L5) version of the 
developed GDF-15 antibodies were administered to the mice at day of tumor inoculation, 
which resembles a prevention model. In accordance with Johnen and colleagues, the 
application of all of our monoclonal antibodies could prevent the tumor associated loss of 
body weight of the animals (section 3.5). Surprisingly, only the intact antibodies were 
effective while GDF-15 specific Fab fragments could not counteract the GDF-15 mediated 
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weight loss in mice. It could be speculated, that B1-23-Fab fragments, which have a 
molecular weight of only ~ 110 kDa were cleared earlier from the blood than the 150 kDa IgG 
full antibodies. In this respect, Covell and colleagues reported that Fab fragments are cleared 
from the body 35 times faster than full IgG molecules, whereas the F(ab)2 clearance is 
situated in between the full length IgG and Fab molecules (Covell et al., 1986). In line with 
Covell´s reported pharmacokinetic of immunoglobulin clearence, the in vitro depletion of 
UACC-257 cell line secreted GDF-15 works efficiently, when using F(ab)2, but no longer than 
four days. In contrast, all three GDF-15 antibodies (B1-23, ChimB1-23, H1L5) were able to 
deplete GDF-15 over a period of more than 7 days. With this study we could demonstrate that 
the human melanoma cell line UACC-257 induces GDF-15 mediated cachexia in nude mice 
which could be prevented with all monoclonal GDF-15 antibodies. This effect is GDF-15 
specific, since PBS, the isotype IgG1 antibody, the F(ab)2 fragments as well as dacarbazine 
could not halt the loss of body mass. We did not expect to observe anti cachectic effects of 
Dacarbazine. However, dacarbazine (DTIC) was supposed to serve as antineoplastic 
chemotherapeutic control group, leading to tumor growth arrest in melanoma studies (Zhang 
et al., 2013). Surprisingly, no tumor growth reduction could be observed in our model, when 
treating the animals for five consecutive days with 80 mg /kg dacarbazine. Since Dacarbazine 
is mainly used for the treatment of advanced metastatic melanoma (Zhang, Qiao et al., 2013), 
the missing efficacy could be explained by the UACC-257 cell line, which was reported to 
highly express GAS1, a suppressor of metastasis (Gobeil et al., 2008). 
 
Summarizing the in vivo effects of anti-GDF-15 blocking antibodies in an 
immunocompromised melanoma model, B1-23, ChimB1-23 and H1L5 prevents the GDF-15 
mediated cachexia, proofing the functionality of the antibodies. Antitumor effects could not 
be observed with these GDF-15 specific antibodies, whereas external CRO could demonstrate 
growth inhibition in an analogous melanoma model. Thus, we speculate that either athymic 
mouse strains, which at least contain NK cells and macrophages, might differ in their NK cell 
activity. This would mean that tumor growth inhibition caused by the GDF-15 antibody B1-
23 would only take an effect, if NK cells are potent enough to be inhibited by GDF-15.  
Furthermore, one cannot exclude, that keeping of animal differs in different facilities in regard 
to certain pathogens, leading to NK cells of distinct potency.          
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Conclusion 
In my thesis, it could be shown that different types of cancer overexpress and secrete GDF-15. 
This growth factor is mainly expressed under pathological conditions and to low extent in 
healthy tissue, which is – from a regulatory perspective- a prerequisite for a contemplable 
therapeutic target molecule. GDF-15 expression was not only described to correlate with poor 
prognosis in several types of cancer. Several reports even attributed an immunomodulatory 
function to GDF-15, which was in line with our observation, that GDF-15 repressed the 
expression of the surface NKG2D receptor on NK and CD8
+
 T cells. Furthermore, the 
adhesion of CD4
+
 and CD8
+
 T cells to primary human endothelial cells (HUVEC) was 
decreased. Accordingly, GDF-15 might negatively influence effector cells of the lymphoid 
lineage in regard to their killing capability as well as their ability to transmigrate into the 
tumor microenvironment. A proper antitumor response requires not only functional cytotoxic 
T cells but also the presence of these immune subsets at the site of malignancy in order to 
ensure the necessary effector to target cell contact. Our in vitro findings therefore led to the 
conclusion that GDF-15 might contribute to tumor immune evasion. The fact, that tumor 
growth inhibition as well as an enhanced immune cell infiltration within the tumor 
microenvironment could be observed in GDF-15 knock down glioma cell bearing mice, 
supported this conclusion.  
We speculate, that GDF-15 bears different mode of actions which harm cancer patients: On 
one hand GDF-15 induces tumor associated cachexia, a syndrome caused by anorexia, which 
in turn leads to a reduced food uptake (Johnen, Lin et al., 2007). On the other hand, GDF-15 
seems to keep away immune cells from the tumor microenvironment and weakens their 
killing ability by mediating inter alia a NKG2D downregulation. This might be an important 
mode of action, which could also occur during pregnancy, where GDF-15 is required to 
prevent fetal abortion. Interestingly, there are remarkable analogies in the immune regulation 
of the human conceptus and a growing tumor (Ridolfi et al., 2009). Both tissues are 
recognized by the “host” immune system as an (semi-) allogenic transplant. The embryo 
comprises of about 50% paternal antigens recognized as foreign. Tumors typically acquire 
many mutations, which inevitably leads to the recognition of tumor associated antigens by the 
human immune system. Tumors might abuse GDF-15 to evade immune destruction by 
detaining effector immune cells from infiltration into the allogenic microenvironment, a 
mechanism initially developed in evolution to ensure a successful pregnancy.  
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Conclusion 
We suggest that GDF-15 is a key factor, which contributes to escape the attack by the human 
immune system and thus represents a valuable target for a potential cancer therapy using 
blocking antibodies.  
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